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Although inflammation is a crucial mechanism in response to injury and pathogen 
clearance, inappropriate or excessive induction of the inflammatory response in 
pregnancy can cause initiation of the labour cascade and subsequent preterm 
delivery. 
Host Defence Peptides (HDPs) have important anti-microbial properties but are also 
implicated as multifunctional modulators of immunity and infection. They are 
predominantly secreted by mucosal epithelial cells and released by leukocytes. The 
specific HDPs that are the focus of this thesis are Human beta-defensin 3 (hBD3) and 
Human Cathelicidin (hCAP-18/LL-37). The immunomodulatory effect of HDPs in 
reproductive tissues in response to infection/inflammation has not been well studied. 
In a pregnant state, the hypothesis of this thesis is that HDPs have a dual role in 
preventing ascending infection, but also preventing an exacerbated inflammatory 
response that can cause preterm birth by initiation of the labour cascade. To explore 
this I determine whether bacterial stimuli can regulate HDPs expression in pregnancy 
tissues. I also explore what interactions HDPs have on the production/induction of 
important cytokines that are vital to the inflammatory response. With the aid of HDP 
knockout mice, the role of these peptides in infection/inflammation and continuation 
of pregnancy is investigated in a mouse-model of induced preterm-labour. To 
understand how ascending infection might be controlled by HDPs in pregnancy, I 
explore how HDPs regulate commensal and pathogenic bacteria. This is achieved by 
interrogating the maternal microbiome at mucosal sites in HDP knockout animals, 
utilising the bacterial 16S rRNA gene and next generation sequencing. 
Results 
Placental explants respond to Lipopolysaccharide (LPS) challenge by increasing 
production of pro-inflammatory cytokines. LL-37 but not hBD3 peptide was able to 




To establish whether HDPs are critical in the continuation of pregnancy I use a LPS 
induced mouse–model of preterm labour in animals lacking the genes for the HDPs, 
Defb14 (Defb14-/-), or Camp (Camp-/-). Intrauterine injection of LPS induced 
preterm labour in wildtype mice. However, the Defb14-/- and Camp-/- mice do not 
have an increased rate of preterm labour. Key inflammatory mediators are increased 
in response to LPS-induced PTL. Camp-/- animals have a similar inflammatory 
response to wildtype mice when given LPS during pregnancy.  
To understand how ascending infection might be controlled by HDPs, I interrogated 
the maternal microbiome at mucosal sites in HDP knockout animals, utilising the 
bacterial 16S rRNA gene. I established a workflow for 16S rRNA gene sequencing 
on next-generation sequencing platforms and a bioinformatic pipeline for data 
analysis. Using this approach I was able to show the mucosal microbiome of Camp-/- 
animals were significantly different to that of wildtype controls, showing increased 
diversity in the microbes present.  
In murine pregnancy, there were very little global cumulative or progressive shifts in 
bacteria, with the exception of Candidatus arthromitus, which significantly increases 
with gestation compared to non-pregnancy 
This thesis has demonstrated that Host Defence Peptides are expressed in pregnancy 
tissues and have anti-inflammatory properties in response to bacterial stimuli. It is 
not clear whether the HDPs, hBD3 and LL-37 are fundamental to the immune 
defence in pregnancy by preventing excessive inflammation, Although, I have shown 






Preterm birth occurs in 8% -12% of all pregnancies and is the main cause of death in 
newborn infants. We still cannot predict which women will have a preterm birth, 
although infection and inflammation in the area around the baby increases the risk.  
There is increasing evidence suggesting that the lining of the female reproductive 
tract is more than just a physical barrier protecting from invading pathogens. The 
epithelial cells lining this area secrete proteins that kill invading pathogens and 
regulate the traffic and activity of incoming immune cells to the area. 
The aim of this thesis is to understand how a group of these proteins called, Host 
Defence Peptides (HDPs), which are present in the reproductive tract, regulate both 
the ‘good’ and pathogenic bacteria. This thesis also investigates what role these 
proteins have on inflammation in response to any invading bacteria. This is of 
importance in pregnancy as inappropriate or excessive induction of inflammation can 
cause initiation of the labour cascade leading to preterm delivery. 
A better understanding of these defence mechanisms within the female reproductive 
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Chapter 1 Literature Review 
1.1 Labour and Preterm Labour 
1.1.1 Preterm Labour 
The World Health Organisation estimates that 1 in 10 babies are born preterm (<37 
weeks gestation) which is a global annual incidence of 15 million (World Health, 
2013). Neonatal preterm labour is the main cause of morbidity and mortality in 
newborn infants, resulting in a multitude of developmental, neurological and 
cognitive problems (Galinsky et al., 2013). In addition to the huge burden on quality 
of life, these long-term associated problems increase the need for medical care and 
allied services. 
In many developed countries antenatal care has greatly increased the survival of 
extremely premature babies; however, the proportion of babies which survive with 
major health complications has not changed (Martin et al., 2010). Research into 
preterm labour has vastly increased in the last decade but this has not translated into 
a reduction in the incidence of preterm labour and improved neonatal outcomes. 
There are several low level risk factors for having a preterm labour; a prior history of 
a preterm labour, multiple pregnancy, maternal stress, excessive physical work, 
smoking, excessive alcohol consumption and infection. Gestational diabetes is also 
associated with a 4-fold increase in the rate of Preterm Labour (Norman et al., 
2009b). In addition, pre-existing diabetes is the highest risk factor of any maternal 
conditions associated with having a premature delivery. 
Nearly 40% of preterm deliveries are associated with intrauterine infection (Romero 
et al., 2006) (Figure 1.2). There are conflicting reports whether antibiotic 
intervention is beneficial in preventing preterm labour associated with intrauterine 
infection (Lamont, 2015, King and Flenady, 2002). A review of meta-analysis 
studies highlighted that the beneficial effects of antibiotics may have been masked by 
some negative studies which were methodologically flawed (Lamont, 2015). There is 




pregnancy to those women who have a clinical diagnosis of vaginal bacteria 
dysbiosis (Bacterial Vaginosis), has benefit (Thinkhamrop et al., 2015). 
There is therefore a great need to understand the pathophysiology of 
infection/inflammation in the context of preterm labour concerning both host-genetic 
and environmental risk factors. It is of importance to understand how the 
inflammatory process leads to preterm labour with the end goal of delaying or 
preventing this process in women. 
1.1.2 Term and Preterm Labour Common Components 
Preterm and term labour share common terminal pathways characterised by 
anatomical, biochemical, and endocrine events (Snegovskikh et al., 2006) (Figure 
1.1). Labour is a clinical diagnosis characterised by regular painful uterine 
contraction, progressive cervical effacement and dilatation. The uterine components 
of this shared pathway include 1) increases in uterine contractility, 2) cervical 
effacement and dilatation 3) decidual activation. In preterm labour the events are 
similar, although the stimuli that initiate and contribute to labour may differ. Clinical 
manifestations in preterm labour include; preterm premature rupture of the 
membranes (PPROM), preterm uterine contractions and cervical insufficiency. 
Understanding the upstream molecular mechanisms involved in the onset of labour at 
term is therefore important when looking at this labour cascade in preterm labour.  
 
Figure 1.1 Common Components of Term and Preterm Labour  
Schematic showing the overlapping factors of parturition at term and in preterm 
labour. Multiple factors are involved that lead to the clinical diagnosis of labour. 



















Figure 1.2 Schematic of Types of Infection/Inflammation in Human 
Pregnancy 
The types of inflammation and infection seen at the fetal-maternal interface. 
Bacterial infections within the uterine compartment can occur between fetal and 
maternal tissue (choriodecidual infection), within and between the two fetal 
membranes (chorioamnionitis), within the placenta, in the amniotic cavity or within 
the umbilical vessels (vasculitis) and cord substance (funisitis). Chorioamnionitis, 
choriodecidua infection, and amniotic fluid infections are more prevalent in 
association with ascending infectious agents through the cervix. Source: Goldenberg 






1.1.3 Labour as an Inflammatory Event 
Labour is now generally accepted to be an inflammatory event where the emphasis 
from an anti-inflammatory pregnancy state shifts pro-inflammatory preceding labour 
(Youssef et al., 2009). At term, an infiltration of neutrophils and macrophages into 
the cervix and maternal fetal membrane is observed (Osman et al., 2003, Gomez-
Lopez et al., 2010), in addition to increases in circulating leukocytes (Yuan et al., 
2009). Selective immune cell recruitment from the circulating blood involves the 
production of chemotactic signals.  
NF-𝜅B, a transcription factor family, is increased in the myometrium, the smooth 
muscle tissue of the womb, and amnion in term labour (Pieber et al., 2001, Lappas 
and Rice, 2009, Vora et al., 2010). This transcription factor has binding sites in key 
pro-labour genes controlling their activity (Lindström and Bennett, 2005).  
Increase in transcription factor NF-𝜅B, and also AP-1 and STAT (Stein et al., 1993) 
result in the production of cytokines including IL-6, TNF, IL-1𝛼, IL-1𝛽, and IL-8 
within the fetal membranes and uterine lining (Elliott et al., 2001, Lappas et al., 
2003). The relative contribution of these inflammatory transcription factors has been 
shown to be spatial, regardless, alone their activity results in a similar myometrial 
contractile pathways highlighting redundancy (Migale et al., 2016, MacIntyre et al., 
2014). These cytokines can stimulate prostaglandin production that in turn initiate 
mobilisation of neutrophils (Lockwood et al., 2006, Arcuri et al., 2009). These 
neutrophils infiltrate the tissue causing the production and release of 
metalloproteases (MMPs). Prostaglandins directly stimulate myometrial contractions 
in addition to indirect stimulation by the up-regulation of the oxytocin receptor 
(COX-2) (Liggins, 1989, Crankshaw and Dyal, 1994). COX-2 is an inducible labour 
associated gene, which is expressed at term labour in the human myometrium, while 
release of MMPs can aid tissue remodelling in the cervix and fetal membrane (Heng 





1.1.3.1 Inflammatory Mediators  
Microarray studies have highlighted labour is associated with a core inflammatory 
response when comparing cervical, myometrial and fetal membrane tissue of women 
before and after the onset of labour (Sharp et al., 2016, Bollapragada et al., 2009, 
Nhan-Chang et al., 2010). Collectively these studies highlight that the genes up-
regulated during term labour are involved in inflammatory response, inflammatory 
pathway signalling, cytokine-cytokine receptor interaction and extracellular matrix–
receptor interactions. Cytokines are cell-signalling molecules and were shown to be 
the most up-regulated genes in normal term labour (Bollapragada et al., 2009). 
1.1.3.2 NF-κB  
NF-κB is a transcription factor family that has classic association to infection/ 
inflammation and is involved in innate and adaptive immune responses. NF-κB is 
normally inactive in the cytoplasm, but in response to stimuli, such as LPS and pro-
inflammatory cytokines, its associated inhibitors, IκB proteins, are phosphorylated 
and proteolytically degraded. This degradation releases NF-κB dimer that can 
translocate to the nucleus (Ghosh and Baltimore, 1990, Hayden and Ghosh, 2004). 
Within the nucleus, NF-κB binds to genes with receptive NF-κB biding sites where it 
regulates the transcription of the associated genes.  
Many key pro-labour genes are regulated by the NF-κB transcription activity (Figure 
1.3). Some studies have shown NF-κB to be increased in the amnion, decidua and 
fetal membrane in normal term labour (Lappas and Rice, 2009, Vora et al., 2010). 
Although, in the absence of infection, its increased activity has not been conclusively 
established as other studies failed to confirm its action in fetal membrane tissue from 
labouring women (Yan et al., 2002). Mouse models of preterm labour have provided 
evidence for a key involvement for NF-κB in the process of labour. Condon et al., 
(2004) showed that mice receiving NF-κB locally had delayed onset of preterm 
labour compared to control injection. 
Blocking the activity of NF-κB in-vitro can inhibit the expression of IL-8, TNF and 




Lappas et al., 2003). It has also been shown to inhibit COX-2 expression and 
production of prostaglandins in fetal membrane tissues and the release of MMPs 




Figure 1.3 Schematic of Core Labour-associated Pathways 
Lipopolysaccharide (LPS); Corticotrophin Releasing Hormone (CRH); Surfactant 
Protein-A (SP-A,); Progesterone Receptor (PR); Glucocorticoid Receptor (GR); 
Phospholipase A2 (PLA2); Oxytocin Receptor (OTR). Source: Lindström and 
Bennett (2005) 
 
1.1.3.3 Immune Cells 
Neutrophils are a mature type of white blood cell that have vital role in protecting 
against diseases and infections. They can participate via direct actions such as; 
phagocytosis, degranulation and generation of neutrophil extracellular traps (NETs). 
Neutrophils also work by producing cytokines that can recruit and activate further 
immune cells to the area of infection/inflammation.  
Labouring-women at term and preterm have higher total numbers of circulating 




labouring women are also more primed than non-labouring neutrophils; they show 
increased migration potential and have a higher production of reactive oxygen 
species (Yuan et al., 2009).  
The observation of leukocyte influx into reproductive and pregnancy tissues during 
labour has been widely reported (Osman et al., 2003, Gomez-Lopez et al., 2010). It 
has also been widely observed in combination with an increase in the neutrophil 
chemokine IL-8 (CXCL8) mRNA gene transcript. Neutrophils in pregnancy tissues 
release pro-inflammatory cytokines and MMPs, which degrade the extracellular 
matrix of the fetal membranes and contribute to the labour cascade. However, it 
remains to be established whether these leukocytes are a causative factor for the 
initiation of labour, or predominantly involved in the subsequent tissue remodelling 
following labour. 
In animal studies, term-labour and preterm labour induced by inflammation, results 
in an influx of neutrophils into the decidua and myometrium (Shynlova et al., 2013a, 
Shynlova et al., 2013b, Rinaldi et al., 2014). This was not seen when preterm labour 
was induced by blocking the hormone progesterone with mifepristone (Shynlova et 
al., 2013a), suggesting a role for decidual neutrophils in labour. Similarly in humans, 
the number of neutrophils in the decidua of women with infection-associated preterm 
labour is greater than preterm/term labour not associated with infection (Hamilton et 
al., 2012). Despite these findings, Rinaldi et al., (2014) showed that neutrophil influx 
to the decidua is not necessary for initiation of preterm labour in an animal model of 
PTL. The authors demonstrated that depleting neutrophils did however reduce the 
amount of IL-1β produced in response to LPS. 
Most macrophages are monocyte derived from the blood; however, tissues also have 
their own type of tissue resident macrophages that are not always derived from the 
bone marrow. Resident macrophages are mostly involved in homeostasis; patrolling 
the microenvironment for damage signals from cell death and cells undergoing 
phagocytosis.  
Macrophages have dual functions in the response to inflammation. Macrophages are 




cells, but are also involved in resolution of inflammation and regulating the levels of 
tissue repair to avoid tissue damage. In response to infection and other intrinsic cell 
damage signals, they can phagocytose, releasing IL-1β and TNF as potent pro-
inflammatory cytokines. In resolving infection, macrophages can produce anti-
inflammatory cytokines including TGF-β and IL-10. 
Macrophages are important in secreting cytokines, including IL-1β, IL-6, TNF but 
also MMPs and nitric oxide (NO). Human and rodent studies have shown that uterine 
macrophage numbers increase with gestation and there is an associated increase in 
NO production (Tan et al., 2014), although there are conflicting reports of their role 
in parturition. Some studies in rodents (Shynlova et al., 2013a, Buhimschi et al., 
1996, Mackler et al., 1999) have suggested that uterine macrophages are depleted 
directly prior to the initiation of labour, which is in keeping with the report that NO 
prevents uterine contractions in-vitro (Yallampalli et al., 1993).  
Various studies have shown macrophage numbers in the cervix increase during 
parturition. Elegant studies looking at macrophage surface markers have shown that 
cervix macrophages are more favoured towards MMP activation and cell matrix 
remodelling, and less favoured for adhesion and migration. This suggests a key role 
in functions associated with ripening and dilation of the cervix, which is in keeping 
with an animal study that showed depleting macrophages prevented cervical 
remodelling (Gonzalez et al., 2011b). Depleting macrophages also protects mice 
from LPS-induced PTL suggesting macrophages also have a key role in parturition 
(Gonzalez et al., 2011b). 
Although neutrophils and macrophages are the main infiltrating immune cells, 
pregnancy tissues also have other resident and patrolling immune cells, including 
granulocyte-derived mast cells, antigen-presenting dendritic cells and NK-T cells, 
which are suggested to have a role in mediation of parturition. Adaptive immune 
cells, such as T cells, B cells and regulatory T cells (T regs), are also resident in 
pregnancy tissues and participate mostly in fetal-maternal tolerance during 





1.1.3.4 Toll Like Receptors  
Many cells have pattern recognition receptors (PAMPs) at the cell surface, including 
the transmembrane TLR proteins. Cells also have multiple intracellular receptors 
such as NOD domains, which recognise bacterial and extracellular stimuli.  
There are 11 transmembrane Toll like receptors described in humans and mice 
collectively (TLR-1-11) (Akira and Takeda, 2004). These include TLR-4, where the 
main ligand is LPS, and TLR-3, which detects dsRNA. TLR-2 is involved in the 
detection of many Gram-positive bacteria products such as lipoteichoic acids (LTA). 
TLR-9 is essential in the recognition of CpG motifs, which are abundant in many 
bacteria. TLR-3 and TLR-7-9 are intercellular receptors, while TLR-1, TLR-2, TLR-
4-6 and TLR-11 are located at the cell surface. 
TLR signalling is mediated by two main pathways; the Myeloid Differentiation 
Primary Response 88 (MyD88) dependent, and MyD88 independent (Figure 1.4). 
The MyD88 dependent pathway is common to all the TLRs except TLR-3, whereas 
the MyD88 independent pathway is distinctive to signalling by TLR-3 and TLR-
4(Takeda and Akira, 2001). TLR-4 has a unique property where it can use both 
MyD88 dependent and independent pathways. TLR-4 co-adaptor molecules include; 
LPS-binding protein (LBP), cluster of differentiation 14 (CD14) and MD-2 also 
known as Lymphocyte antigen 96. 
Ligand binding in the MyD88 dependent pathway recruits the adapter proteins, IL-1 
receptor associated kinases (IRAKs), which when activated interacts with the 
intracellular signalling molecule TNF Receptor Associated Factor 6 (TRAF6). This 
activates complexes that signal MAP kinase pathways, JNK, and the NF-ĸB 
pathway. The MyD88 independent pathway is mediated by the adaptor protein, TIR-
domain-containing adapter-inducing interferon-β (TRIF), which triggers TRAF6, in-
turn signalling the NF-ĸB pathway. TRAF6 also induces an interferon response by 
increasing the interferon transcription factor, IRF3.  
Transcripts for TLR1-10 have been found expressed in multiple tissues of the female 




membranes (reviewed in Nasu and Narahara (2010). TLR-2 and TLR-4 are stated to 
be increased in the myometrium, cervix and fetal membrane of labouring women at 
term (Kim et al., 2004, Bollapragada et al., 2009, Youssef et al., 2009). Interestingly 
TLR-2 and TLR-4 are also increased in women with signs of infection (Kim et al., 
2004). Spontaneous preterm labour is associated with an increased expression of 
TLR4 on maternal human blood monocytes (Pawelczyk et al., 2010). 
There is also some evidence that low expression of TLR-4 may be protective against 
preterm labour (Hirsch et al., 2006). TLR-4, has been shown to mediate 
inflammation-induced preterm labour in animal models (Elovitz et al., 2003). Elovitz 
et al., (2003) showed C3H/HeJ, TLR-4 mutant, mice had reduced levels of LPS-
induced preterm labour compared to the CD1 strain. In this study, TLR-4 did not 
reduce the rate of fetal demise, whereby those animals that had no preterm labour 
still displayed high rates of LPS-induced fetal death. 
Interestingly, genetic variation in TLR-4 and TLR-9 have been associated with 
incidences of dysbiosis in the vaginal microbiota, suggesting host-immune genotype 
is important in maintaining bacteria homeostasis (Royse et al., 2012, Macones et al., 
2004). 
Pioli et al., (2004) show TLRs have spatial expression patterns in the female 
reproductive tract. Hirata et al. (2007) went on to show the expression of many of 
these TLRs alters during the menstrual cycle (Hirata et al., 2007). TLR-1-9 are also 
in the female reproductive tract of mice, where they similarly show temporal and 
spatial expression patterns throughout estrus in the vagina and uterus (Soboll et al., 





Figure 1.4 Schematic of the TLR-4 Signalling Pathway 
TLR-4 singling through both the MyD88 (MyD88 dependent) and TRIF pathways 





1.1.4 Onset of Labour at Term 
Humans first maintain pregnancy by the production of progesterone in the corpus 
lutum; this is then superseded by placental progesterone production. In humans 
labour is not associated with a systemic withdrawal of progesterone (Elovitz and 
Mrinalini, 2004). However, emerging evidence suggests there may be local 
functional progesterone withdrawal prior to the onset of labour (Pieber et al., 2001, 
Mesiano et al., 2002).  
In contrast in mice, placental progesterone is not thought to supersede that of the 
corpus lutum and so removal of the ovaries during pregnancy induces labour 
(Condon et al., 2004). The onset of labour in mice has been proposed to involve 
Surfactant Protein A (SP-A) which is released from the pup lung. SP-A causes 
mobilisation of macrophages from the amniotic fluid into the maternal tissues of the 
uterus, this process activates pro-inflammatory cytokines such as IL-1β that in turn 
stimulates NF-κB activation (Condon et al., 2004, Mendelson and Condon, 2005). 
However, the causative factor that initiates the inflammatory cascade in Human term 
labour still remains unclear. 
1.1.5 Infection/Inflammation and Preterm Labour 
There are many infectious agents that when contracted by the mother can transfer to 
fetus and cause inflammation and fetal demise. Infectious agents include; 
Toxoplasma gondi (toxoplasmosis), Cytomegalovirus, Herpes simplex virus, and 
Lyme disease. However, these infections do not explain the infection/inflammation 
seen in most preterm births. A local immune response in the decidua and chorion is 
more commonly associated with preterm labour (Galinsky et al., 2013, Vrachnis et 
al., 2010). These are frequently caused by ascending opportunistic commensal 
bacteria from the vagina, through the cervix and into the fetal membrane (Allam et 
al., 2013, DiGiulio et al., 2010). The upper genital tract is generally considered 
sterile prior to the onset of labour (Jones et al., 2009) nonetheless nearly 40% of 
preterm deliveries are associated with intrauterine infection and/or clinical 




and fetal membranes discovered women who present with preterm labour have a 
greater diversity of bacteria in these tissues (Prince et al., 2016, Aagaard et al., 
2014). It is therefore important to investigate the role of local infection when 
considering premature labour.  
1.1.6 Mechanisms for Inflammation/Infection 
NF-𝜅B can also be activated by pro-inflammatory cytokines in response to pathogens 
such as endotoxins from bacterial cell walls.  
The surface of many immune cells including leukocytes, dendritic cells, epithelial 
cells and trophoblasts, have pattern recognition receptors (e.g. TLRs) which when 
stimulated by bacterial endotoxin or pro-inflammatory cytokines release transcription 
factors including NF-𝜅B, STAT, and AP-1. This in turn results in the production of 
cytokines and chemokines, such as IL-6, TNF, IL-1β, and IL-8, within the uterine 
lining and the fetal membranes (Figure 1.3). 
The involvement of cytokines/chemokines in maternal and fetal inflammation has 
been well investigated in humans. Experimentally, animal models have been used 
which allow for collection of gestational tissues at various time-points during 
pregnancy. 
Systemic LPS treatment in pregnant mice induces maternal inflammation and 
preterm labour that is associated with rises in amniotic fluid cytokines (IL-1 and IL-
6) and maternal serum cytokines (IL-1, TNF, and IL-6) (Baumann et al., 1993, Fidel 
et al., 1994).  
A similar cytokine response was seen in a localised fetal inflammatory model, where 
heat-killed E.coli was injected into ligated uterine horns (Hirsch et al., 2006). These 
cytokines can stimulate the production of prostaglandins, which initiate mobilisation 
of neutrophils. These neutrophils infiltrate tissue causing the production and release 
of metalloproteases (MMPs) and induction of COX-2. COX-2 is expressed at term 
labour in the human myometrium and also animal cervical fibroblasts (Sato et al., 




preterm labour (Hirsch et al., 2006). As discussed previously, TLR-4 has been shown 
to mediate inflammation-induced preterm labour in animal models (Elovitz et al., 
2003). 
Prostaglandins produced in the amnion can stimulate uterine contractions when in 
proximity to the uterine lining (Cheung et al., 1992). This activity is supressed during 
pregnancy by the release of prostaglandin dehydrogenase in chronic tissue which acts 
as a buffer for its activity (Cheung et al., 1992). In the context of an amniotic 
infection, activity of prostaglandin dehydrogenase is reduced, which allows the 
prostaglandins to reach the myometrium which in-turn can lead to premature 
contractile activity (Van Meir et al., 1996). Infection can also increase MMPs, which 
can weaken the chorion amniotic membrane causing it to prematurely rupture 
(Catalano et al., 2010). Increased concentrations of iNO and prostaglandins in 
amniotic fluid are also associated with intrauterine infection and continue to 
propagate the labour cascade (Bethea et al., 1998). 
LPS and exposure to some bacteria can cause hypoxia-inducing oxidative stress and 
apoptosis in the placenta and fetal membranes (Garnier et al., 2008). Increases in cell 
turn-over and apoptosis at the fetal-maternal interface could result in increased 
apoptotic bodies and cell-free fetal DNA (cffDNA) from the placenta entering the 
maternal circulation (Bischoff et al., 2005). High levels of cffDNA, which is 
hypomethylated and a TLR-9 agonist, have previously been associated with preterm 
labour, preterm rupture of the membrane and preeclampsia (Farina et al., 2005, 
Jakobsen et al., 2012, Lim et al., 2013).  
1.1.7 Therapeutics for Preterm Labour  
Research into preterm labour has vastly increased in the last decade but this has not 
translated into a reduction in the incidence of preterm labour. There are few 
treatment options for preventing a preterm birth to improve neonatal outcomes.  
A cervical cerclage is a suture inserted close to the cervix during pregnancy. It is 




the cervix. Kindinger et al., (2016) demonstrated that the type of material used for 
the suture can affect the vaginal microbiome and inflammatory cytokine profile.  
Drugs can be used in an attempt to supress the myometrial contractions in women 
who are high risk of preterm labour. The main mechanisms for these tocolytic drugs 
are to reduce the supply and transfer of intracellular calcium in the myometrium, 
which is a key component in processes for myometrial contractions. Inhibitors for the 
oxytocin receptor COX-2 are also used as tocolytic treatment; as COX-2 is the rate-
determining step for Prostaglandin synthesis and Prostaglandins directly stimulate 
myometrial contractions.  
Progesterone also acts on suppressing the availability and transport of intracellular 
calcium ions and Prostaglandin synthesis in myometrial tissue. There have been 
multiple randomised control-studies which show a reduction in PTL with weekly 
injections of 17α-hydroxy progesterone caproate (Meis et al., (2003) reviewed in 
Norwitz and Caughey (2011)). This protective effect was also shown in a study 
which applied progesterone daily to the vagina (da Fonseca (2003) reviewed in 
Norwitz and Caughey (2011)). Progesterone was not shown to be effective for 
women presenting with PROM (Briery et al., 2011) or multiple pregnancies (Rouse 
et al., (2007), Durnwald et al., (2010), Norman et al., (2009a) reviewed in Norwitz 
and Caughey (2011)). Reviews have suggested that progesterone can also improve 
neonate morbidity and mortality. Although recent published results from the 
OPTIMUM randomised placebo-controlled trial, looking at progesterone as a 
prophylaxis, showed no harm or benefit from vaginal progesterone on neonatal 
outcome at 2 years of age, moreover no benefit to preterm labour (Norman et al., 
2016). 
There are conflicting reports whether antibiotic intervention is beneficial in 
preventing preterm labour associated with intrauterine infection (Lamont, 2015, King 
and Flenady, 2002). There is however, increasing support that certain prophylactic 
antibiotics given very early in pregnancy to those women who have a clinical 




Novel drug development and clinical trials, especially in pregnancy is very restricted, 
so looking towards currently available drugs already used for other conditions may 
prove a quicker mode for translational medicine. An encouraging human study 
looking into administration of chloroquine chemoprophylaxis, a known TLR-9 
inhibitor and antimalarial agent, in pregnant mothers in West Africa reported lower 
rates of preterm labour in those who had a ‘complete’ course of chloroquine (Sirima 
et al., 2003).  
Taken together, the development of preventative therapies for preterm labour 
requires a mechanistic understanding of how key modifiers of the inflammatory 




1.2 Host Defence Peptides 
Antimicrobial peptides provide the first line of defence against infectious pathogens 
in multicellular organisms. Peptides with antimicrobial functions have also been 
defined in archaea, fungi, plants and bacteria. Over 1,972 animal host defence 
peptides are currently described and they are evolutionarily conserved (Wang et al., 
2016). Structurally, antimicrobial peptide families are very diverse, but they are 
categorised by their sequence composition and protein confirmation. 
The most studied cationic antimicrobial peptides in humans are the Defensins and 
Cathelicidin. Due to the discovery that these antimicrobial peptides have an array of 
additional immunomodulatory properties (Figure 1.5), they are commonly adopting 
the broader name of Host Defence Peptides (HDPs). 
 
Figure 1.5 Overview of HDPs Modes of Action 
HDPs have potent microbicidal activity against a broad spectrum of bacteria, fungi, 
and viral organisms; acting directly on the invading pathogens (blue). They can 
supress the inflammatory process by binding and blocking receptors but also directly 
binding to bacterial pathogens (yellow). They also influence immune response by 
attracting inflammatory cells, inducing an inflammatory state, modulating apoptotic 
cell death and cell degranulation (green). HDPs can play a role in tissue homeostasis; 




1.2.1 Defensins  
1.2.1.1 Defensins 
Human defensins are small cationic peptides, predominantly released by epithelial 
cells at mucosal surfaces where their main role is in host innate immunity. In 
addition to acting directly on invading pathogens, they also influence immune 
response by attracting inflammatory cells and inducing an inflammatory state. There 
is also evidence to suggest that certain defensins can function to modulate apoptotic 
cell death (Yamaguchi et al., 2007) and some have immunosuppressive activity (Shi 
et al., 2007, Semple et al., 2010)  
Defensins are divided into three categories; alpha-defensins, beta-defensins, and 
theta-defensins. Alpha and theta defensins arose from ancestral beta-defensin genes. 
In other species such as snakes, beta-defensin derivatives have become specialised as 
toxins (crotamines). Almost all defensins contain a canonical six-cysteine motif and 
have a beta-sheet structure. They are distinguishable by their; genomic organisation, 
the spacing of these cysteines, and their disulphide bond interactions. In-silico 
analysis has predicted 28 defensin like sequences at 5 loci in the human genome 
based on the six- cysteine motif (Schutte et al., 2002).  
Alpha-defensins and beta-defensins are found in most vertebrate species. Leukocytes 
and Paneth cells (specialised cells in the small intestine), are the main source of 
alpha-defensins. Beta-defensins are expressed in a variety of tissues and cell types, 
including epithelial cells, macrophages and dendritic cells.  
In humans and many higher mammals, beta-defensin sequences have been found to 
cluster together on chromosome arrangements. In humans, 10 beta-defensins are 
clustered on an 8MB region of chromosome 8p23.1. Seven of the genes in this region 
(DEFB103 – DEFB108 and DEFB4) are arranged in a copy number variable (CNV) 
cluster, which ranges from 2-7 copies. CNV has been shown to some extent to be 
correlated to protein level and CNV of this loci has been linked to the inflammatory 
disease psoriasis (Hollox et al., 2008). A few beta-defensins are expressed 




defensins, such as Human beta-defensin 3 (hBD3) and Human beta-defensin 2 
(hBD2), are inducible upon stimulation with bacteria or cell damage signals. 
Interestingly many beta-defensins are expressed in the male and female reproductive 
tract. The epididymis expression of beta-defensins is segmental and influences sperm 
maturation (Zhou et al., 2013).  
In mice, the genomic arrangement containing the alpha-defensins is flanked by two 
beta-defensin regions. Mice have 27 beta-defensins, 26 cryptdin genes (defensin 
related) and multiple defensin pseudogenes. Mouse defensins are highly repetitive in 
nature with regard to their chromosomal position; this arrangement supports a 
positive diversifying-selection model of evolution (Patil et al., 2004, Patil et al., 
2005). Unlike humans, mice have no neutrophil alpha defensins but they have 
multiple cryptdin alpha-defensins in the small intestine. 
There are several published beta-defensin mouse knockouts. Two studies suggest that 
Defb1 homozygous null mice retain Haemophilus influenzae in the lung, and 
Staphylococcus spp. in the bladder longer than wildtype mice. This implicates a role 
of Defb1 in respiratory and urinary tract infection, resistance and pathogen clearance 
(Morrison et al., 2002, Moser et al., 2002). There has been direct evidence linking 
gut alpha-defensins to the modulation of microbiota in mice. Salzman et al., (2010) 
demonstrated that Paneth cell alpha-defensins contributed to mucosal host defence 
and regulate the composition of murine intestinal microbiota.  
1.2.1.2 Beta-defensins 
In humans, seven of the beta-defensin genes on chromosome 8 are copy number 
variable and five of these, DEFB4 (encodes peptide hBD2), DEFB103 (encodes 













Defb1 (57%) DEFB1 hBD1 Beta-defensin 1 
Defb4 (45%) DEFB4 hBD2 Beta-defensin 2 
Defb12/ Defb35 DEFB105 -   
Defb13 DEFB107 -   
Defb14 (69%) DEFB103 hBD3 Beta-defensin 3 
Defb15/ Defb34 DEFB106 -   
Defa5 DEFA5 HD5  Alpha Defensin 5 
- - HNP 1-3 Human Neutrophil Peptide 1-3 
Table 1.1 Mouse and Human Orthologous Defensin Genes  
Percentage of sequence identity between human and mouse at the protein level to the 
mature peptide are shown in parentheses. 
 
Impaired stimulation of hBD2 and hBD3 has been characterised in Crohn's disease 
(Wehkamp et al., 2003, O'Neil et al., 1999). In addition, genome wide CNV profiling 
highlighted a predisposition to Crohn’s disease with low hBD2 CNV (Fellermann et 
al., 2006).  
Human beta-defensin 1 (hBD1) is not located within the copy number variable 
region on chromosome 8p23.1, and is ubiquitously expressed in human epithelia 
cells. Reduction of hBD1’s disulphide bonds exposes its powerful antimicrobial 
activity against Candida albicans, (the opportunistic pathogenic fungus), 
Bifidobacteria, and Lactobacillus species (commensal Gram-positive bacteria) 
(Schroeder et al., 2011). 
Murine beta-defensins are not copy number variable; however, they are contained 
within an extended locus of 27 beta-defensins and may demonstrate redundancy. 
Many human and mouse beta-defensins show epididymis-specific expression 
patterns. Human beta-defensin 126 (DEFB126) is an epididymis-specific secretory 
protein which has the ability to inhibit LPS-induced inflammation in macrophage cell 
lines (Liu et al., 2012). This could have a role in the female reproductive tract, where 
DEFB126 in semen could suppress inflammatory response in the vaginal epithelium. 
Other HDPs also display this immunomodulatory activity in macrophage cell lines 




A major site of beta-defensin expression is in the male reproductive tract of both 
humans and mice. Zhou et al., (2013) has shown that homozygous deletion of 9 beta-
defensins on mouse chromosome 8 results in infertility in male mice. Infertile mice 
displayed reduced sperm motility, increased sperm fragility and increased 
spontaneous acrosome reaction. This is partly due to defects in sperm microtubule 
formation and consequently results in increased intracellular calcium content.  
Many human and mice beta-defensins have chemotactic properties. hBD1, hBD2 and 
hBD3 are able to induce chemotaxis through CCR6 (Hoover et al., 2002, Oppenheim 
and Yang, 2005). Similarly, the mouse Defb4 and Defb14 genes, orthologues of 
genes encoding hBD2 and hBD3 respectively, also have chemotactic activity for 
CCR6-expressing cells (Rohrl et al., 2008, Rohrl et al., 2010).  
1.2.1.3 Human beta-defensin-3 (hBD3) 
DEFB103 gene, which encodes hBD3, has two exons; the first exon contains 
sequence for the 5’UTR and pre-protein, while the second exon contains the 
sequence for the mature protein. The six-cysteine motif spacing, which forms the di-
sulphide bonds in hBD3, is different from the other defensins, namely hBD2 and 
hBD1. However, the general shape of these defensins is similar despite lack of 
identity between family members (Bauer et al., 2001). hBD3 is the most cationic and 
when folded has the ability to form symmetrical amphipathic dimers (Dhople et al., 
2006); this is thought to be responsible for its salt in-sensitivity compared to other 
HDPs. 
1.2.1.3.1 Expression and Regulation 
hBD3 is found highly expressed in psoriatic skin (Harder et al., 2001) (where it was 
first isolated) but also in cells of the oral cavity, endometrium, placenta, and immune 
cells. A broad range of bacteria (Gram-positive and Gram-negative) in addition to 
pro-inflammatory cytokines such as IL-1β, TNF-α and INF-γ are able to 




hBD3 in human keratinocytes is increased by bacterial challenge via stimulation of 
the epidermal growth factor receptor (EGRF). In gingival fibroblasts, hBD3 
expression increases in response to infection with Candida albicans (Gursoy and 
Kononen, 2012). Oral squamous cells (Shuyi et al., 2011), gingival epithelial cells 
and dendritic cells (Yin et al., 2010) all show a marked increase in hBD3 in response 
to LPS treatment in-vitro. 
In women, hBD3 and other defensins are known to show temporal expression 
patterns in the reproductive tract during the menstrual cycle; where higher levels of 
hBD3 are seen in the early and late secretory phase (King et al., 2003b, Das et al., 
2007). 
DEFB103 at the transcript level is inhibited by corticosteroids (Duits et al., 2001); 
these corticosteroids can also inhibit pro-inflammatory cytokines and cell surface 
markers (Barnes, 2006). The activity of hBD3 can be impaired through the direct 
inhibition and degradation of the protein. Saliva and serum can inhibit the 
microbicidal activity of hBD3 to Gram-positive and Gram-negative bacteria 
(Maisetta et al., 2005). hBD3 was also found to have reduced killing activity to 
Gram-positive bacteria in low pH environments (Abou Alaiwa et al., 2014). Cysteine 
proteases and streptococcal inhibitor complement produced by group-A 
Streptococcus (GAS) can also directly degrade hBD3 peptide (Cogen et al., 2010). 
1.2.1.3.2 Antimicrobial and Immunomodulatory Properties 
hBD3 is known for its potent antimicrobial activity against a broad spectrum of 
bacteria, fungi, and viral organisms. hBD3 can act on many Gram-negative and 
Gram-positive bacterial species including methicillin-resistant Staphylococcus 
aureus (MRSA) and vancomycin-resistant Enterococci (VRE) (Harder et al., 2001). 
The exact mechanisms of how hBD3 kills bacteria are not fully understood, but are 
thought to involve ionic interactions with the bacterial cell surface, blockage of 
bacterial biosynthetic pathways, and bacteria cell wall lipid interaction (Sahl et al., 
2005). Staphylococcus aureus when treated with non-folded hBD3 shows rapid 




hBD3 also show a similar activity suggesting disulphide structure is not essential for 
the antibacterial mode of action (Harder et al., 2001).  
hBD3 can supress biofilm production in single organisms of Pseudomonas 
aeruginosa and Staphylococcus aureus, but also biofilms of multiple-species (Zhu et 
al., 2013, Lee et al., 2013). Studies have shown that hBD3 not only represses the 
initiation and maturation of biofilms, but also represses those already established 
(Zhu et al., 2013).  
hBD3 and DEFB14 have potent anti-inflammatory effects on human and mouse 
primary monocyte derived macrophages. This action effectively inhibits the LPS-
activated TLR4-induced TNF and IL-6 response, through both the MyD88 and TRIF 
pathways. This effect has been shown both in-vitro and in-vivo (Semple et al., 2010, 
Semple et al., 2011). hBD3 can act in synergy with other HDPs. For example, LL-37 
and hBD3 have a combined effect reducing the LPS-induced secretion of cytokines 
in gingival cells (Bedran et al., 2014). 
Semple et al., (2015) showed that hBD3 exacerbates the production of INF-β in 
response to polyI:C, a viral mimic and TLR-3 agonist, in both human and mouse 
primary macrophages. Conversely, the authors showed reduction of CXCL10 in 
response to this TLR-3 agonist in the presence of hBD3. This effect was also seen in-
vivo where co-treatment of mice with hBD3 peptide and polyI:C enhanced the 
increase in INF-β, compared to polyI:C treatment alone. Using macrophages from 
knockout mice, Semple et al., (2015) went on to show that hBD3 suppressive effects 
were mediated by TICAM1 (TRIF in mouse), while the exacerbating effects were 
mediated by MDA5 (IFIH1 in mouse). 
In addition, hBD3 can bind to CpG and self-DNA to form net complexes; these 
complexes are up-taken by pDCs and induce an INF-α response, acting as a TLR-9 
agonist (Tewary et al., 2013). Such complexes are increased in patients with 





1.2.1.4 Murine Orthologue of hBD3; Mouse Defb14 
Mouse beta-defensin 14 (Defb14) has the highest sequence identity to hBD3 protein; 
sharing 69% sequence identity at the protein level. Multiple studies have confirmed 
similar activity of the human and mouse peptide suggesting they are functional 
orthologues (Rohrl et al., 2008, Semple et al., 2010). 
Like hBD3, DEFB14 exhibits broad-spectrum antimicrobial activity. Defb14 
responds to INF-γ and TGF-α treatment in keratinocytes (Hinrichsen et al., 2008), 
which were also identified as stimuli of hBD3 in human keratinocytes (Harder et al., 
2004). hBD3 and DEFB14 have the same potent anti-inflammatory effects on human 
and mouse primary monocytes (Semple et al., 2010, Semple et al., 2011). Moreover, 
hBD3 and Defb14 also have similar expression profiles in the female and male 
reproductive tract (King et al., 2003b, Hickey et al., 2013, Zhou et al., 2013, Garcia-
Lopez et al., 2010) 
1.2.2 Cathelicidin 
1.2.2.1 Cathelicidin 
Cathelicidins are cationic antimicrobial peptides, found mostly in neutrophils, 
keratinocytes and epithelial cells, which have a vital role in protecting against 
diseases and infections. 
Multiple cathelicidins have been identified in mammals such as sheep, goat and pigs. 
However, rodents and humans have only one gene for cathelicidin. The gene 
encoding the sole human cathelicidin, CAMP is located on chromosome 3p21.3 and 
is comprised of 4 exons. The N-terminal and the coding regions of the first three 
exons, which include the cathelin and signal domain, are highly conserved. Exon 4 
codes the antimicrobial peptide domain. The 16kDa preprotein, hCAP18, does not 
exhibit antimicrobial activity and can either be immediately cleaved, or stored as a 
proprotein in granules without the signal domain. Extracellular proteolytic cleavage 
of the C-terminal of hCAP18 by proteinases 3, or kallikrein generates the active LL-




The LL-37 peptide has cationic and amphipathic properties forming an alpha- helical 
structure. 
Alternative microbicidal active forms of LL-37 have been reported in select 
environments (Sorensen et al., 2001, Sorensen et al., 2003, Murakami et al., 2004). 
These alternative fragments can be formed either by the additional degradation of 
LL-37 by host/bacterial proteases, or by alternative cleavage of the pro-protein. 
hCAP18 in seminal fluid can be processed by gastricsin derived from the prostatic 
gland to form an antimicrobial peptide of 38 amino acids (Sorensen et al., 2003). 
This peptide, ALL-38, has the same antimicrobial properties as LL-37 (Sorensen et 
al., 2003). Gastricsin cleavage only occurs at low pH, akin to what is seen in the 
vagina suggesting a mechanistic involvement preventing infection following sexual 
intercourse. LL-37 is found to have reduced killing activity to Gram-positive bacteria 
in low pH environments (Abou Alaiwa et al., 2014). Serine proteases in sweat can 
also degrade LL-37 into reduced fragments; KR-20, RK-31, and KS-30 (Murakami 
et al., 2004).  
1.2.2.2 Expression and Regulation 
CAMP gene expression is found at varying levels in many cell types; hCAP18/LL-37 
is also present in many bodily fluids such as breast milk, sweat, saliva and vaginal 
secretions (reviewed in Durr et al., (2006)). CAMP is commonly upregulated in many 
immune and epithelial cells when challenged in infectious disease. Leukocytes and 
epithelial cells can rapidly release hCAP18/LL-37 molecules extracellularly 
following uncontrolled cell death, infection and degranulation (reviewed in Durr et 
al., (2006)). TLR activation and various cytokines can also directly upregulate 
CAMP gene expression (Mookherjee et al., 2006).  
Upstream of the CAMP gene is a SINE repeat, which contains the putative Vitamin 
D response element (VDRE). This is the primary element that is bound by Vitamin D 
receptor (VDR) and responsible for the Vitamin D induced expression of CAMP in 
many cell and tissue types. This element is not highly conserved, and is absent in all 




Bacteria produce short chain fatty acids such as butyrate from fermentation of dietary 
fibres in the colon. SCFAs such as butyrate can also regulate the expression of 
CAMP gene (Kida et al., 2006). In the gut, SCFA’s are mostly anti-inflammatory 
involved in promoting gut barrier function and homeostasis. SCFA’s demonstrate 
anti-inflammatory function by inhibiting NF-Kb signally by the suppression of pro-
inflammatory cytokines (Zeuthen et al., 2008, Segain et al., 2000). In contrast, 
SCFA’s in the vagina show more of a pro-inflammatory response in those women 
with bacterial vaginosis (Mirmonsef et al., 2012, Aldunate et al., 2015). The 
difference in SCFA immune response could be inherent properties of the cell type, 
pH, and TLR ligand combination in the different environments (Mirmonsef et al., 
2012). 
Immune-Mediated Inflammatory Diseases 
Chronic inflammatory disease has associations with dysregulation of the careful 
cytokine/chemokine homeostatic balance. Several HDP, including LL-37 are 
elevated in systemic lupus erythematosus (SLE) (Kreuter et al., 2011), and 
rheumatoid arthritis (RA) (Paulsen et al., 2002). 
Some conditions are associated with a downregulation of hCAP18/LL-37. Morbus 
Kostmann is a condition where patients display reduced neutrophil counts and no 
LL-37 in granulocytes, these patients also commonly display severe periodontal 
disease (Putsep et al., 2002). Without treatment Morbus Kostmann patients die from 
bacterial infection in infancy. Patients treated with recombinant granulocyte colony-
stimulating factor (G-CSF), retain reduced neutrophil defensins and absolute 
deficiency in LL-37. Crohn’s, atopic dermatitis and chronic ulcers are all reported to 
be associated with a decrease in CAMP gene expression or hCAP18/LL-37 levels 
(Schauber et al., 2006, Sun et al., 2016, Reinholz et al., 2012).  
Mice null for Camp, the murine orthologue of LL-37/hCAP18, have many inducible 
phenotypes; showing increased vulnerability to bacterial infections of the 
gastrointestinal tract (Chromek et al., 2012), urinary tract (Chromek et al., 2006), 




The mechanisms for the anti-inflammatory and immunomodulatory activities of 
human and mouse cathelicidin are very complex. Involving such processes as, 
intracellular uptake, endocytic mobilisation and receptor interaction (reviewed in 
Choi et al., (2012). These mechanisms result in signalling pathways being altered and 
activation of various transcription factors. 
Receptors 
The most classic LL-37 receptor is formyl peptide receptor 2 (FRP2), but there are 
also others such as CXR2, EGFR, and P2X7 (De et al., 2000). Major downstream 
pathways of these receptors involve activation of protein kinases, the release of 
intracellular calcium, and NF-kB activation. Activation of these receptors and 
signalling pathways cause cell proliferation, mobilisation and cytokine release. These 
processes are important for the immunomodulatory activity of LL-37 in chemotaxis, 
angiogenesis and tissue repair (Carretero et al., 2008, Koczulla et al., 2003). The 
ability for LL-37 to cross the cell membrane where it can bind proteins, such as 
GAPDH intracellularly has also been shown to be an important factor in LL-37’s 
immunomodulatory activity (Mookherjee et al., 2009). It has been shown that cells 
such as vaginal epithelial and placenta cells express the classic LL-37 receptor FRP2 
(Dong and Yin, 2014, Frew, 2013), but it is unclear if this is the main receptor for the 
immunomodulatory properties of LL-37 in these cells (Frew, 2013). 
1.2.2.3 Antimicrobial Properties 
LL-37 like hBD3, is known for its broad-spectrum antimicrobial activity; acting on 
many Gram-positive, Gram-negative bacteria, viruses, and also on the yeast Candida 
albicans (reviewed in Vandamme et al., (2012)). LL-37 preferentially binds to 
bacteria where its antibacterial action involves disrupting cell membrane integrity 
using a toroidal pore carpet like mechanism (Oren et al., 1999, Henzler Wildman et 
al., 2003, Lee et al., 2011). This process involves LL-37 binding parallel to the 
membrane, where oligomers and monomers cause membrane strain and subsequent 
translocation into the periplasm. This process of LL-37 molecules translocating into 
the periplasm opens pores and causes leakage (Oren et al., 1999). Antifungal 




ROS production (Rapala-Kozik et al., 2015). Antiviral properties of LL-37 have been 
shown by its ability to directly interact with the viral envelope (Currie et al., 2016). 
In addition, this peptide has shown strong inhibitory effects on the HIV-1 reverse 
transcriptase where it can inhibit HIV-1 replication in PBMCs and T-cells (Bergman 
et al., 2007).  
Like hBD3, LL-37 has been reported to have anti-biofilm activity at sub-minimum 
inhibitory concentrations (MIC) of a number of organisms, namely, Staphylococcus 
epidermidis (Hell et al., 2010) Staphylococcus aureus (Mishra et al., 2016, Dean et 
al., 2011), Pseudomonas aeruginosa (Overhage et al., 2008) and Escherichia coli 
isolates (Kai-Larsen et al., 2010). This feature is not unique to all cathelicidins where 
the mouse peptide, CAMP, did not show anti-biofilm activity on Pseudomonas 
aeruginosa (Overhage et al., 2008). In addition to its activity against pre-establish 
biofilms, LL-37 peptide can also inhibit biofilm formation of Staphylococcus aureus 
(MRSA) (Dean et al., 2011). In animal in-vivo infection-models, LL-37 peptide 
prevents Escherichia coli and Candida albicans from adhering to the urinary tract 
cell wall, stopping subsequent biofilm formation (Chromek et al., 2006, Tsai et al., 
2011). 
1.2.2.4 Modulation of Inflammation/Infection 
Chemotactic Properties 
LL-37 can act as a direct chemoattractant for cell types including; neutrophils, iDCs, 
eosinophils, T lymphocytes and monocytes (Tjabringa et al., 2006, Soehnlein et al., 
2008, Chertov et al., 1997, Wang et al., 1996). Tjabringa et al., (2006) showed that 
eosinophils and neutrophils are directly mobilised by LL-37 using a calcium chamber 
assay. Soehnlein et al., (2008) went on to show a direct LL-37-induced mobilisation 
of inflammatory-monocytes.  
At and around the site of infection, low/modest physiological concentrations of LL-
37 induces the secretion of chemokines such as IL-8. This process also indirectly 
recruits additional innate immune cells to the area. LL-37 induces secretion of these 




and fibroblasts (Bowdish et al., 2004, Montreekachon et al., 2011). IL-8 is a 
chemokine, which promotes the attraction of neutrophils, and along with LL-37 
works to respond to the infection. After treatment with LL-37, primary monocytes 
can produce CCL20, CCL4, and CXCL1 in-vitro (Niyonsaba et al., 2010, 
Vandamme et al., 2012). LL-37 on macrophages can also up-regulate the expression 
of receptors including the IL-8 receptor, IL-8RB, and CCR2 (Scott et al., 2002). 
Human umbilical vein endothelial cells (HUVEC) and RAW cells also release CCL2 
after LL-37 treatment, (Vandamme et al., 2012). 
 
Chemokine/Cytokines Alternative name  Receptor 
CXCL8 IL-8 CXCR1,CXCR2 
CCL2 MCP-1 CCR2 
CXCL10 IP-10 CXCR3 
CCL5 RANTES CCR1, CCR3, CCR5 
CXCL1 GROα CXCR2 
CCL4 MIP-1β CCR5 
Table 1.2 Chemokine/Cytokines and Receptor Nomenclature 
 
Immune-cell Modulation 
In addition to attracting immune cells to combat infection, LL-37 is capable of 
modulating their action once recruited to the site. In mast cells, LL-37 peptide causes 
increases of IL-4, IL-2, and IL-6, and also causes cell degranulation that results in 
histamine being released (Niyonsaba et al., 2001). This activity in mast cells has also 
been shown for hBD2 peptide (Niyonsaba et al., 2001, Niyonsaba et al., 2002). 
Histamine works as a ‘alarmin’ causing blood vessels to dilate; increasing capillary 
permeability, thus allowing more white blood cells to reach the site of 
infection/inflammation. 
LL-37 can promote sensing of CpG motifs through TLR-9 from bacterial DNA in 
plasmacytoid dendritic cells (pDCs) and human B lymphocytes (Hurtado and Peh, 




CpG motifs. ODNs, which have a natural phosphodiester backbone (akin to human 
genomic DNA), can also elicit a similar response when un-methylated.  
LL-37 increases the life span of neutrophils at the site of infection; suppressing 
neutrophil apoptosis via FPR2 and P2X7 receptor (Nagaoka et al., 2006). The effect 
of LL-37 on apoptosis in other cells shows an alternate effect, depending on the dose 
of peptide used. High concentrations of the peptide in lung epithelial cells promote 
apoptosis (Barlow et al., 2006), whereas suppression of apoptosis has been observed 
in primary human keratinocytes and HaCaT cells (immortalised human 
keratinocytes) (Chamorro et al., 2009). 
Neutrophil extracellular traps (NETs) are shown to contain LL-37 (Ciornei et al., 
2005) which is able to induce their formation and stabilisation (Neumann et al., 
2014). Interestingly the bacterial killing properties of LL-37 when bound to NET 
DNA are diminished, suggesting it might be having an alternate role here.  
LL-37 DNA Aggregates  
LL-37 can bind to extracellular self-DNA fragments forming aggregates, which are 
taken up by pDCs. These aggregated particles enter pDCs through lipid-raft-
mediated endocytosis and are retained in early endocytic compartments, which in-
turn triggers a robust TLR-9 mediated interferon response (Gilliet and Lande, 2008). 
Gilliet and Lande, (2008) have subsequently shown hBD3 has the same properties to 
form DNA complexes. One study proposed that such activation of pDCs is central to 
the pathogenesis of SLE (Lande et al., 2011).  
TLR Pathway Suppression 
Apart from indirectly recruiting immune cells and directly inducing cytokines, LL-37 
has other modulatory roles sensing signals from cell damage and pathogen associated 
molecular patterns (PAMPs). LL-37 like hBD3, in the presence of exogenous 
inflammatory stimuli has the ability to target inflammatory pathways such as NF-κB 
signalling by TLRs, supressing certain pro-inflammatory responses. LL-37 has a 




al., 2006). RAW cells treated with LPS, a TLR4 agonist, release less TNF and NO 
when treated with LL-37, hence supressing inflammation (Scott et al., 2002). 
Extracellular LL-37, and the mouse orthologue CAMP, can form complexes with 
LPS by directly binding to it; these complexes prevent LPS interaction with TLR-4 
signalling molecules (Scott et al., 2000, Scott et al., 2011). The formation of these 
complexes is due to the physicochemical properties of LL-37/CAMP, such as its 
charge, helicity, amphipathicity and hydrophobicity. It has also been suggested that 
LL-37 can exhibit anti-endotoxic effects by binding the CD14 receptor directly, or by 
dissociating LPS oligomers; both mechanisms prevent binding to the LPS binding 
receptors (LBP) (Suzuki et al., 2011).  
1.2.2.5 Wound Healing and Tissue Remodelling 
As previously mentioned LL-37 can activate the FPR2 and P2X7 receptors on 
epithelial cells and fibroblasts. It is proposed that this results in a similar proliferative 
effect as EGFR activation. In endothelial cell lines, it has also been suggested that 
LL-37 acts on the FPR2 receptor to induce angiogenesis (Salvado et al., 2013). One 
study showed electroporation of a LL-37 plasmid in an ischemic hind limb model 
upregulated antigenic chemokines, and also reduced muscular atrophy (Steinstraesser 
et al., 2014). 
 
1.2.3 HDPs and the Female Reproductive Tract 
Cells in the female reproductive tract are a major source of multiple microbicides. 
Reproductive tract epithelial cells, cervical glands, and neutrophils generate a wide-
range of HDPs that target viruses, bacteria and fungi, both directly and indirectly 
(Figure 1.6). 
LL-37 is found at high levels in fetal skin, amniotic fluid, vaginal fluid and the 
vernix caseosa (reviewed in Yarbrough et al., (2015)). Steady state defensin 




pregnant and non-pregnant women. hBD1-4 and human alpha defensin 5 (HD5) have 
all been reported to be expressed with distinctive temporal profiles in the endometrial 
epithelium, vagina and cervix (King et al., 2003a, Fleming et al., 2003, Quayle et al., 
1998). The kinetics of this differential expression most likely reflects the differing 
immunological requirements along the length of the female reproductive tract. 
In women, HDPs are known to show temporal expression patterns during the 
menstrual cycle (King et al., 2003b). The mechanism of menses shares many 
characteristics of acute inflammatory processes, involving localised increase in pro-
inflammatory cytokines, prostaglandins, and leukocyte migration. In women, hBD3 
is higher in the early and late secretory phase of the menstrual cycle (Fleming et al., 
2003). Hickey et al., (2013) found that in non-pregnant mice Defb14 also had 
specific estrus cycle mRNA expression profiles in the vagina and uterus. Like hBD3, 
LL-37 is not uniformly expressed throughout the cycle. Mice null for Camp, the 
murine orthologue of LL-37/hCAP18 have increased susceptibility to bacterial 
urinary tract infections (Chromek et al., 2006). Defb1 homozygous knockout mice 
also have increased susceptibility to urinary tract infections whereby they were 
shown to retain Staphylococcus spp. in the bladder longer than wildtype mice 
(Morrison et al., 2002). 
Like LL-37, multiple alternative fragments of hBD1 with varying amino-acid termini 
have been found in the human reproductive and urogenital system (Valore et al., 
1998, Zucht et al., 1998, Valore et al., 2002). These alternative forms have been 
isolated in vaginal lavage fluids and urine, where they appear to have different levels 






Figure 1.6 Mechanisms for HDPs in Epithelial Cells of the Female 
Reproductive Tract  
Mechanisms for HDPs in female reproductive tract epithelial cells (FRT EC). HDP 
have potent microbicidal activity against a broad spectrum of bacteria, they can 
supress the inflammatory process by binding and blocking receptors but also directly 
binding to bacterial pathogens. They also influence immune response by attracting 
inflammatory cells, inducing an inflammatory state, modulating apoptotic cell death 
and cell degranulation. HDPs play a role in tissue homeostasis; including the 





1.2.4 HDPs and Preterm Labour 
The development of preventative therapies for preterm labour requires a mechanistic 
understanding of how the pro-inflammatory profile is induced. HDPs have been 
shown to have multiple roles in this pro-inflammatory process. 
Researchers have found that an immune genotype variation in human DEFB1 may 
contribute clinically to women who deliver preterm (James et al., 2013). This 
retrospective genotyping study highlighted rs1799946, a SNP in DEFB1, to be 
associated with a doubled risk of preterm delivery and four-fold increase in the risk 
of extreme preterm delivery (<28 weeks) (James et al., 2013). A second SNP, 
rs1047031, was found to be protective. However, a larger GWAS study, which 
included a different SNP in the DEFB1 gene, failed to highlight an association of this 
locus to preterm labour (Uzun et al., 2013). 
Women with elevated concentrations of cervicovaginal HNPs at 24-29 weeks of 
gestation have a greater risk of delivering preterm (before 32 weeks) (Balu et al., 
2003). Further work on human extra-placental membrane in ex-vivo cultures has 
shown increased hBD2 in the amnion when the choriodecidua were exposed to group 
B streptococcus (GBS) (Boldenow et al., 2013).  
An in-vitro study on human gingival fibroblasts found that hBD3 is pro-
inflammatory and increases both COX-2 expression and prostaglandin E2 (PGE2). 
COX-2 is an inducible labour associated gene, which is expressed at term labour in 
the human myometrium and also in rabbit cervical fibroblasts (Sato et al., 2001). The 
importance of this effect in cervical and myometrial stromal fibroblasts in mouse and 
human has yet to be determined. 
As previously discussed, the active form of Vitamin D is a potent inducer of 
CAMP/LL-37. LL-37 is upregulated by Vitamin D in placental explants and primary 
human trophoblasts in a dose-dependent manner (Liu et al., 2009). This response is 
similar to that observed in primary cultures of human macrophages (Martineau et al., 
2007). hBD2 but not hBD3 also shows a similar Vitamin D response in keratinocytes 




1.3 Mouse Models of Preterm Labour 
Nearly 40% of preterm deliveries are associated with intrauterine infection (Romero 
et al., 2006). Mouse preterm labour models have focused on stimulation with agents 
to create an infection and/or inflammatory state; such as heat-killed E.coli, heat 
killed bacteria, LPS, group B streptococci (GBS), Lipoteichoic acids (LTA), TNF 
and IL-1β (Elovitz et al., 2003). Stimulation of the TLR4 pathways with LPS has 
been the central method of invoking preterm labour in animal models (Table 1.3). 
Live and heat-killed bacteria have also been used for preterm-labour models, 
however the reproducibility has been reported to be low (Reznikov et al., 1999). In 
humans, amniotic fluid cultures from most preterm births are negative for bacteria 
(Romero et al., 2007), although amniotic inflammatory cytokines and LPS binding 
proteins have been shown to be increased (Gardella et al., 2001). This lack of 
bacterial detection could be due to the limitations of the culture-dependent detection 
method. There is however, evidence to support signal transduction to the amnion 
when the choriodecidua is stimulated with bacteria (Boldenow et al., 2013), this 
could account for the increase in inflammatory response in the amnion without direct 
bacterial invasion. 
The mode of agent administration has a large impact on the immune response 
mounted against the endogenous stimulating agent in animal models; intravaginal 
(i.vag), intraperitoneal (i.p) intracervical (i.c) intrauterine (i.u) have all been used as 
routes of administration.  
The i.p model of preterm labour most likely mimics that associated with sepsis and 
severe bacteraemia (Elovitz et al., 2003). As most women with preterm labour do not 
present with elevated white blood cells or symptoms of illness, a localised model of 
inflammation at the maternal-fetal interface would likely recapitulate what is seen in 
women. In addition, systemic models of induced preterm-birth in mice are highly 
variable, with high incidence of maternal morbidity (Aisemberg et al., 2013). 
A more recent model for preterm labour involves intrauterine (i.u) administration of 




to expose the gestational uterine horn and inject between two fetal sacs. 
Administering LPS using this method is reported to induce high preterm labour rates 
while maintaining low maternal mortality. However, the biological relevance of 
delivering a bolus of purified LPS into the uterus in the hope of mimicking human 
ascending bacterial infection could be questioned. 
There has been one study that used medical endoscope to navigate through the 
murine cervix to administer infectious agents (Reznikov et al., 1999), however, due 
to the dense mucus plug and small opening, results were highly variable and others 
have failed to replicate this method.  
Reznikov et al., (1999) developed a mouse model of infection/inflammation-induced 
preterm labour by injecting E.coli intracervical (i.c) in pregnant mice. In this model, 
the expression of fetal and/or maternal cytokines was demonstrated to up-regulate a 
number of uterine factors such as prostaglandin hormones, prostaglandin receptors 
and matrix metalloproteinases, which leads to premature initiation of parturition. 
There has been some work on an intravaginal (i.vag) model of preterm labour, where 
the agent is applied distal to the cervix and causes preterm labour by transcending the 
cervix and/or through signal transduction (Gonzalez et al., 2011b, Gonzalez et al., 
2011a). The mucus plug during pregnancy is very dense and the quantity of agent 
breeching this barrier is likely to be small, therefore higher loads of agent are needed.  
There is variability across animal studies which use LPS as the inflammatory agent, 
this could be due to several compounding factors, such as serotype of the LPS used 
(Migale et al., 2015). The gestational age at which LPS is administered to induce 
preterm labour is also a factor in animal models as early administration can lead to 






Reference Route Conc. Mouse Strain n = Gestation PTB Time-points/ 
Comments 
Reznikov et al., 
(1999) 




14/15 48hrs Controls taken 24hr 
after administration 








14/15 48 hrs Controls taken 24hr 
after administration 
Burd et al., (2011) Intrauterine  250µg/mouse 
LPS 
CD1 N/A 18.5 6 hrs Culled after 6 hrs 




C57BL6 94.7% 15 36 hrs  
Salminen et al., 
(2008) 
Intraperitoneal 25µg/mouse C57BL6 FVB 58% -38%  16/17 17 hrs  Less than 
20µg/mouse no PTL 
Sykes et al., (2013) Intrauterine 20µg/mouse CD1 100%  16 7.7hrs No pup survival 
>10µg 
Sykes et al., (2013) Intrauterine 2.5µg/mouse CD1 100%  16 48 hrs  
Wakabayashi et 
al., (2013) 
Intraperitoneal 100µg/kg C3H/HeN  15.5 72 hrs  




20μg/mouse C57BL6 6/7 17 36 hrs  No pup survival 6/7 
Table 1.3 Animal Models used to Study Infection/Inflammation-induced Preterm Labour 





1.4 Microbiome  
Researchers have often quoted that the numbers of microbial cells in the human body 
easily out-number the human cells 10:1. New data suggested this was a vast 
overestimate and the number of human and bacterial cells in an average adult male is 
actually about equal 1:1 (Sender and Milo, 2016). Nonetheless, bacterial cells offer a 
plethora of microbial genes, providing important metabolic functions that have 
specific selections based on co-adaptions.  
The term ‘Microbiome’ refers to the full composition of genetic material of all the 
microorganisms in a community. This includes the widely reported prokaryotic 
entities but also eukaryotic, archaea and viral organisms, more frequently being 
referred to as the ‘virome’. This thesis interrogates the prokaryotic organisms of the 
microbiome using the general term bacteria. 
Bacteria are an essential part of human health; they break down un-digestible food 
fibres, and also provide a source of Vitamin K and Biotin. Many selections in the 
bacterial gene complement can be induced by alterations in the host-environment, 
such as antibiotic exposure (Langdon et al., 2016), dietary changes (Aron-
Wisnewsky and Clement, 2016) and hormone regulation (Sudo, 2014). Selective 
metabolic functions also occur in other animal species. Rodents lacking exposure to 
microorganisms (germ free) display severely stunted growth, reduced cardiac output, 
reduced cell proliferation and other pathologies (Schwarzer et al., 2016, Blanton et 
al., 2016). 
The majority of the time the relationship between host and bacteria is synergistic, 
existing in perfect homeostasis. However, disruptions or aberrations in this 
relationship can sometimes cause pathologies and disease. Pathogenic 
microorganisms are not the only causes of disease; disruption in commensal bacteria 
that are typically held in check by the microbial network and host immune defence 




Recent studies have provided evidence that some inflammatory diseases can be 
caused or associated with community disturbance, often referred to as dysbiosis 
(Srinivasan and Fredricks, 2008, Carding et al., 2015). 
The ‘hygiene hypothesis’ suggests that, reducing the diversity of pathogens humans 
are exposed to in early childhood leads to defects in the establishment of normal 
immune tolerance (Strachan, 1989). This causes an increase in susceptibility to 
allergic diseases such as asthma and hay fever (Strachan, 1989), but also 
autoimmune and chronic inflammatory diseases such as type 1 diabetes and multiple 
sclerosis (Bach, 2002).  
Historically much of our understanding of the human microbiome had come from 
culture-based approaches, but as many human-associated bacteria are not easily 
cultivable, culture-independent approaches such 16S rRNA gene sequencing are 
becoming ever important. The bacterial 16S Ribosomal RNA gene is approximately 
1500bp and consists of nine hyper-variable regions (V1-V9), that when sequenced 
can be used to identify bacteria taxonomy to the species or genus level. The Human 
Microbiome Project is an initiative which, using high throughput technologies, aims 
to characterise the microbiome across body sites associated with both health and 





Figure 1.7 Human Microbiome Diversity 
Phylogenetic tree of the common human phyla found at various body sites. The 
coloured rings are coded by body site and the height of the bars are proportional to 
the relative abundance at each site. Source:  Morgan et al.,  (2013) 
 
 
Both culture-independent and dependent approaches have widely established that 
humans are dominated by just 4 main phyla (Bacteroidetes, Firmicutes, 
Actinobacteria and Proteobacteria), which show site-specific distributions 
(Dethlefsen et al., 2007) (Figure 1.8). The highest bacterial load in humans and 
animals is in the colon, whereas the bacterial load in the vagina is much lower. The 
relative abundance at the phylum level within body sites tends to be consistent 




colon is dominated by Bacteroidetes and Firmicutes (Dethlefsen et al., 2007, Lay et 
al., 2005, Eckburg et al., 2005). The composition in the vagina at the phylum level 
shows a little more variation, most women are dominated by just Firmicutes in the 
vagina, but some women have a dominance of Actinobacteria phyla (Dethlefsen et 
al., 2007).  
 
Figure 1.8 The Human Microbiome; Site Specific Distribution of Phyla 
Coloured proportions represent the percentage of each 4 main phyla found in 
different body-sites as determined by 16S rRNA gene sequencing (n=11 women). 
The area of the pie chart somewhat represents the bacterial load, the number in 
parentheses shows the mean number of phylotypes (approximated species level taxa).  






1.4.1 The Vaginal Microbiome 
1.4.1.1 Vaginal Microbiome Development 
The mode of delivery (caesarean or vaginal) has impact on the baby’s whole-body 
biota, including the gastrointestinal tract, skin and first colonisation of the baby’s 
reproductive tract (Dominguez-Bello et al., 2010). 
Through childhood, the vaginal microbiota is sparsely populated with a variety of 
anaerobic bacteria, with few or no Lactobacilli spp. (Hammerschlag et al., 1978, Hill 
et al., 1995). In adolescence estrogen levels rise and Lactobacilli spp. become more 
prevalent while anaerobic populations begin to diminish (Thoma et al., 2011, 
Alvarez-Olmos et al., 2004). At reproductive age, estrogen cycling stimulates the 
thickening of the vaginal epithelium and in turn glycogen production, which is when 
Lactobacilli spp. become most abundant. Lactobacilli spp. help to maintain low pH 
by metabolising glycogen to produce lactic acid (Linhares et al., 2011). There is 
evidence that amylase is a key component in this process by breaking down glycogen 
into smaller components for Lactobacillus spp to metabolise (Spear et al., 2014). At 
menopause estrogen levels decline, the vaginal epithelium thins, Lactobacilli spp. 
diminish and anaerobes become more prevalent again (Muhleisen and Herbst-
Kralovetz, 2016). This is akin to the adolescent microbial profile suggesting a strong 
hormonal factor in driving microbial composition. 
1.4.1.2 Vaginal Microbiome Stability  
Most of our understanding of the vaginal microbiome has come from reproductive 
age women; fewer studies have been done on the stability of the vaginal microbiome 
in childhood or post-menopause. 
In a large study Ravel et al., (2011) recruited 396 healthy women across 4 ethnic 
groups, and sequenced their vaginal bacteria to assign taxonomic species. Bacterial 
profiling in these 396 women confirmed variability of bacterial at the phyla level 
between individuals. However, hierarchal clustering at the species level showed the 




of which there are 5. These community state types are defined by the dominance or 
absence of certain Lactobacillus spp. (Table 1.4). Ravel et al., (2011) concluded at 
95% confidence that women in North America will fit into one of these community 
state types. Nonetheless, it still remains that one in every 20 women will not have a 
bacteria profile which fits into one of these 5 groups. 
 
Community State Type Group Dominant Bacteria/ Defining Feature 
Group I Lactobacillus crispartus 
Group II Lactobacillus gasseri 
Group III Lactobacillus iners 
Group IV Little/no Lactobacillus spp., 
Atopobium, Prevotella, Sneathia, Gardnerella  
Group V Lactobacillus jenseni 
Table 1.4 Human Vaginal Community State Types (CST) 
Vaginal community state type group of reproductive age women. Summary as 
described by Ravel et al., (2011) 
 
CST IV, which is a group defined as having very little Lactobacillus spp., is 
interesting concerning vaginal homeostasis. Women with CST IV have a high 
Nugent score (Gram stain scoring system from vaginal swabs) because of the lack of 
Lactobacilli spp., however they are reported healthy and have not presented with 
symptomatic Bacterial Vaginosis (BV), which is dysbiosis of the vaginal microbiota. 
This is interesting as it highlights that the metabolic functions of bacteria in the 
vagina are most likely conserved. Lactobacillus spp. are not the only bacteria to 
produce lactic acid; Streptococcus spp. and Megaspherea spp. are also lactic acid 
producing bacteria (LAB). Community sate types vary across ethnic groups (Ravel et 
al., 2011); CST IV has a more frequent occurrence in black and Hispanic 
populations, which interestingly is also the ethnic group which displays the highest 
incidences of BV and PTL (Burris et al., 2011, Ness et al., 2003).  
Longitudinal sampling (16 weeks) of women’s vaginal bacteria show that CST is not 
a stable trait (Gajer et al., 2012). Women can transition between CST; some shifts are 




for driving these dynamic shifts remains to be determined. It is likely that estrogen, 
mechanism of menses, host genetics, microbicides and environmental factors all 
might play a role. Knowledge of CST kinetics is important because each community 
state type might differ in a risk to invasive diseases. A women’s relative risk 
therefore might be a factor of the duration spent in the more vulnerable community 
state types or transitioning between them. 
1.4.1.3 Vaginal Microbiome Dysbiosis  
Bacterial Vaginosis (BV) is a dysbiosis of the normal proportions of commensal 
microbial species in the vagina, commonly shifting towards a depletion of 
Lactobacilli spp., which are proposed to be the protective species in the healthy 
vagina. BV affects 30% of women of reproductive age, has a high rate of 
reoccurrence and is associated with a high risk of secondary infections (Lambert et 
al., 2013). 
Bacterial Vaginosis is a disease associated with increased inflammatory cytokines in 
cervicovaginal secretions and mucosal epithelial cell damage (reviewed in Kumar et 
al., (2011)). It has been proposed that this damage to the vaginal epithelial surface 
may play a role in the increased susceptibility of women with BV to sexually 
transmitted secondary infections/disease such as Neisseria gonorrhoeae, Chlamydia 
trachomatis and HIV (Taha et al., 1998, Wiesenfeld et al., 2003). A recent study 
suggests that the shedding of epithelial cells seen in patients with BV may be caused 
by a single organism, Gardnerella vaginalis (Gilbert et al., 2013). 
Genetic variation in immune-regulatory genes such as TLR-4, TLR-9, IL-8, IL-6 and 
TNF are associated with incidences of BV, suggesting host-immune genotype is 
important in the disease (Royse et al., 2012, Macones et al., 2004).  
The standard treatment for BV in the UK is a course of oral/intravaginal antibiotics, 
commonly metronidazole or in some cases clindamycin. As most women following 
this treatment course will clinically present with recurrent BV, metronidazole is 




1.4.2 Vaginal Microbiome in Pregnancy 
Using bacterial 16S rRNA gene sequencing Aagaard et al., (2012) compared the 
vaginal microbiome of pregnant women to those women not pregnant. Aagaard et al., 
(2012) showed that the pregnant bacterial complement is different, being less diverse 
to those women not pregnant. Romero et al., (2014) sampled women through 
pregnancy and classified their community state types as described by Ravel et al., 
(2011). The authors found the vaginal community of pregnant women differed to that 
of non-pregnant women; having a higher abundance of Lactobacillus 
vaginalis, Lactobacillus gasseri, Lactobacillus crispatus, and Lactobacillus jensenii. 
CSTs in pregnant women were also more stable than non-pregnant women; showing 
less CST shifts, which rarely included CST IV (group with little Lactobacillus spp.).  
MacIntyre et al., (2015) included vaginal samples taken after delivery and showed 
the postpartum community has a rapid decrease in Lactobacillus spp. The authors 
displayed Prevotella and Anaerococcus spp. were increased in replacement of the 
diminished Lactobacilli in a high proportion of postpartum women. It was proposed 
the quick drop in estrogen levels postpartum is causing this alteration in community 
structure. 
1.4.2.1 Bacterial Vaginosis in Pregnancy 
Although not generally a reportable disease, the occurrence of BV in pregnancy has 
been estimated to be around 50% (Nelson and Macones, 2002). There have been 
many studies that link dysbiosis of the vaginal microbiota, clinical BV and preterm 
labour (Gravett et al., 1986, Svare et al., 2006). BV identified before 20 weeks 
gestation has been indicated in preterm delivery and chorioamnionitis (Svare et al., 
2006). There is increasing support that certain prophylactic antibiotics given very 
early in pregnancy to those women who have a clinical diagnosis of BV has benefit 
(Thinkhamrop et al., 2015). 
Bacterial vaginosis is associated with lower vaginal concentrations of hBD3, but not 
hBD2 or HNP-3, in pregnant women (Balu et al., 2003, Mitchell et al., 2013). 




trimester of pregnancy, and Vitamin D can induce hCAP18/LL-37 and hBD2 gene 
expression in multiple cells (Wang et al., 2004b). 
1.4.2.2 Vaginal Microbiome and Preterm Labour 
Many bacterial species have been isolated from the amniotic fluid, placenta and 
chorion/amnion from pregnancies that have delivered preterm. The most common 
species observed are commensal bacteria from the lower genital tract and bacteria 
associated with bacterial vaginosis. Other bacteria such as those associated with 
STI’s and the gingival cavity have also been isolated from amniotic samples (Han et 
al., 2004, Mitchell et al., 2013).  
Hyman et al., (2014) studied the vaginal microbial diversity of women at high and 
low risk of preterm labour. The authors concluded that there were differences in the 
overall diversity between the two risk groups; showing a correlation between high 
alpha diversity and preterm labour (Hyman et al., 2014). As previously mentioned 
the type of material used in a cervical cerclage can have an impact on the vaginal 
microbiome (Kindinger et al., 2016). Using braided sutures over monofilament 
sutures increases the risk of women developing vaginal dysbiosis, inflammation, and 
preterm labour (Kindinger et al., 2016). Taken together, this supports the hypothesis 
that infection-induced preterm labour is associated with vaginal disruption of 
commensal bacteria as well as invading pathogens. 
 
1.4.3 Modulation of Vaginal Microbiome 
Vaginal Lactobacilli dominance in reproductive age women could be a protective 
mechanism to reduce pathogenies in the newborn infant. A baby’s first whole-body 
microbiome is highly correlated with the organisms exposed to at the peri-partum 
period. Those babies born by caesarean-section have microbiota resembling the 
mothers’ skin, whereas those born by natural delivery have microbiotas resembling 
the mother’s vagina. Multiple studies suggest that caesarean-section babies have a 




higher in caesarean section children (Sevelsted et al., 2016, Sevelsted et al., 2015). 
Caesarean section babies also pick-up more MRSA infections following birth than 
vaginally delivered babies (CDC, 2006). 
If the types of microbes in the mother’s vagina are pathogenic at the time of delivery, 
these can also be passed on to baby. Lactobacillus dominance during pregnancy 
could therefore have selective protective effects. Indeed as previously mentioned, 
Romero et al., (2014) had shown that Community state type IV (group defined by 
little/no Lactobacillus spp.) transition and occurrence was rarely seen in pregnant 
women.  
Probiotics have been considered as a therapy to colonise the vagina, by preventative 
prophylaxis or to treat dysbiosis/pathogenic infection. Probiotics have the ability to, 
selectively displace pathogenic organisms, provide metabolic compounds of different 
kinetics, and directly compete with the resident bacteria. In-vitro studies have shown 
that Lactobacillus spp. can disrupt biofilms of common BV associated bacteria and 
inhibit the growth of urogenital pathogens including yeast. Clinical studies have 
taken Lactobacillus spp. probiotics into women as a therapy for BV (Bradshaw and 
Brotman, 2015). The most promising Lactobacillus spp. in these studies is 
Lactobacillus rhamnosus GR-1, and Lactobacillus reuteri RC-14 (Martinez et al., 
2009). Studies have shown that orally administered Lactobacillus rhamnosus GR-1, 
and Lactobacillus reuteri RC-14 can be recovered from the vagina (Reid and Burton, 
2002), highlighting possible fecal-vaginal transfer of microorganisms. Combinations 
of these bacteria are currently sold as oral live-cultures to promote urogenital 
microbial health. 
 
1.4.4 Murine Vaginal Microbiome  
Animals offer researchers a vital tool by providing a model to test out host-
microbiome interactions under controlled environmental conditions. They also allow 




reproductive tract disease investigations, such as humanised mice as a model to study 
vaginal transmission of HIV (Deruaz and Luster, 2013). 
There has been very little work done on the commensal bacteria of the mouse 
reproductive tract, presumably due to its extremely low bacterial load and 
dependency on microbial burden in each animal facility.  
Previous bacterial species identified to reside in the murine reproductive tract has 
been through culture-dependent techniques (Noguchi et al., 2003). More work has 
focused on colonisation and clearance of exogenous bacteria both in a probiotic 
approach and in infectious models (Reid and Burton, 2002, Meysick and Garber, 
1992). 
There is very little known about the species level richness of bacteria that colonise 
the murine vaginal mucosa. Publications that use techniques such as qPCR and 
culture-dependent methods have shown that in contrast to humans, only a small 
percentage of female mice harbour Lactobacillus species at the vaginal mucosa 
(Noguchi et al., 2003, McGrory and Garber, 1992). Such culture-dependent studies 
listed Streptococci, gram-negative rods, Bacteroidaceae and Staphylococci as found 
in the non-pregnant vagina, however, these observations were not consistent and 
were highly variable (Noguchi et al., 2003).  
MacManes (2011) conducted a study looking at two different strains of wild mice, 
one known to be promiscuous and the other monogamous. By using 16S rRNA gene 
cloning and sanger sequencing MacManes (2011) showed that there was a greater 
degree of diversity in the vaginal bacteria of the promiscuous strain of mice.  
After review of the literature, only one study attempts to categorise the vaginal 
microbiome of lab animals using high throughput16S rRNA gene sequencing 
(Barfod et al., 2013). Barfod et al., (2013) study highlighted that the vaginal 
community of BALB/c mice is highly variable. Although the authors only had n=8 
samples they showed the vaginal community had two sub-clusters. One sub-cluster 
appeared to be closely related to the lung microbiota, whereas the other sub-cluster 




investigated (lung and cecum). Streptococcus (Gram-positive) was attributed to the 
separation of the two clusters; the authors also listed Acinetobacter, Sphinogmonas, 
Enterococcus and Polaromonas as genera from the vaginal mucosa.  
 
1.4.5 The Gut Microbiome 
Microbes in the gut are essential for the break down of complex carbohydrates where 
they can manipulate host metabolism by altering nutrient availability. The presence 
and abundance of each bacterial group is fundamental since different species 
differentially metabolise these nutrients.  
The stomach has the lowest bacterial loads of the gastrointestinal tract, where 
stomach acids maintain low bacteria numbers, the load then increases further from 
the stomach as pH levels become less acidic and more favourable for anaerobic 
growth. The mammalian gastrointestinal tract is dominated by two main phyla, 
Firmicutes and Bacteroidetes. Shifts in the ratio of these two phyla have been 
observed in many conditions such as obesity (Ley et al., 2006, Ley et al., 2005). Diet, 
age, host genetics, and local immune defence also influence on the community 
composition of these phyla (Mariat et al., 2009, Ussar et al., 2015, Salzman et al., 
2007). The Human Microbiome Project is an initiative which, using high throughput 
technologies, aims to characterise the microbiome across body sites associated with 
both health and disease (Peterson et al., 2009). 
The gut epithelium, as the outermost single cell layer of the gut, secretes many 
antimicrobial peptides including LL-37, defensins, but also S100 proteins, and C-
type leptins. Speciality cells such as Paneth cells also selectively secrete HDPs such 
as the human alpha defensin 5 (HD5) and human alpha defensin 6 (HD6). 
Interestingly HD6 has the ability to polymerize forming nanonets that are believed to 
prevent bacteria translocating across the gut wall (Chu et al., 2012). These Paneth 
cell defensins have also been shown to have anti-viral properties (Wang et al., 2013, 




Gut epithelia cells have multiple pattern recognition receptors, including the 
transmembrane TLRs, and also intracellular NOD receptors (Lavelle et al., 2010). 
These pattern recognition receptors are not uniformly expressed along the 
gastrointestinal tract. This is most probably a co-adaption strategy, to allow host 
tolerances of commensal and mutualistic species. For example in the gut, in a steady 
state, the numbers of TLR-4 and TLR-2 molecules are reduced, whereas TLR-3 
(viral ligand) and TLR-5 (flagellin ligand) are more abundant. Another co-adaption 
strategy to allow tolerances of commensals is the mucus barrier; this layer reduces 
the ability of the effector molecules to sense bacteria. The colonic mucus barrier has 
two constantly renewing layers; the innermost is predominantly kept sterile.  
Germ-free mice have shown that bacteria are essential for the development of normal 
gut epithelium. The major adaptor molecule MyD88 is essential for signalling via 
TLRs. The gut epithelia of MyD88 knockout mice show abnormal development 
(Frantz et al., 2012) and mice are consequently more susceptible to DSS colitis 
(Araki et al., 2005). This was supported in a conditional MyD88 knockout which 
displayed down regulation of mucus genes, antimicrobial peptides, and had 
compromised antibacterial immunity (Frantz et al., 2012). 
In the absence of infection and inflammation beta-defensins in humans and mice are 
not prominently expressed in the small intestine, although in the colon beta-defensins 
have been shown to be important (Meyer-Hoffert et al., 2008). 
Crohn's and IBD are linked to key deficiencies in HD5 and HD6 Paneth cell function 
(Wehkamp and Stange, 2010). Impaired induction of hBD2 and hBD3 have also 
been characterised in Crohn's disease (Wehkamp et al., 2003, O'Neil et al., 1999). 
Genomic variation in several defensin genes have been linked to the disease. 
Genome wide CNV profiling highlighted that low hBD2 copy number predisposes to 
Crohn’s disease (Fellermann et al., 2006), while a SNP in the DEFB1 gene (encodes 
hBD1) was associated with an increased risk (Kocsis et al., 2008). 
LL-37/Camp is upregulated during ileitis/colitis dependent on the level of 
inflammation (Schauber et al., 2006), and mice null for Camp have more severe 




Addition of exogenous CAMP could reverse some of the phenotypic severity of DSS 
treatment in Camp-/- animals, such as cytokine production, apoptosis and mucus 
production (Tai et al., 2013). Intracolonic CAMP peptide treatment in mice pre-
infected with Clostridium difficile also show large improvements in phenotypic 
consequences of the pathogen (Hing et al., 2013). Mice showed better colonic 
histology score, reduced apoptosis and supressed induction of myeloperoxidase 
(MPO) and TNF-α. Although, endogenous cathelicidin was not shown to have 
protective benefits in a similar model which delivered Clostridium difficile toxin A, 
to Camp-/- and wildtype mice (Hing et al., 2013), suggesting LL-37 has more effect 
on live bacteria in this model. 
Graft versus host disease, a possible deadly side effect of bone marrow and stem cell 
transplants, targets Paneth cells and causes subsequent impairment of defensin 
secretion in mice; including Defa1, Defa4, and Defa5 (Eriguchi et al., 2012). 
Interestingly, giving Blautia spp. to mice could protect them from graft versus host 
disease (Jenq et al., 2015). 
There has been direct evidence linking gut alpha-defensins to the modulation of 
microbiota in mice. Salzman et al., (2010) demonstrated that Paneth cell alpha-
defensins contributed to mucosal host defence and regulate the composition of 
murine intestinal microbiota. Mice deficient in defensins displayed increased 
Firmicutes and decreased Bacteriodes in the gut. Whereas mice expressing the 
human defensin (HD5) have Firmicutes decreased and increased Bacteriodes when 




1.4.6 Gut Microbiome in Pregnancy  
There are vast metabolic changes that occur during pregnancy, especially in late 
gestation, which could affect microbial communities. Different points in gestation 
have different biochemical and physiological changes that could also have temporal 
and dynamic impact on the microbiome. Indeed, alterations in the maternal 
gastrointestinal microbiome have been implicated in metabolic adaptations to 
pregnancy (Koren et al., 2012, Collado et al., 2008). Body weight is an obvious 
contributing factor; pre-pregnancy weight has been linked to microbial change, 
where obese mothers display higher bacterial diversity (Collado et al., 2008). Koren 
et al., (2012) demonstrated that the gut microbiome of pregnant women changed 
dramatically between the first and the third trimester, showing an increase in inter-
individual diversity. The authors also showed that the bacterial load of the gut 
changed with gestation; increasing from the first to the third-trimester. Conflicting 
reports whether pregnancy is truly connected with substantial shifts in gut bacteria, 
has come from a larger longitudinal study that failed to show significant remodelling 
of the gut microbiota in pregnant women (DiGiulio et al., 2015).  
 




Aims and Hypothesis 
The work in this thesis is based on the hypothesis that Host Defence Peptides play a 
fundamental role in mucosal immune defence. In a pregnant state, the hypothesis is 
that HDPs have a dual role in preventing ascending infection, but also preventing an 
exacerbated inflammatory response that can cause preterm birth by initiation of the 
labour cascade. 
To explore this I determine whether bacterial stimuli can regulate HDPs expression 
in pregnancy tissues. I also explore what interactions HDPs have on the 
production/induction of important cytokines, which are vital to the inflammatory 
response.  
As hBD3 and LL-37 suppress the inflammatory response of cells to LPS through 
TLR-4, the hypothesis is that in-vivo they might offer protection from preterm birth 
caused by inflammation. With the aid of HDP knockout mice, the role of these 
peptides in infection/inflammation and continuation of pregnancy is investigated in a 
mouse-model of induced preterm-labour. 
Infection-induced preterm labour in women is associated with vaginal disruption of 
commensal bacteria as well as invading pathogens. To understand how ascending 
infection might be controlled by HDPs in pregnancy, I explore how HDPs regulate 
commensal bacteria. This is achieved by interrogating the maternal microbiome at 






Chapter 2  





Chapter 2 General Materials and Methods  
2.1 Animal Experiments 
All mice were sourced ‘in-house’ and kept under specific pathogen free (SPF) 
conditions at the University of Edinburgh. Mice were permitted food and water ad 
libitum and maintained in 12-hour cycle of light and dark. Animal experiments were 
conducted under a UK Home Office licence in line with the Animals Scientific 
Procedure Act (1986). For full details of reagents and supplies, see Appendix on 
page 314.  
2.1.1 Fertility Experiments 
Virgin female mice were set-up in mating pairs within genotype with a stud male. 
During timed male exposure (96 hours), females were checked for the occurrence of 
a vaginal plug each morning. Once a vaginal plug was found the female was 
removed and monitored for subsequent confirmation of pregnancy. On day 17 of 
gestation females were culled and the number of viable fetus in-utero counted. The 
fertility of Camp-/- and Defb14-/- mice was determined by looking at several 
pregnancy indices; plug rate, pregnancy rate and first litter size. The plug rate was 
determined as the fraction of female mice where a copulatory plug was found, 
compared to the total number set-up. Subsequent pregnancy rate is the fraction of the 
plugged females who continued pregnancy to gestational day 17, compared to the 
total number plugged. First litter sizes are described here as the number of viable 






2.1.2 Preterm Birth Model; Laparotomy Method 
Virgin female mice were set-up in mating pairs with a Stud male of the same 
genotype and checked for a copulatory plug each morning. The day the copulatory 
plug was found is determined to be Day 0. On day 17 of murine gestation, pregnant 
dams were anaesthetised for surgery using Isoflurane with oxygen as standard 
(Isoflurane flow rate 5% for initial anaesthetisation, thereafter by 2.5% for 
maintenance). Vetergesic analgesic [0.05mg/kg] and intra-operative fluid support 
[25mls/kg] of sterile physiological saline [Sodium Chloride 0.9%] were both given 
subcutaneously. A laparotomy was then performed which involves making a small 
incision into the abdomen, where the uterine horns can be externalised from the 
abdominal cavity (Figure 2.1). Treatment of either 25µl sterile physiological saline 
[Sodium Chloride 0.9%] or 25µl of Ultrapure LPS (E.coli O111:B4) [0.8µg/µl] were 
injected between the first and second fetal sac using a Hamilton 33-gauge needle. 
The uterine horn selected for injection was the side with the greater number of 
fetuses. Uterine horns were then returned to the cavity; the abdominal wall was 
closed with rolling sutures and the skin closed with interrupted sutures. Dams 
initially recovered in post-surgery heated chambers and then transferred to cages 
with video recording equipment for observation. Labour was defined as the time 
when a single pup was delivered or found in the lower vagina, either by video or by 
observations. 
Non-surgery and non-aesthetic control animals were also set-up in cages in parallel 





Figure 2.1 Mouse Model of Preterm Labour; Laparotomy Method 
(a) Exposed uterine horns, (b) Intra-uterine injection of agent, (c) Uterine horns 






2.1.3 Preterm Birth Model; Ultrasound Method 
On day 17 of murine gestation, pregnant dams were anaesthetised using Isoflurane 
with oxygen as standard (Isoflurane flow rate 5% for initial anaesthetisation 
thereafter by 2.5% for maintenance). Treatment of either 25µl sterile physiological 
saline [Sodium Chloride 0.9%] or 25µl of LPS Ultrapure [0.8µg/µl] / [0.04µg/µl] 
were injected between two fetal sacs guided by ultrasound sonography (Figure 2.2). 
Dams were allowed to initially recover in post-procedure heated chambers and then 
transferred to cages with video recording equipment for observation. Labour was 
defined as the time when a single pup was delivered or found in the lower vagina, 
either by video or by observations. 
Non-surgery and non-aesthetic control animals were also set-up in cages in parallel 





Figure 2.2 Mouse Model of Preterm Labour; Ultrasound guided Injection 
Method 
(a) Intra-uterine injection of agent, (b) sonogram showing two fetal sacks and site of 
intra-uterine injection. Source: Adrian Thomson; Edinburgh Preclinical Imaging; 





2.1.4 Interval to Delivery and Number of Live-Born Pups 
Labour was defined as the time when a single pup was delivered or found in the 
lower vagina, either by video or by observation. Interval to delivery was recorded for 
each animal as the number of hours between injection and labour. Preterm labour is 
defined as an interval of <36 hours. The number of live-born pups was determined at 
the first observation following labour; any pups found live in-utero were not counted 
as ‘live-born’. The proportion of live-born pups was the number of viable fetus 
counted at the time of injection divided by the number of live-born.  
 
2.1.5 Timed Collection 
Preterm labour model was conducted as detailed in section 2.1.3, but animals were 
culled 6-hours post treatment by lethal CO2 exposure, where tissue (placenta, fetal 
membrane, uterus, vagina, and cervix) and blood serum were collected for molecular 
analysis. In parallel non-anaesthetic non-treatment day 17 pregnant females (NTxC) 
were also culled for control tissue and blood serum for comparison.  
Immediately after CO2 lethal exposure blood was collected by cardiac puncture using 
a 21-gauge needle into BD Microcontainers®. Blood was allowed to sit for 20 
minutes and then centrifuged at 8000 rpm for 5 minutes. The serum was then 
collected and centrifuged at 14000 rpm for 10 minutes at 4°C to pellet any remaining 
blood cells, supernatant was then stored at -80°C. 
All tissue collections and dissections were conducted on large sterile petri-dishes 
kept on ice. Where possible tissues were divided into 3 portions; 1) For RNA 
extraction; collected in RNAlater®, kept at 4°C and extracted within 48 hours. 2) 
For protein extraction; snap frozen on dry ice and stored at -80°C. 3) For histology; 
collected into 4% solution of paraformaldehyde, fixed overnight and then transferred 




The uterus was carefully dissected to release all fetal sacs. Uterine tissues were 
collected from both uterine horns (right and left), mid-way from the cervix. Fetal 
membranes were dissected from the placenta and pooled where possible, according 
to which uterine horn the fetal sac was obtained. One placenta from the left and right 
horn was dissected into two parts for RNA and Protein, a separate placenta from each 
horn was selected for histology. Vagina and cervix were excised internally, releasing 
any connecting tissues. Cross-sections of the cervix and vagina were taken for 
histology; remaining vagina and cervix tissue was collected for RNA extraction. 
 
2.1.6 Microbiome Sample Collection 
Sampling and methods for microbiome analysis are described in Chapter 4. For full 





2.1.7 HDP Expression in the Murine Reproductive Tract 
Experiments 
2.1.7.1 Estrus Cycling and Staging 
Eight week old C57BL/6N mice were super-ovulated with pregnant mare's serum 
gonadotropin (PMSG) and human chorionic gonadotropin (hCG) combination. 
Specifically, mice were given intraperitoneal administration of 5 IU of PMSG, 48 
hours later mice received intraperitoneal administration of 5 IU hCG. Animals were 
culled 18 hours after hCG injection by lethal CO2 exposure, where tissue (placenta, 
fetal membrane, ovary, uterus, vagina, and cervix) were collected for molecular 
analysis. Prior to tissue collection, vaginal cell cytology was also conducted to 
confirm all mice were in estrus stage at the time of collection (see below).  
2.1.7.2 Vaginal Cell Cytology 
Estrus cycling in mice is continuous but there are discrete phases; diestrus, proestrus, 
estrus and metestrus. Mouse estrus cycling is accompanied with vaginal 
manifestations in vaginal morphology and cell cytology. Cytological estrus staging 
requires the collection and staining of vaginal cells to characterise the proportions of; 
leukocytes, cornified squamous epithelial cells, and nucleated epithelial cells. Crystal 
violet was used for vaginal cell cytology in this study as described by McLean et al., 
(2012) (Figure 2.3). In brief, 200µl of sterile H2O is lavaged in the mouse vagina, 
smeared onto a glass slide and then air dried. Once dry, crystal violet solution 0.1% 
(w/v) is applied for 1 minute then the slide is washed in sterile water for a further 1 
minute. Slides are mounted in glycerol and imaged immediately. The number of 
cornified squamous epithelial cells, leukocytes, and nucleated epithelial cells are 
counted and the relative ratio of these cell types is used to determine estrus stage 






Figure 2.3 Mouse Vaginal Cytology for Estrus Staging 
Diestrus stage is mostly dominated by leukocytes, proestrus is mostly dominated by 
nucleated epithelial cells and estrus is mostly dominated by cornified epithelial cells. 





2.2 Molecular  
2.2.1 RNA Extraction and Reverse Transcription 
Two methods of RNA extraction were used in this study. All human tissues were 
extracted using the TRI reagent method; while all murine tissues were extracted 
using the RNA Bee method. The TRI Reagent method is the protocol of choice for 
the Edinburgh Reproductive Biobank and was implemented for uniformity across 
study-sets. For full details of reagents and supplies, see Appendix on page 314.  
2.2.1.1 TRI Reagent Method  
Tissue was transferred to 2ml tubes containing 1ml of TRI reagent® with sterile 
stainless steel bead. Homogenisation was supported using TissueLyser I for 2 x 3 
minutes at 25HZ. Samples were left to incubate for 15 minutes at room temperature 
then centrifuged at 14,000 rpm for 15 minutes maintained at 4°C. The supernatant 
was then transferred to phase-lock tubes and 200µl of bromochloropropane added, 
samples were then left to participate at room temperature for 15 minutes. Samples 
were centrifuged at 14,000 rpm for 15 minutes maintained at 4°C; the aqueous phase 
was then collected into equal volume of ice cold 70% ethanol. To isolate the RNA 
the RNeasy kit was used following the manufactures protocol. Isolated RNA was 
quantified on the Nanodrop ND-1000 at 260nm and 280nm as standard; all RNA is 
stored at -80°C.  
2.2.1.2 RNA Bee Method 
Tissue was transferred to 2 ml Lysing Matrix D tubes, containing 1ml of RNA Bee, 
then homogenised for 30 seconds at 5000 rpm on the Precellys®24 lyser. 100µl of 
chloroform was added and samples were left to incubate on ice for 5 minutes. 
Samples were then centrifuged at 10000 rpm for 15 minutes maintained at 4°C. The 
subsequent upper aqueous phase was transferred to a new tube containing equal parts 
of ice-cold isopropanol. Samples were then incubated at -20°C for 20 minutes and 




were washed twice with 75% ice cold ethanol and RNA was re-suspended in 20-
100µl RNase and DNase-free water.  
2.2.1.3 Reverse Transcription 
High-Capacity cDNA Reverse Transcription Kit was used to reverse transcribe RNA 
following the manufactures protocol for a 20µl reaction using oligo (dT) primers and 
1µg of each RNA sample. Where possible a representative reverse transcription 
negative (RT-NEG) and template negative (NTC-NEG) were included in each batch. 
cDNA was stored at -20°C until required. 
 
2.2.2 RT-qPCR 
The amount of mRNA transcript was quantified using qPCR, where the cDNA is 
amplified for specific genes of interest in the presence of fluorescent reporter probes 
and quenchers. The majority of the gene expression analysis in this study was done 
using pre-designed Taqman probes, which have been optimised for use on the ABI 
PRISM® 7000 Sequence Detection System. These probes were sourced from 
Applied Biosystems and are listed in Table 2.1. Some gene expression analysis was 
supported on the LightCycler® 480 Real-Time PCR System. For this approach, 
primers for specific genes of interest were designed to be compatible with the 
universal hydrolysis probes system (UPL), utilising the Universal ProbeLibrary 
Assay Design Center (Table 2.2). 
Several qPCR negatives (PCR-NTC) and reverse transcription negatives (RT-NEG) 
and calibrators were run on every plate. The individual calibrators (CAL) are detailed 






2.2.2.1 Taqman Assay (ABI PRISM)  
A reaction mix containing the ABI Taqman Mastermix (x2), template, reference gene 
Primer-Probe Assay (x20) or the primer-probe mix for the gene of interest were set 
up as per manufacturer’s instructions. cDNA template was diluted 1:2.5 in molecular 
grade water prior to reaction. All Taqman PCR primers are intron-spanning and the 
ABI assay ID numbers are given in Table 2.1. Samples were run in triplicate and 
PCR cycling and fluorescence detection was supported on the ABI PRISM® 7000 
Sequence Detection System. Standard 4 stage PCR cycling method was used; 50°C 
for 2 minutes, 95°C for 10 minutes, [95°C for 15 seconds, 60°C for 1 minute] 
repeated for 35 cycles.  
 
Gene Human/Mouse ABI Assay ID 
Defb14  Mouse Mm00806979_m1 
Camp  Mouse Mm00438285_m1 
Cxcl1 Mouse Mm04207460_m1 
Cxcl2 Mouse Mm00436450_m1 
Il-1β Mouse Mm00434228_m1 
Tnf Mouse Mm00443258_m1 
Ptgs2 Mouse Mn00478374_m1 
Atcb Mouse 4352341E (cat number) 
DEFB103 (hBD3) Human  Hs00218678_m1 
CAMP (LL-37) Human Hs00189038_m1 
ACTB Human 4310881E (cat number) 
18S Eukaryotic  4319413E (cat number) 





2.2.2.2 Universal ProbeLibrary Assay (Roche LightCycler) 
A reaction mix containing the LightCycler Mastermix, template, reference gene 
primer-probe mix or the primer-probe mix for the gene of interest were set up as per 
manufacturers instruction. All samples were run in triplicate and PCR cycling and 
fluorescence detection was supported on the LightCycler® 480 Real-Time PCR 
System. cDNA template was diluted 1:2.5 in molecular grade water prior to reaction. 
All PCR primers were synthesised by Sigma and are intron-spanning; the primer 
sequences and corresponding UPL probe ID numbers are given in Table 2.2. The 
efficiencies of each primer and probe-set were evaluated using a serial dilution of a 
calibrator cDNA sample (epididymis cDNA). All efficiencies were within the 
acceptable range of E= 1.9-2.1. Mouse beta-actin (Actb) predesigned primer-probe 
mix was used as the reference gene control for all samples. For all primer-probe pairs 
the PCR cycling parameters were; 95°C for 10 minutes, [95°C for 15 seconds, 60°C 




Forward Primer (5’-3’) 
Reverse Primer (5’-3’) 

















Actb N/A Pre-designed primer-probe mix 
Table 2.2 Primers and Probes Designed in Universal ProbeLibrary 




2.2.2.3 RT-qPCR analysis method 
All qPCR in this study were set up in technical triplicates where any intra-sample 
outliers were removed. Ct value is the cycle at which the fluorescence signal crosses 
a threshold, where the threshold is an estimate of the first point where samples are in 
exponential phase above background. Ct values were normalise to the reference gene 
and then samples compared to calibrator using the formula 2
-ΔΔCT
. This gives a fold 
change in gene expression of the target relative to the calibrator. This method also 
allows comparison across multiple plates if the same calibrator is used. Where two 
reference genes were used as the control, their geometric mean was used to 
normalise the Ct value of the gene of interest.  
 
2.2.3 ELISA 
ELISA quantitatively measures the amount of a protein of interest in solution by 
comparing to a known sample using a serial dilution. Sandwich ELISA involves 
coating a plate with monoclonal antibody raised against the protein of interest. After 
the protein of interest is bound to this primary antibody, a secondary antibody that 
has an epitope for the protein is then bound. These secondary antibodies are coupled 
to substrates that allow for detection and quantitative measurement.  
All ELISA kits in this study were R&D duosets, the detection range for each protein 
is given in Table 2.3. All ELISA in this study were conducted using the following 
protocol. Flat-bottom ELISA plates were coated with 50µl of capture antibody, 
diluted appropriately in PBS, and incubated overnight at room temperature. Plates 
were then washed 3 times in PBS-Tween (0.05%) to remove unbound antibody and 
blocked for 2 hours in 0.5% (v/v) Reagent Dilute Concentrate in PBS. After removal 
of the blocking solution, 50µl of sample was added to the plate in duplicate. In this 
study all blood serum and cell culture supernatants were diluted 1:5 in Reagent 
Diluent. Serial dilution of standards were also made in Reagent diluent and added in 
duplicate in 50µl volumes. Plates were incubated overnight at 4°C and then washed 3 




applied and incubated overnight at 4°C, thereafter washed 3 times in PBS-Tween 
(0.05%). Following this, 50µl of HRP-conjugated antibody was applied to each well 
and incubated at room temperature for 30 minutes. Wells were washed 3 times in 
PBS-Tween (0.05%), and then 50µl of substrate (TMB solution) was added to each 
well to detect activity. Reactions were stopped with 25µl of acid solution (1N HCL). 
The intensity of the colour was measured using spectrophotometry with absorbance 
at 450nm and corrected for background at 570nnm. 
 
R&D duosets Detection Range 
Human TNF DuoSet ELISA 2000 – 31 pg/ml 
Human Il-8 DuoSet ELISA 2000 – 31 pg/ml 
Human IL-1β DuoSet ELISA 250 – 4 pg/ml 
Human RANTES DuoSet ELISA 2000 – 31 pg/ml 
Human IL-6 DuoSet ELISA 1300 – 20 pg/ml 
Human IP-10 DuoSet ELISA 1000 – 16 pg/ml 
Mouse IL-6 DuoSet ELISA 2000 – 31 pg/ml 
Mouse TNF DuoSet ELISA 2000 – 31 pg/ml 
Mouse IL-1β DuoSet ELISA 1000 – 16 pg/ml 






2.3 HDPs in Placental Explants Experiment 
Placenta was obtained from women undergoing elective Caesarean section at 38-39 
weeks. All women were healthy, non-smokers with a normal BMI. Women had no 
indication of infection and all were singleton pregnancies. 
Full thickness placental lobule was collected from the central cotyledons region of 
the placenta and transported directly to the lab in PBS. Placenta tissue was washed 5 
times in sterile PBS and the chorionic surface removed. Any visible connective tissue 
deposits and blood clots were also removed. Villous tissue was obtained from the 
middle cross-section where 0.05g was placed in each well of a 24-well flat bottom 
culture dish. Each well contained 1ml of pre-warmed RPMI 1640 media with 10% 
fetal calf serum (FCS) and penicillin and streptomycin [50ug/ml]. Tissues were left 
to acclimatise for 1 hour in 5% CO2 at 37°C before treatments applied. Treatments 
and concentrations are detailed in section 3.3.2. The scrambled LL-37 peptide 
sequence is RSLEGTDRFPFVRLKNSRKLEFKDIKGIKREQFVKIL. All treatments 
were applied in triplicate and cultures incubated in 5% CO2 at 37°C for 3 hours, 
unless detailed otherwise. Culture supernatant was collected and centrifuged at 800 
rpm for 10 minutes maintained at 4°C to remove debris. To further pellet red blood 
cells this supernatant was transferred to a new tube and centrifuged at 8000 rpm for 
10 minutes maintained at 4°C. Final supernatants were used immediately for LDA 
assay or stored in aliquots at -80°C. Placenta tissue was blotted dry on sterile paper 
and collected in RNAlater for RNA extraction as described in section 2.2.1.1. For 
full details of reagents and supplies, see Appendix on page 314.  
2.3.1 LDH assay 
Cytotoxicity of each treatment was measured using Pierce™ LDH Cytotoxicity 






2.4 HDPs in Human Term Labour study 
Human myometrium, fetal membrane, and placenta tissue was obtained from the 
Edinburgh Reproductive Biobank; REC number 13/ES/0126. Informed consent was 
obtained and approved under South East Scotland Scottish Academic Health 
Sciences Collaboration (SAHSC) Human Annotated BioResource (HAB). Tissues 
were collected from healthy singleton pregnancies undergoing elective Caesarean 
section. All samples were collected into RNAlater and stored at -80°C until RNA 











Chapter 3 Host Defence Peptides 
3.1 Introduction 
Nearly 40% of all preterm deliveries are associated with intrauterine infection and/or 
clinical inflammation (Romero et al., 2006). The female reproductive tract has 
biochemical and physiological barriers to prevent bacteria ascending from the vagina 
into the amniotic cavity during pregnancy. These physiological barriers include the 
cervix and fetal membranes which also produce multiple Host Defence Peptides; key 
mediators in defence against invading pathogens. HDPs are released by epithelial 
cells, trophoblastic cells and immune cells where their action can be by disrupting 
bacteria cell membranes, but also by an array of immunomodulatory processes.  
Labour is generally accepted to be an inflammatory event where the emphasis from 
an anti-inflammatory pregnancy state shifts pro-inflammatory preceding labour 
(Youssef et al., 2009). 
hBD3 and the murine orthologue DEFB14 have potent anti-inflammatory effects 
shown both in-vitro and in-vivo (Semple et al., 2010, Semple et al., 2011). Exposure 
of human and mouse primary monocytes to LPS in the presence of hBD3 effectively 
inhibited the TLR-4 mediated TNF, IL-6 and type I interferon responses (Semple et 
al., 2010). This inhibitory response has been shown to be through both the MyD88 
and TRIF pathways. Contrastingly, a study has also suggested hBD3 can be pro-
inflammatory when mediated by TLR1/2 (Funderburg et al., 2007). Funderburg et 
al., (2007) displayed that hBD3 increases the production of co-stimulatory molecules 
on monocytes and dendritic cells enhancing their chemoattractant potential. The 
chemoattractant property of hBD3 has also been shown in many other cell types, 
such as T cells, immature dendritic cells and macrophages (Wu et al., 2003, Yang et 
al., 1999). Other pro-inflammatory properties of hBD3 are displayed in its potential 
to exacerbate the MDA5 cytoplasmic receptor in response to dsRNA, a viral ligand 




LL-37 has been shown to have biphasic action, having both pro-inflammatory and 
anti-inflammatory functions. In human monocytes, exogenous LL-37 can inhibit the 
release of the pro-inflammatory cytokine TNF in response to LPS. This has also been 
shown for the mouse peptide CAMP on BMDMs (Pinheiro da Silva et al., 2009). LL-
37 can also inhibit the pro-inflammatory response to PAMPS in other myeloid cells 
(Mookherjee et al., 2006). The anti-endotoxic effects of LL-37 and the mouse 
orthologue CAMP have been mostly attributed to their ability to directly bind to LPS 
(Scott et al., 2000, Scott et al., 2011).  
With regard to promoting inflammation, exogenous LL-37 in-vitro increases the 
production of cytokines and chemokine such as IL-8 and IL-6 in lung epithelial cells 
(Tjabringa et al., 2003, Pistolic et al., 2009), skin cells (Niyonsaba et al., 2007), and 
cervical epithelial cells (Frew et al., 2014). LL-37 also preferentially promotes 
apoptosis in lung epithelial cells in the presence of an infection (Barlow et al., 2006) 
and is a potent modifier of dendritic cell differentiation (Davidson et al., 2004). 
In a pregnant state the hypothesis of this chapter is that HDPs have a dual role, in 
preventing ascending infection, and also preventing an exacerbated inflammatory 
response that can cause preterm birth by initiation of the labour cascade. The 
immunomodulatory effects of LL-37 and hBD3 in reproductive tissues in response to 
bacterial stimuli has not been well studied. The spatial function most likely reflects 
the differing immunological requirements along the length of the female 
reproductive tract and pregnancy tissues. 
This chapter investigates whether the HDPs, hBD3 and LL-37, are affected by the 
inflammatory cascade of normal term labour. This was done by looking at the 
mRNA gene expression in the myometrium, amnion/chorion, and placenta of women 
in either labour at term or not in labour at term. These tissues were chosen for the 
relative ease of collection. 
To test the anti-inflammatory properties of HDPs in pregnancy I investigated the 
effects of endogenous LL-37 and hBD3 on placental explants in response to bacterial 




however, it is reported that different trophoblast cell lines express differences in cell 
surface markers when cultured in isolation (Nakada et al., 2011, Grasso et al., 2014).  
I also determined the expression of the mouse orthologues of LL-37 and hBD3; 




3.2 Experimental Details 
3.2.1 Patient Characteristics 
HDPs in Labour Study 
Human myometrium, fetal membrane, and placenta tissue were obtained from the 
Edinburgh Reproductive Biobank. Tissues were collected from healthy singleton 
pregnancies from women undergoing caesarean sections. All non-labouring women 
had no evidence of cervical dilatation. Those women in labour had spontaneous 
induction of labour but failed to progress and underwent caesarean section. All 
samples were selected on the criteria that women were non-smokers, had healthy 
BMI with no signs of an infection including chorioamnionitis 
 
Clinical Details Non-Labour (n=7) Labour (n=8) 
Maternal Age (years) 38 ± 1.4 31 ± 2.1 
Maternal BMI (kg/m
2
)^ 27 ± 0.87 23 ± 1.2 
Gestation at collection (weeks) 39 ± 0.22 41 ± 0.29 
Parity  1.1 ± 0.26 0.38 ± 0.18 
Sex of baby (M; F) 2 ; 5 4 ; 4 
Dilatation at CS nil 6 ± 2.5 cm 
Table 3.1 Clinical Details of Patients; HDPs in Labour study 






HDPs in Placental Explants Study 
Placenta was collected from women undergoing elective caesarean section at 38-39 
weeks and immediately processed for ex-vivo experiments as detailed in section 2.3. 
All women were healthy non-smokers with a normal BMI, had no indication of 
infection, and were all singleton pregnancies.  
 
Clinical Details No Labour (n=3) 
Maternal Age (years) 33 ± 2.4 
Maternal BMI (kg/m
2
)^ 28 ± 1.4 
Gestation at collection (weeks) 39 ± 0.12 
Parity  1.0 ± 0.20 
Sex of baby (M; F) 2 ; 1 
Dilatation at CS nil 
Table 3.2 Clinical Details of Patients; HDPs in Placental Explants study 
Data presented as mean and SEM. ^ at first trimester antenatal visit.  
 
 
3.2.2 Assays and Statistical Analysis 
RT-qPCR; HDPs in Labour Study 
The level of DEFB103, CAMP, and TNF gene transcripts in myometrium, placenta 
and amnion/chorion tissues was measured by RT-qPCR as described in section 2.2.2. 
As detailed, the Ct values were normalised to the geometric mean of the reference 
genes, ACTIN and 18S. Values were then compared to a calibrator sample (CAL) 
which was from myometrial tissue. CAMP and DEFB103 expression data was log 
transformed prior to analysis. Unpaired t-test was conducted that compared the 





RT-qPCR; HDPs in Placental Explants Study 
The level of DEFB103, CAMP, and TNF gene transcripts in placenta was measured 
by RT-qPCR as previously described. Samples were normalised to a calibrator 
(CAL) from a placenta explant tissue that received no treatment.  
For TNF gene transcript (excluding hBD3 treatment), a two-way ANOVA with 
Tukey’s post-test compared to no-peptide treatments within LPS groups was 
performed. Significant interactions in LPS treatment were identified with 
Bonferroni's post-test compared to no-treatment groups. As there was no hBD3 
peptide only group, the effect of hBD3 peptide was measured by paired t-test 
between LPS [100ng/ml] alone and LPS [100ng/ml] + hBD3 [25µg/ml] group.  
Significant differences in the level of DEFB103 and CAMP in response to LPS were 
conducted using a paired t-test comparing no-treatment to LPS alone.  
RT-qPCR; HDPs in Murine Reproductive Tract 
The mouse beta-defensins; Defb1, Defb4, Defb6, Defb14, the alpha defensin, Defa5, 
and the murine cathelicidin, Camp, transcripts were measured in ovary, uterus, cervix 
and vagina by RT-qPCR as described in section 2.2.2. The Ct values were 
normalised to the reference gene, Actb. Where a calibrator was used to normalise 
values; the calibrator was from epididymis tissue. Data presented as mean fold 
change and SEM relative to either the calibrator (CAL) or mean expression in the 
ovary. 
ELISA; HDPs in Placental Explants Study 
To detect the amount of secreted protein in culture supernatants from human placenta 
explants post-treatment, ELISA’s were conducted as described in section 2.2.3. The 
proteins of interest were TNF, IL-8, IL-6, IL-1β, IP-10, and RANTES. 
All ELISA data is presented as the mean concentration ± SEM. Two-way ANOVA 
was used to highlight the effect of the presence of LPS and LL-37 compared to 




Tukey’s post-test. A two-way ANOVA with Dunnett’s post-test for matched samples 
was conducted on the data looking at LPS effect over time. One-way ANOVA with 
Dunnett’s post-test was conducted when comparing dose of LL-37 with LPS 
treatment. 
As there was no hBD3 peptide only group, the effect of hBD3 peptide was measured 
by paired t-test between LPS [100ng/ml] alone and LPS [100ng/ml] + hBD3 





3.3.1 HDPs in Human Term Labour  
The level of DEFB103 (Figure 3.1) and CAMP (Figure 3.2) gene transcripts was 
measured by RT-qPCR in myometrium, placenta and amnion/chorion tissues 
collected from term pregnancies of women not in labour (n=7) and in labour (n=8). 
3.3.1.1 Human beta-defensin 3 in Term-Labour 
There was a small but significant increase in DEFB103 levels in myometrium from 
women in labour compared to myometrium from women not in labour (unpaired t-
test; P <0.05) (Figure 3.1). Compared to non-labouring samples, labour increased the 
average DEFB103 expression in the myometrium 18.7 ± 13.4 fold. Labour, however, 
did not affect the mRNA expression level of DEFB103 in the placenta or 
amnion/chorion in this study. 
 
Figure 3.1 Expression of DEFB103 (hBD3) during Term Labour  
Relative DEFB103 mRNA gene expression in myometrium, placenta and 
amnion/chorion tissues collected from non-labouring women (n=≥5) and women in 
labour (n=≥5). Normalised to β-ACTIN and 18S, relative to calibrator (CAL). 





3.3.1.2 Human Cathelicidin in Term-Labour  
There was a small but significant increase in CAMP mRNA gene expression in 
placenta tissue from women in labour compared to placenta from women not in 
labour (unpaired t-test; P <0.05) (Figure 3.2). Placental tissue from women in labour 
displayed a 6.8 ± 3.1 mean fold increase compared to tissue from women not in 
labour. Labour did not affect the mRNA expression level of CAMP in the 
myometrium or amnion/chorion. 
 
 
Figure 3.2 Expression of CAMP (LL-37) during Term Labour 
Relative CAMP gene expression in myometrium, placenta and amnion/chorion 
tissues collected from non-labouring women (n=≥6) and women in labour (n=≥6). 
Data presented as mean and SEM, normalised to β-ACTIN and 18S, relative to 






3.3.2 HDP Anti-inflammatory effect on Placental Explants  
To investigate the effects of HDPs on the inflammation caused by infection, placenta 
tissue explants were cultured with LPS in combination with exogenous peptides of 
hBD3, LL-37 and scrambled LL-37 control. Placenta was collected from women 
undergoing caesarean section at term (n=3), but prior to the initiation of labour. The 
main read-out of inflammation was the secreted pro-inflammatory cytokine TNF, 
which was assessed by ELISA in culture supernatants as described in section 2.2.3. 
Other secreted cytokine levels were also determined; IL-8, IL-6, IL-1β, IP-10 
(CXCL10), and RANTES (Regulated on Activation, Normal T Cell Expressed and 
Secreted) as measured by ELISA. TNF mRNA gene expression levels were assessed 
by RT-qPCR as described in section 2.2.2. 
Cytotoxicity assay showed that LPS and exogenous HDP treatments did not induce 
any significant cell death in the doses and time-points investigated here compared to 






3.3.2.1 LPS Dose and Time Response in Placental Explants 
The time and dose-responsive effects of LPS on placental explants was determined 
by culturing at two LPS doses, 1µg/ml or 100ng/ml for 24 hours. Culture 
supernatants were taken at 1, 3, 6 and 24 hours post treatment, and the amount of the 
pro-inflammatory cytokine TNF was measured by ELISA (Figure 3.3). 
1µg/ml and 100ng/ml of LPS both increased TNF secretion significantly compared 
to non-LPS treated samples at all time-points considered (two-way ANOVA with 
Dunnett’s post-test; P <0.0001). 100ng of LPS appeared to produce less secreted 
TNF compared to 1µg at all time-points, but this was not significant in this small 
sample size with repeated measures. Nonetheless, as the lower dose of 100ng LPS 
could elicit a robust TNF response, this dose was chosen for subsequent experiments 
to be closer to physiological/clinical levels of LPS (Guo et al., 2013). As TNF 
protein levels in this system peak at 6-hours; culture supernatants in subsequent 
experiments were collected at 3-hours post treatment to capture initial TNF response 





Figure 3.3 Placental Explants; TNF levels in LPS dose and Time 
Response 
TNF protein levels from cultures supernatants as measured by ELISA. Presented as 
mean and SD of technical replicates, n=3 per group. All treated samples are from one 
patient. (Two-way ANOVA with Dunnett’s post-test; P <0.0001 for LPS effect at all 
time-points, no significant difference in 1µg compared to 100ng LPS dose at any 





3.3.2.2 LL-37 Dose Response in Placental Explants 
The effect of LL-37 on LPS-induced inflammation in the placenta was determined by 
culturing explants with increasing doses of exogenous LL-37 peptide in the presence 
of 100ng/ml of LPS. Culture supernatants were taken at 3-hours post treatment and 
the amount of the secreted pro-inflammatory cytokine TNF was measured by ELISA 
(Figure 3.4). 
In placental explants from all 3 patients; increasing the dose of LL-37 peptide 
reduced the levels of secreted TNF in response to 100ng/ml of LPS. This reached 
statistical significance at 25µg/ml of LL-37 (one-way ANOVA with Dunnett’s post-
test; **, P <0.01 compared to LPS alone). 
 
 
Figure 3.4 Placental Explants; TNF levels in LL-37 Dose Response 
TNF protein levels from cultures supernatants with 100ng/ml of LPS and increasing 
doses of LL-37. All data presented as mean and SD of technical replicates, n=3 per 






3.3.2.3 HDPs in Placental Explants  
To confirm that the anti-inflammatory effects of LL-37 were specific to the addition 
of the peptide, scrambled peptide control (Control) was also used as a treatment at 
the optimal dose seen for LL-37, [25µg/ml]. In addition, placental explants were also 
treated with hBD3 peptide at 5µg/ml; a dose previously shown to have anti-
inflammatory functions in human and mouse macrophages (Semple et al., 2010). The 
secreted cytokines; TNF, IL-8, IL-6, IL-1β, IP-10, and RANTES were measured by 
ELISA (Figure 3.5). TNF (Figure 3.6), CAMP and DEFB103 (Figure 3.7) mRNA 
gene expression levels were also assessed in these treated placenta tissues by RT-
qPCR. 
Exogenous scrambled control peptide or LL-37 alone, had no effect on the secretion 
of IL-1β, IL-8 or IL-6 (two-way ANOVA’s with Tukey’s post-test) (Figure 3.5). LL-
37 treatment alone however, did show a small but significant decrease in TNF 
protein level in culture supernatants (Figure 3.5.c) (two-way ANOVA with Tukey’s 
post-test; P <0.05 compared to no treatment). 
Addition of 100ng/ml of LPS to placental explants robustly and significantly 
increased the levels of; IL-8 (P <0.01), IL-6 (P <0.05), TNF (P <0.0001), and IL-1β 
(P <0.0001) in culture supernatants collected 3-hours post treatment (two-way 
ANOVA; Bonferroni's post-test; no treatment compared to LPS only). LPS treatment 






Figure 3.5 Effects of HDPs on Cytokine Secretion in Placenta Explants 
Placenta explant cultures (n=3 patients) cytokine secretion after treatment; LPS 
[100ng/ml], control scrambled peptide [25µg/ml], LL-37 [25µg/ml] and hBD3 
[5µg/ml]. (a) IL-8 (b) IL-6 (c) TNF (d) IL-1β (e) IP-10 and (f) RANTES protein 
measured by ELISA in culture supernatants 3 hours post-treatment. All data 
presented as mean concentration and SEM. (Two-way ANOVA (excluding hBD3 
treatment), with Tukey’s post-test; *, P <0.05, **, P <0.01, ***, P<0.001 compared 
to no-peptide treatments within LPS groups. Paired t-test comparing hDB3+LPS 




LL-37 was able to significantly reduce the LPS induced increase in IL-8 (P <0.05), 
IL-6 (P <0.0001), TNF (P <0.0001), and IL-1β (P <0.0001). The addition of 
scrambled control peptide did not result in any significant change in levels of any 
cytokine compared to LPS treatment alone (two-way ANOVA with Tukey’s post-
test; compared to LPS alone).  
hBD3 treatment did not have an effect on the levels of any of the cytokines measured 
in an environment of 100ng/ml of LPS (paired t-test, hBD3+LPS compared to LPS 
alone).  
Although IP-10 and RANTES did not respond to LPS treatment, LL-37 peptide 
treatment alone did result in increased IP-10 (P <0.001) and RANTES (P <0.001) 
compared to no-treatment. As scrambled control peptide was also able to induce a 
significant RANTES response this effect does not look peptide specific. In addition 
IP-10 levels were at the lower limits of detection in this system and more likely 





To investigate whether the levels of TNF were also affected at the mRNA level, TNF 
gene expression was measured in the placental explants in response to LPS and 
HDPs by RT-qPCR (Figure 3.6). Exogenous scrambled control peptide or LL-37 
alone had no effect on TNF gene expression (two-way ANOVA with Tukey’s post-
test). Addition of 100ng/ml LPS to placental explants significantly increased TNF (P 
<0.01) in tissue collected 3-hours post treatment (two-way ANOVA; Bonferroni's 
post-test; no treatment compared to LPS only). Exogenous LL-37 (P <0.05) but not 
scrambled control peptide was able to significantly reduce the LPS-induced rise in 
TNF mRNA expression. 
 
Figure 3.6 Effects of HDPs on TNF Gene Expression in Placenta 
Explants 
Relative TNF gene expression levels in placenta explant cultures (n=3 patients) after 
treatment with; LPS [100ng/ml], control scrambled peptide [25µg/ml], LL-37 
[25µg/ml] and hBD3 [5µg/ml]. Data presented is mean fold-increase and SEM, 
normalised to β-ACTIN and 18S, relative to CAL (Two-way ANOVA (excluding 
hBD3 treatment) with Tukey’s post-test; *, P <0.05 compared to no-peptide 
treatments within LPS groups. Two-way ANOVA (excluding hBD3 treatment) with 
Bonferroni's post-test; ##, P <0.01 no-treatment compared to LPS only. Paired t-test 




Levels of endogenous DEFB103 (hBD3) and CAMP (LL-37) were measured by RT-
qPCR in placental explants from no treatment compared to LPS [100ng/ml]. There 
was a trend for both of the HDPs to be increased following LPS treatment but neither 
reached significance in the sample size of 3 (paired t-test) 
 
 
Figure 3.7 Endogenous DEFB103 and CAMP mRNA in Placental 
Explants 
Relative (a) DEFB103 and (b) CAMP gene expression levels in placenta explant 
cultures (n=3 patients) with no-treatment (NTxC) or LPS [100ng/ml]. Data presented 
is mean and SEM, normalised to β-ACTIN and 18S relative to calibrator (CAL). 







3.3.3 HDPs in the Murine Reproductive Tract 
The relative expression of multiple defensin genes and cathelicidin were determined 
by RT-qPCR in non-pregnant C57BL/6N mice (n=6) (Figure 3.8). To account for 
variation in HDP gene expression during estrus cycling; mice were super-ovulated 
with PMSG/hCG combination prior to tissue collection as detailed in section 2.1.7.1. 
Vaginal lavages were also taken and stained with crystal violet to confirm vaginal 
cell cytology was similar across all mice as described in section 2.1.7.2. The genes 
considered were the mouse beta-defensins; Defb1, Defb4, Defb6, Defb14, the alpha 
defensin Defa5, and the murine cathelicidin Camp. Relative gene expression results 
are displayed compared to samples from the ovary, which was the site of lowest 
expression of all the defensins but not cathelicidin. 
All beta-defensins investigated in this chapter show spatial expression patterns along 
the female reproductive tract. Beta-defensins were found to be highly expressed in 
tissues of the lower reproductive tract; the vagina and cervix. Comparatively there 
was lower expression of beta-defensins in tissues collected from the upper 
reproductive tract; the uterus and ovary. The mouse cathelicidin, Camp, displayed 
contrasting mRNA gene expression patterns to that of beta-defensins. Camp was 
only expressed at low levels in the vagina and had higher expression in the cervix, 
uterus and ovary (Figure 3.8.f). 
Defb1 was expressed in vaginal tissues 2840 ± 476 fold higher than tissue from the 
ovary (Figure 3.8.a). Similarly, although high variation in a small sample size, the 
vaginal expression of Defb6 and Defb4 was on average 377 ± 134 and 5416 ±1476-
fold higher respectively, compared to the expression in the ovary (Figure 3.8.b, 
Figure 3.8.d). Defa5 was expressed in all tissues of the reproductive tract but did not 





Figure 3.8 HDPs Gene Expression in the Mouse Reproductive Tract 
Relative gene expression of (a) Defb1, (b) Defb4, (c) Defb14, (d) Defb6, (e) Defa5, 
and (f) Camp in non-pregnant mouse (n=6) tissue from ovary, uterus, cervix and 
vagina. Data presented as mean fold change and SEM, normalised to β-Actin, relative 
to ovary. (one-way ANOVA with Dunnett's post-test compared to ovary; *, P <0.05, 




3.3.3.1 Murine Defb14 (hBD3 orthologue) in Pregnancy 
The mRNA gene expression of Defb14 was assessed in the uterus, placenta and fetal 
membrane of C57BL/6N mice on day 17 of gestation (Figure 3.9). The uterus and 
placenta were positive for low levels of Defb14 mRNA transcript but this was not 
reliably detected in fetal membrane tissues from the same animals in a steady-state. 
 
Figure 3.9 Defb14 Gene Expression in Mouse Pregnancy Tissues 
Relative Defb14 gene expression in uterus (n=4), placenta (n=5) and fetal membrane 
tissues (n=5) in C57BL/6N mice. Data presented as mean and SEM, normalised to β-







3.3.3.2 Murine Camp (LL-37 orthologue) in Pregnancy 
The mRNA gene expression of Camp was also assessed in the uterus, placenta and 
fetal membrane of C57BL/6N mice on day 17 of gestation (Figure 3.10). All tissues 
were positive for low levels of Camp gene by RT-qPCR. In a steady-state, the 
expression of Camp in the placenta and fetal membrane is higher than in the uterus. 
 
 
Figure 3.10 Camp Gene Expression in Mouse Pregnancy Tissues 
Relative Camp gene expression in uterus (n=3), placenta (n=3) and fetal membrane 
tissues (n=3) in C57BL/6N mice. Data presented as mean and SEM, normalised to β-




3.4 Discussion  
HDPs in Labour  
In tissues and cells not of the reproductive tract, HDPs have been shown to modulate 
inflammation. Infection and inflammation are frequently associated with preterm 
labour in women. Preterm and term labour share a common terminal pathway 
characterised by anatomical, biochemical, and endocrine events (Snegovskikh et al., 
2006). One aim of this chapter was to determine the effect of human term labour on 
the expression of HDPs in the fetal membranes, myometrium and placenta of 
women.  
There was a small but significant increase in DEFB103 levels in labouring tissue of 
the myometrium compared to non-labouring tissue. In humans, six of the beta-
defensin genes on chromosome 8 are copy number variable, this includes DEFB103. 
Copy number has been shown to correlate with the protein expression and peptide 
level (Hollox et al., 2008, Jansen et al., 2009, Fellermann et al., 2006). The beta-
defensin copy number of the women in this chapter was not determined, and could 
account for some inter- patient variation in gene transcript levels.  
In the placenta there was a slight increase in CAMP gene expression in labour 
compared to non-labouring women. No difference in CAMP gene level was seen in 
the myometrium or amnion/chorion. This leads to the conclusion that resident 
epithelial cells of the myometrium and fetal membrane are not upregulating CAMP 
during labour.  
LL-37 is a chemoattractant for the stimulation and mobilisation of neutrophils and 
eosinophils (Tjabringa et al., 2003). As leukocytes infiltrate uterine tissues around 
the time of labour (Osman et al., 2003), it was estimated that the myometrial samples 
in this chapter might have shown an increase in CAMP in labouring women. 
Although there may be leukocytes infiltrating to the myometrium in labouring 
samples; this is not contributing to mRNA gene transcript in this chapter. LL-37 
peptide is stored pre-processed in neutrophils so it may have activity in labour at the 




with leukocyte markers would provide evidence for these cells supplying additional 
stores of LL-37 during labour. Indeed this is what Lim et al., (2015) had shown in the 
fetal membrane and myometrium. Lim et al., (2015) displayed that in labouring 
women, immunostaining for hCAP18/LL-37 co-localised with infiltrating leukocytes 
but also increased in resident amnion epithelium, chorionic trophoblasts and decidua, 
which is not what I found in this chapter at the mRNA gene transcript level. 
HDPs in Placenta Explant Cultures 
In this chapter, I have shown that LL-37 was able to significantly reduce the LPS 
induced increase in IL-8, IL-6, TNF, and IL-1β in placenta explant cultures. This 
anti-inflammatory effect of LL-37 ex-vivo is likely due to LL-37 directly binding to 
LPS. LL-37 can downregulate signalling through TLR-4 when coadministered with 
LPS by preventing the interaction with LPB, essential for TLR-4 activation. Not all 
of LL-37 anti-inflammatory properties are due to direct binding to LPS; pre-
treatment with LL-37 prior to LPS can also suppress TNF protein production 
(Mookherjee et al., 2006). LL-37 can also act through disruption of TLR-4 receptor 
complex function when LPS is already bound to macrophage receptors (Rosenfeld et 
al., 2006). All actions can result in lower levels of pro-inflammatory cytokine 
production. It would be interesting to further investigate the mechanism of LL-37’s 
anti-inflammatory action in placental explants. This could be achieved using 
inhibitors of known LL-37 receptors to elude what proportion of the effect might be 
due to actions other than LL-37 and LPS binding.  
It would be interesting to investigate whether the mouse peptide, CAMP is also anti-
inflammatory on murine placental tissues. This can be achieved by primary culture of 
mouse placental tissue with exogenous CAMP and LPS. Camp-/- mice also provide 
an additional control to that of human experiments where the endogenous CAMP 
contributing to the LPS response can be accounted for. The in-vivo equivalent to this 
has already somewhat been done in Chapter 7 of this thesis, where LPS was given 
intrauterine during pregnancy in wildtype and Cathelicidin knockout animals. In 
placental tissue, with a low dose of intrauterine LPS (1µg), there was a small but 




animals in this treatment group was small and this difference was not seen when a 
higher dose of 20µg LPS was used. 
It was surprising that RANTES was not increased in response to LPS in the placenta 
explant cultures in this chapter. Higher expression of RANTES (CCL5) and IL-8 
(CXCL8) has been shown in trophoblast cell lines (Swan-71) after stimulation with 
LPS (Grasso et al., 2014). Interestingly, after interacting with maternal monocytes, 
these trophoblast cells did not modulate the expression of RANTES and IL-8 by LPS 
stimulation (Grasso et al., 2014). In this chapter, the placental explant cultures have 
high levels of blood, where maternal monocytes could modulate the expression of 
these cytokines. Moreover, there are conflicting reports as to whether placenta tissues 
express RANTES. Villous trophoblast only express very small amounts of RANTES 
(Nakada et al., 2011) whereas trophoblast cell lines (Swan-71, SVneo) express high 
amounts of RANTES which is increased in response to LPS and TNF (Grasso et al., 
2014). This might be the reason for the difference in levels of RANTES in placenta 
explant cultures seen in this chapter compared to that reported in cell lines.  
hBD3 has been shown to have potent anti-inflammatory effects on human and mouse 
primary monocytes in response to LPS (Semple et al., 2010, Semple et al., 2011). 
However, in this chapter, hBD3 treatment did not have an effect on the levels of any 
of the cytokines measured in an environment of 100ng/ml of LPS on placental 
explants. Only a single dose of hBD3 peptide [5µg/ml] was used in this chapter as 
this has previously been shown to have anti-inflammatory effects in-vitro. It would 
be ideal to conduct a dose response for hBD3 to further test any anti-inflammatory 
effects in the placenta.  
Other defensins are present in the female reproductive tract, including Human beta-
defensin 126 (DEFB126), an epididymis-specific secretory protein, which has the 







HDPs in Mouse Pregnancy  
There are only a few studies that investigate defensins and cathelicidins in the mouse 
female reproductive tract (Hickey et al., 2013, Soboll et al., 2006). Hickey et al., 
(2013) measured the expression of several defensin genes in the murine vagina and 
uterus at different stages of estrus. In line with what this paper reported, in this 
chapter I have shown that many defensins are expressed at specific spatial patterns 
along the reproductive tract. Estrus cycling in mice is continuous but there are 
discrete phases; diestrus, proestrus, estrus and metestrus. In this chapter I used 
hormones to induced estrus in mice, which coincides with ovulatory follicle growth 
and vaginal neutrophil accumulation. I found beta-defensins including Defb14 and 
Defb4 were highly expressed in the lower reproductive tract during this phase which 
has continuous exposure to bacteria. Most defensins displayed reduced expression 
the further up the reproductive tract, which is presumably a sterile environment. 
Mice in the estradiol-dominant phase have peak defensin expression and it has been 
shown that treating mice directly with estradiol can protect against pathogens 
(Kaushic et al., 2003, Kaushic et al., 2000). The load of commensal bacteria in the 
vagina is also elevated in estrus compared to other stages (Noguchi et al., 2003). 
Estradiol treatment in-vitro has also been shown to enhance the production of HDPs, 
namely beta-defensin 2 (human orthologue of Defb4) in uterine epithelial cells. 
However, in humans the phase of the menstrual cycle dominated by progesterone has 
been shown to display more resistance to infection with various pathogens (reviewed 
in Wira et al., (2010). Another reason for lower defensin expression in the uterus 
could be to support implantation of the fetus that is immunologically different to the 
host. 
Defb1 homozygous knockout mice have increased susceptibility to urinary tract 
infections whereby they were shown to retain Staphylococcus spp. in the bladder 
longer than wildtype mice (Morrison et al., 2002). Defb6 has been shown to have 
tissue-specific expression in skeletal muscle along with esophagus, tongue, and 
trachea (Yamaguchi et al., 2001). Defa5 has been found in epithelial cells of the 





In this study Camp mRNA was expressed highly in the ovary during estrus, the 
reasons for this are not clear but as Camp and LL-37 have been shown to be involve 
in tissue repair it could be playing a role in proliferation of the ovarian surface.  
Pattern recognition receptors are not uniformly expressed along the reproductive 
tract and also show temporal expression patterns that coincide with estrus cycling in 
mice. The numbers of TLR-2 and TLR-5 molecules are higher in the vagina than 
uterus, whereas in general, TLR-4 is higher in the uterus than in the vagina (Hickey 
et al., 2013). This is most probably a co-adaption strategy, to allow host tolerances of 
commensal and mutualistic species while still being effective to detect invading 
pathogens. This has also been shown in humans where TLR-4 and the NOD-2 
receptor are found at higher levels in the upper reproductive tract and reduces the 
further down the reproductive tract (Pioli et al., 2004, Hart et al., 2009). Other TLRs 
are more uniformly expressed along the reproductive tract, namely TLR-9, TLR-8 
and TLR-7 (Hart et al., 2009), these TLRs in mice also displayed more consistent 
expression in the vagina and uterus regardless of the stage of estrus (Hickey et al., 
2013, Soboll et al., 2006). 
Whether changes in HDP levels alter the vaginal microbiome directly has not been 
established, but changes in levels are accompanied by alterations of commensal and 
pathogenic bacteria in humans and in mice (Mitchell et al., 2013, Fan et al., 2008, 







In summary, in this chapter I have shown: 
- DEFB103 and CAMP are expressed in myometrium, placenta and 
amnion/chorion tissues in term pregnancy. 
- DEFB103 expression was upregulated in the myometrium during normal 
labour, whereas CAMP expression was upregulated in the placenta. 
- Placental explants respond to LPS challenge by increasing production of pro-
inflammatory cytokines. 
- LL-37 but not hBD3 peptide was able to modulate LPS induced inflammatory 
response by inhibiting the release of pro-inflammatory cytokines in the 
placenta. 
- Beta-defensins; Defb1, Defb4, Defb6, Defb14, and the cathelicidin Camp 





Chapter 4  






Chapter 4 Microbiome - 16S rRNA Gene Sequencing 
4.1 Introduction 
Several methods for bacterial species identification and quantification are available 
to researchers; these methods classify bacteria to varying taxonomic levels and all 
have their associated advantages and disadvantages. Culture based studies can cause 
misrepresentation of some species due to selection in culture conditions. There are 
various indirect molecular based methods for measuring cell viability, such as 
membrane staining, membrane potential, flow cytometry and reporter gene analysis. 
Fluorescent in situ hybridization (FISH) is a commonly used technique for 
localisation and quantification of bacterial species. FISH probes, usually for the taxa 
specific expanse of the 16S rRNA gene, can be used on tissues sections of interest 
for localising bacterial taxa. FISH probes are advancing the specificity of genus-
specific identification, however, the throughput and multiplexing capability is still 
limited compared to broad range techniques such as 16S rRNA gene sequencing. 
Whole-genome shotgun metagenomic sequencing can also be undertaken for 
microbiome analysis, where the entire genomic content in a sample is sequenced. 
This is becoming an ever more popular method for public health surveillance in 
analysis of outbreaks, but also in the study of antimicrobial resistance mechanisms 
and pathogenicity. While full genome sequencing generally can offer researchers the 
ability to classify bacteria to a greater taxonomic level, there is often a compromise 
with regards to sequencing depth. A metagenomic approach sequences the entire 
genomic content of a sample, which depending on how and where the sample is 
collected from can contain high levels of host DNA. This is not ideal when trying to 
keep the per sample cost low, as greater depth is needed to obtain microbial 
sequences. Target gene approaches such as 16S rRNA gene sequencing can offer 
increased read depth, which puts this approach in a better position to highlight low-
abundant taxa that may be overlooked in shotgun sequencing.  
The objectives of this chapter were to establish a next generation sequencing 
workflow for microbial species identification in murine vaginal and fecal samples. 




reconstruction and species identification. The microbiome field has yet to establish a 
gold standard for looking at microbial communities; workflows need to be tailored 
and validated for specific sites of interest. Multiple considerations are needed at 
almost every point of the workflow. In relation to sample processing, consideration is 
needed in; sampling method, sample storage duration, sample storage temperature 
and method of DNA extraction. Multiple considerations are also required when 
selecting a 16S rRNA gene interrogation method with regards to the amplicon 
primers, amplicon length, and sequencing platform limitations. Having sufficient 
read quality, read depth and choosing an appropriate method for OTU picking are 
also important factors in microbial species identification. Chimeric reads produced 
by PCR artifacts can lead to the false discovery of unique organisms and effect 
community inference. In this regard optimisation is needed to keep PCR cycles to the 
minimum needed for amplification, in addition to the stringent downstream 
bioinformatic filtering of proposed chimeric reads. Employing a paired end 
sequencing approach has the added benefit of sequence overlap, which helps to 
reduce sequencing artefact contribution to community inference. There are many 
bioinformatic tools available to researchers interrogating the 16S rRNA gene. 
Quantitative Insights in to Microbial Ecology (QIIME) (Caporaso et al., 2010b) and 
Mothur (Schloss et al., 2009) are among the most highly used. As 16S rRNA gene 
sequencing is becoming an ever popular choice from microbial species analysis there 
is an increasing amount of rRNA sequence data accessible in open databases such as 
SILVA (Quast et al., 2013), Ribosomal Database Project (RDP) (Cole et al., 2009), 
and Greengenes (DeSantis et al., 2006b). 
 
4.2 Targeted 16S rRNA Gene Amplification 
The bacterial 16S Ribosomal RNA gene is approximately 1500bp and consists of 
nine hyper-variable regions (V1-V9), that when sequenced can be used to identify 
bacteria taxonomy to the species or genus level (Figure 4.1). The microbial field has 
mixed opinion as to which hypervariable region provides the highest number of 




platforms. It is becoming increasingly clear this is dependent on the diversity of 
bacteria in the community sampled (Chakravorty et al., 2007). Nossa (2010) looked 
at sequence data from all nine hyper-variable regions and proposed that in human 
foregut samples the V3 and V4 region is the least effective at class level bacterial 
identification. However, Whiteley et al., (2012) regarded sequencing the V6 region 
not acceptable for environmental samples and suggested the V3-V4 region provides a 
more representative result. Recent in-silico work on human fecal samples 
demonstrated that the V3-V4 and V4-V5 regions would most likely give more OTUs 
than the other variable regions (Claesson et al., 2010). However, this predicted 
advantage was not seen in actual sequencing analysis (Claesson et al., 2010), most 
likely due to accumulation bias from the primers and the extraction method 
employed. 
Comparable to other mucosal body sites, such as the gastrointestinal tract, the human 
vagina has considerably less bacterial species in terms of both diversity and bacterial 
load (Cho and Blaser, 2012, Ravel et al., 2011). At the current level of sequencing, 
the human vaginal microbiome is establishing around 200 bacterial assigned OTUs 
across study sets (Ravel et al., 2011, Drell et al., 2013, Martin et al., 2013). A large 
study on the human vaginal microbiome suggested that the V1-V2 region has greater 
variability than the V3 region for species identification of Lactobacillus and 
Prevotella, giving potential higher OTU counts (Ravel et al., 2012). In addition the 
V1-V3 region has been reported to have a higher degree of accuracy in classifying 








Figure 4.1 Schematic of the 16S rRNA Gene Variable Regions 
(a) The predicted secondary structure of the 16S Ribosomal RNA gene (E.coli). 
Source: Yarza et al., (2014). (b) Schematic of the 16S Ribosomal RNA gene that is 
1500bp and consists of nine hyper-variable regions (V1-V9). Variable regions are in 







4.3 16S rRNA Copy Number qPCR 
For quantification of 16S rRNA copy number, I optimised a qPCR assay using 
universal reference primers for the 16S rRNA gene and comparing to a sample of 
known copy number (gift from Nita Salzman).  
The generation of the qPCR amplicon was detected using SYBR Green as the 
intercalating dsDNA dye. The unbound SYBR Green dye exhibits minimal 
fluorescence, upon binding to DNA the fluorescence is increased 100-fold. Therefore 
during qPCR, the increase in SYBR Green fluorescence is directly proportional to 
the quantity of dsDNA produced.  
The universal primer sequences for 16S rRNA copy number assay were; UniF340 
(5’- ACTCCTACGGGAGGCAGCAGT-3’) and UniR514 (5’- 
ATTACCGCGGCTGCTGGC-3’) which amplify a 179bp product spanning the V3 
region of the 16S rRNA gene. 
A 20µl reaction mix containing the qPCR reaction mastermix, reference gene 
primers and template were made as detailed in Table 4.1. For fecal samples the 
optimised template input was 1µl of a 1:100 dilution of extraction product in sterile 
molecular grade water. For the vaginal samples, which have a lower bacterial load, 
1µl of extraction product, was used as the template. DNA extraction methods are 
detailed in section 4.7. All samples were run in triplicate and PCR cycling and 
fluorescence detection was supported on the LightCycler® 480 Real-Time PCR 
System using the parameters detailed in Table 4.2.  
For absolute quantification, a 5-serial dilution of the sample of known copy number 
was used to create a standard curve. Ct value is the cycle at which the fluorescence 
signal crosses a threshold, where the threshold is an estimate of the first point where 
samples are in exponential phase above background. The Ct values of the standards 
are then used to determine the concentration of target DNA. Several qPCR negatives 
(PCR-NTC) and extraction negatives (EXT-NEG) and calibrators (E.coli DNA) were 




serial dilution of the sample of known copy number; this was determined to be 
within the acceptable range of E= 1.9-2.1. 
 







Prim  F [20µM]  0.4 µM 0.2 
Primer R [20µM] 0.4 µM 0.2 
Template Variable 1.0 
H20 / 8.6 
Table 4.1 qPCR Reaction Mix for 16S rRNA Copy Number Assay 
 
Temperature Time Number of Cycles 
50°C 2 minutes x 1 
95°C 10 minutes x 1 
95°C 30 seconds 
x 45 
63°C 30 seconds 
Table 4.2 qPCR Cycle Parameters for 16S rRNA Copy Number Assay 
  
4.4 16S rRNA Gene Sequencing Primer Design 
4.4.1 In-silico Variable Region Evaluation 
The variable region chosen to sequence for bacterial identification in this study is the 
V1-V2 region of the 16S rRNA gene. This region was highlighted as a good 
candidate; firstly as literature suggested it has an advantage for discrimination of 
Lactobacillus spp. (Ravel et al., 2012), secondly this region displayed higher 
discrimination potential in a test-dataset, ‘TEST-SET’, I created in-silico (detailed 
below). 
The ‘TEST-SET’ was comprised of 949 full length 16S rRNA sequences from 
species likely to be encountered in the; murine female reproductive tract (highlighted 




and sequences of species known to colonise the human vagina (highlighted in 16S 
rRNA studies). The two regions highlighted as potential candidates were the, V1-V2 
region and the V4-V5, as amplicon products from both regions would be less than 
500bp, which was a criterion for selection. Three pairwise percent identity matrixes 
were calculated in Clustal2.1 (Larkin et al., 2007) for; the full length 16S rRNA, the 
V1-V2 and the V4-V5 regions. Pairwise identity above 97% would suggest 
sequences are indistinguishable when clustering OTUs for microbial identification. 
The identity matrix for the full length 16S rRNA region calculated that 0.003% of the 
pairs had sequence similarity above 97%. The V1-V2 region matrix revealed only 
0.0009% of the sequence pairs had higher than 97% similarity, whereas for the V4 -
V5 matrix this was 0.01%. Therefore in this test data-set sequencing the V1-V2 
region will identify more OTUs than if the V4-V5 region were sequenced. As the 
‘TEST-SET’ contains the species which are likely to be encountered in this study the 
V1-V2 region was chosen as the desired amplicon region of the 16S rRNA gene.  
The 16S rRNA V1-V2 hypervariable region is flanked by more conserved regions 
common to all bacteria, this allows for universal primer hybridisation and 
amplification. Even in the denoted ‘conserved’ regions no primer sites are totally 
conserved; where one primer pair will not amplify 100% of bacteria species even 
with miss-matches allowed. Deciding which one/ones to use depends on the 
complement of bacteria in the sample and each pair could slightly bias towards a 
certain type of bacteria (Milani et al., 2013). In the literature, there are over 30 
forward and reverse primers that have been used as universal probes for the V1-V2 
region (Klindworth et al., 2013). Klindworth et al., (2013) provides a great review of 
common universal 16S rRNA gene primers and conducted in-silico evaluation on 
coverage against the SILVA database. 
4.4.2 In-silico Variable Region Primer Evaluation 
An optimized primer set comprising of 27f-YM (universal forward 5’-
AGAGTTTGATYMTGGCTCAG-3’) and 338r (universal reverse 5’- 
TGCTGCCTYCCGTAGGAGT-3’) were chosen to amplify the V1-V2 region based 




temperatures were within 5°C, universal coverage of > 90% 16S rRNA sequences in 
SILVA database (v119), and universal coverage of > 90% 16S rRNA sequences in 
the ‘TEST-SET’. The forward primer 27f-YM has 92.2% coverage (one mismatch) 
and the reverse primer 338r has 95.2% coverage of bacterial sequences in the SILVA 
database (one mismatch). The forward primer is commonly referred to as 27f-YM as 
it ends at E.coli position 27 of the 16S rRNA gene and has the degenerate bases YM. 
The forward 27f-YM represents four discrete primer sequences. The reverse primer 
sequence 338r, which ends at E.coli position 388, also has a degenerate base that 
represents two discrete primer sequences. 
Sequencing in this study was done on two platforms; the Ion Torrent PGM (life 
technologies) and the Illumina MiSeq. Each platform has associated platform 
specific primer sequences that are incorporated into the fusion primers, detailed in 
section 4.8.2 and 4.8.1 respectively. On both platforms 27f-YM (universal forward) 
and 338r (universal reverse) were used as the complementary sequence for 16S 
rRNA gene amplification. 
For the MiSeq primers only, mixtures of four forward 27f primers were used to 
maximise discovery of all bacterial species. This mixture has been shown to 
eliminate PCR bias and maintain the best ratio of Lactobacillus spp. to Gardnerella 
spp. as determined by qPCR (Frank et al., 2008, Romero et al., 2014). The forward 
primer mix consisted of 4 parts 27f-YM (the universal forward), and one part of each 
27f-Bif, 27f-Bor and 27f-Chl, these primers are specific for the amplification of 
Bifidobacteriaceae, Borrelia and Chlamydiales respectively (Table 4.7). The 
universal primer 27f-YM alone would not amplify these species in stringent 
conditions. The degenerate bases within the forward primer mix provide seven 
discrete primer sequences.  
For reference, the universal forward primer (27f-YM) best matches ‘S-D-Bact-0008-
b-S-20’, and the universal reverse primer (338r) best matches ‘S-D-Bact-0338-a-A-





4.5 Contamination Considerations 
An important consideration for microbial sequencing is contamination from 
laboratory equipment, molecular grade water, PCR reagents and extraction kits. 
Many of the extraction kits used for microbiome analysis are known to have low 
level contaminants (Salter et al., 2014). This is of particular importance with low bio-
mass samples such as from the murine vagina in this study. It is often not possible to 
exclude these contaminates without additional sequencing of various negative 
controls from each kit batch.  
In this study extraction kits were ordered in bulk from the same manufacture lot 
number to reduce and account for any lot specific contamination. For quality control, 
extraction negatives were included in every batch of extractions. To reduce potential 
contamination, equipment was cleaned with 70% alcohol, UV treated where suitable, 
and then cleaned with RNAzap. Extractions and subsequent PCRs were carried out in 
a designated PCR clean-room. 
 
4.6 Sampling method  
Fecal Sampling 
Clean autoclaved cages were used as collection containers for fecal sampling of each 
mouse. One fecal pellet per mouse was immediately collected using disposable 
sterile forceps into sterile 2ml tubes and kept at 4°C within 20 minutes and -80°C 
within 2 hours. As the bacterial load in murine fecal samples is very high there was 
little optimisation needed with regards to sampling approach and yield.  
Vaginal Sampling 
As the murine vagina has low biomass, different sampling methods were compared 
to evaluate bacterial load recovery. One sampling method was a vaginal lavage, 
where 200µl of sterile physiological saline [Sodium Chloride 0.9%] is washed in the 




DNA Isolation Kit. In the second method, whole vaginal tissue were internally 
excised, cut longitudinally and then extracted. To determine whether there are higher 
bacteria yield from vaginal lavages as compared to whole vaginal tissue extractions, 
the 16S rRNA gene copy number was determined as previously described. Although 
there was no significant difference in the mean bacteria yield between methods (P; 
0.1791), there was a trend for whole tissue extraction to be more consistent and the 
coefficient of variation was smaller (Figure 4.2). For this reason this study adopted 
post-mortem sampling of whole vaginal tissue for bacterial extraction. 
 
 
Figure 4.2 16S rRNA Copy Number; Murine Vaginal Sampling 
Optimisation  
Copy number of 16S rRNA gene per µl as determined by qPCR for whole vaginal 
tissue (n=7) and vaginal lavage (n=11) extracted using the PowerSoil® DNA 






4.7 Bacterial DNA Extraction 
The method of bacterial DNA extraction has a profound impact in community 
structure as different methods can have bias in the lysis of certain bacterial cell walls 
(Milani et al., 2013, Wesolowska-Andersen et al., 2014). Two different extraction 
kits were used in this study for microbial DNA isolation, the PowerSoil® Isolation 
Kit and the FastDNA® SPIN Kit. DNA extractions using either kit were carried out 
according to the manufacturer’s instructions. The PowerSoil® DNA Isolation Kit is 
the method of choice for the Human Microbiome Project (Human Microbiome, 
2010) and was initially used in this study for samples sequenced on the Ion Torrent 
platform. However, recent publication suggested that for low biomass samples, the 
FastDNA® SPIN Kit with bead-beating may yield better results and less bias 
towards Bacteroidetes phylum than the PowerSoil® DNA Isolation Kit (Milani et al., 
2013, Wesolowska-Andersen et al., 2014). FastDNA® SPIN Kit for DNA extraction 
gave more consistent bacterial yields from vaginal tissue than the PowerSoil® DNA 
Kit (Figure 4.3). This method was adopted for all samples both fecal and vaginal run 
on the MiSeq platform. 
 
Figure 4.3 16S rRNA Copy Number; Extraction Kit Optimisation 
Copy number of 16S rRNA gene per µl as determined by qPCR for whole vaginal 
tissue using the PowerSoil® DNA Isolation Kit (n=9) or the FastDNA® SPIN Kit 




4.8 Library Preparation 
4.8.1 Illumina MiSeq Primer Design and PCR Optimisation  
The number of sequence reads generated on an Illumina MiSeq lane vastly exceeds 
the number of reads needed per sample for species identification. For this reason and 
to reduce per-sample sequencing costs, amplicon libraries were pooled in a 64-plex. 
The complementary forward and reverse primer regions have been designed to be as 
universal as possible for bacterial species likely to be encountered in biological 
specimens from the vagina, but also murine gastrointestinal sites. Specific 
consideration has been given to accurately represent bacterial species common to the 
vagina by mixing 4 different forward primers in specific proportions (see section 
4.4.2). 
For multiplexing capability, the forward and reverse primers are indexed with 
TruSeq index sequences. Primers have been designed such that they contain the 
correctly orientated standard MiSeq sequencing and indexing primer sites that are 
compatible with MiSeq HP10, HP11 and HP12. These Illumina sequencing and 
indexing primers are contained within the reagent cartridge as standard. To account 
for possible low complexity in the library pool, heterogeneity spacers were 
incorporated into the designed fusion primers. To reduce oligo crosstalk, 
oligonucleotides with TruGrade™ processing were synthesised from IDT (Integrated 
DNA Technologies). Full MiSeq primer sequences are given in Table 4.7 and Table 
4.8. Primers were checked for possibility of secondary structure formation and 
primer dimers.  
Optimisation is required to get strong amplification results using fusion primers. To 
optimise PCR conditions for MiSeq library preparation several PCR parameters were 
compared, namely; template volume, template 16S rRNA copy number, cycle 





Component Final Concentration / Reaction 50µl Reaction 
Q5® Reaction Buffer 5x x1 10 
dNTPs [10mM] 0.1mM 1 
Primer F [10µM]  0.1µM 0.5 
Primer R [10µM] 0.1µM 0.5 
Q5 Taq 0.01U/µl 0.2 
Q5® High GC Enhancer 5x x1 10 
Template Variable * Variable 
H20 / # to 50µl vol 
Table 4.3 PCR Reaction Mix; MiSeq 16S rRNA Amplicon Library  
* 2ng for fecal samples/ 20,000 copies of 16S rRNA for vaginal samples/ 5µl PCR 




For fecal samples, the optimised template input was 2ng of extracted DNA as 
quantified by Qubit™ 2 Fluorometer using Qubit dsDNA BS Assay Kit following 
the manufacture’s protocol. For the vaginal samples, which have higher host DNA 
contribution to total DNA, the copy number of 16S rRNA gene was determined by 
qPCR as previously described. Template volumes equal to 20,000 copies or 12µl 
(max volume) were added to each PCR reaction. 
All amplifications were performed in a 50μl total reaction mixture volume according 





Temperature Time Number of Cycles 
98°C 30 seconds x 1 
98°C 10 seconds 
x20 Fecal Samples + Nested 
x30 Vaginal Samples 
50°C 30 seconds 
72°C 30 seconds 





A large proportion of samples from the murine vagina did not show specific bands at 
x20 and x30 PCR cycles using the conditions described in Table 4.4 and Table 4.5. 
Various additional attempts were made to optimise the conditions for these low bio-
mass samples; including changing the PCR annealing temperature, reducing agent 
and PCR approach. A nested PCR protocol was adopted which involves two rounds 
of PCR. The first round of PCR used the universal primer sequences 8f (5’-
AGAGTTTGATYMTGGCTCAG-3’) and 805r (5’-GACTACCAGGGTATCTAAT-
3’) to amplify an extended region of the 16S rRNA gene spanning V1 to V4. 
Unincorporated primers and dNTPs were enzymatically digested using ExoSAP-IT® 
according to the manufacturer’s instructions. 5µl of the cleaned PCR product is then 
used as the template for the second round of PCR, which uses the MiSeq fusion 
primers and PCR conditions previously detailed in Table 4.4. The PCR cycle 
conditions and reaction mix used in both steps were the same, only the primers were 
changed. This type of nested PCR approach is known to have effect downstream on 
community inference and structure (Yu et al., 2015). Therefore for consistency and 
validity a nested PCR approach was adopted for all vaginal samples sequenced on 
the MiSeq platform, including those samples that had a specific band at x20 cycles in 
the one-step method.  
PCR product size and purity of the amplified library were checked by performing gel 
electrophoresis as described in section 4.8.3. A single specific band is seen in all 







Figure 4.4 Gel Photo; MiSeq 16S rRNA Amplicon Library 
Representative gel electrophoresis showing a single specific band in all products of a 
size around 500bp on a 2% agarose gel, with 100bp ladder (Lane 1 and 19). Lane 17 
is extraction negative (EXT-NEG), lane 18 is the non-template control PCR negative 








4.8.2 Ion Torrent PGM Primer Design and PCR Optimisation  
Microbial sequencing on the Ion Torrent PGM platform using the 400bp Sequencing 
Chemistry Kit and PGM 314 chip took advantage of dual-indexed fusion-primers to 
reduce per sample cost. Forward and reverse fusion primers were designed to include 
the sequences 27f and 338r respectively (as described in section 4.4.2) to amplify the 
V1-V2 variable region of the 16S rRNA gene. I designed these primers to include, at 
the 5’ end, one of two adaptor sequences (adaptor trP1 or adaptor A) linking to a 
unique barcode tag (IonXpressBarcode). Short linkers ‘Key’ and ‘Barcode-Adapter’ 
sequences were also included. All primers were HPLC synthesised by Sigma® Life 
Science; the complete list of Ion Torrent fusion-primers used in this study are shown 
in Table 4.9. Primers were checked for possibility of secondary structure formation 
and primer dimers. 
To optimise PCR conditions for Ion Torrent PGM library preparation, several PCR 
parameters were compared as before, namely; template volume, template 16S rRNA 
copy number, cycle number, annealing temperature, polymerase, and use of reducing 
agents.  
For fecal samples the optimised template input was 1.5ng of extracted DNA, as 
determined by Qubit™ 2 Fluorometer using Qubit dsDNA BR Assay Kit. For the 
vaginal samples, which have higher host DNA contribution to total DNA, the copy 
number of 16S rRNA gene was determined by qPCR. Template volumes equal to 
20,000 copies or 12µl (max volume) were added to PCR reaction.  
All amplifications were performed in a 50μl total reaction mixture volume according 









Component Final Concentration / Reaction 50µl Reaction 
Q5® Reaction Buffer 5x x1 10 
dNTPs [10mM] 0.2mM 1 
Primer F [10µM]  0.2µM 1 
Primer R [10µM] 0.2µM 1 
Q5 Taq 0.01U/µl 0.2 
Q5® High GC Enhancer 5x x1 10 
Template 1.5ng / 20,000 copies Variable 
H20  * to 50µl vol 
Table 4.5 PCR Reaction Mix; Ion Torrent 16S rRNA Amplicon Library 
 
 
The optimised PCR thermocycler conditions for amplification are given in Table 4.6. 
For vaginal samples the number of cycles was increased to 30. PCR product size and 
purity were checked by performing gel electrophoresis as described in section 4.8.3. 
A single specific band is seen in all products of a size around 420bp and extraction 
(EXT-NEG) and PCR negatives (PCR-NTC) show no specific band (Figure 4.5). 
 
 
Temperature Time Number of Cycles 
98°C 2 minutes x 1 
98°C 30 seconds 
x20 Fecal Samples + Nested 
x30 Vaginal Samples 
60°C 30 seconds 
72°C 40 seconds 








Figure 4.5 Gel Photo; 16S rRNA Amplicon Library 
Representative gel electrophoresis showing a single specific band in most products of 
a size around 420bp on a 2% agarose gel, with 100bp ladder (Lane 1) and PhiX 
ladder (Lane 19). Lane 18 is extraction negative (EXT-NEG), Lane 20 is non-
template control PCR negative (PCR-NTC). Lanes 2-17 are from vaginal extractions 
using x30 PCR cycles. 
 







Table 4.7 MiSeq Forward Primer Sequences  
Primers are split into components for ease of visualisation. All Primers shown 5’-3’ across the row left to right. 
Forward Primer Name P7 Grafting Sequence: Index (i7): P7 Sequencing Primer: Heterogeneity 
Spacer: 
16S rRNA Complementary 
Region (V1) 
27F_YM_MISEQ_D701 CAAGCAGAAGACGGCATACGAGAT CGAGTAAT GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT  AGAGTTTGATYMTGGCTCAG 
27F_YM_MISEQ_D702 CAAGCAGAAGACGGCATACGAGAT TCTCCGGA GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT  AGAGTTTGATYMTGGCTCAG 
27F_YM_MISEQ_D703 CAAGCAGAAGACGGCATACGAGAT AATGAGCG GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT T AGAGTTTGATYMTGGCTCAG 
27F_YM_MISEQ_D704 CAAGCAGAAGACGGCATACGAGAT GGAATCTC GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT T AGAGTTTGATYMTGGCTCAG 
27F_YM_MISEQ_D705 CAAGCAGAAGACGGCATACGAGAT TTCTGAAT GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT GT AGAGTTTGATYMTGGCTCAG 
27F_YM_MISEQ_D706 CAAGCAGAAGACGGCATACGAGAT ACGAATTC GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT GT AGAGTTTGATYMTGGCTCAG 
27F_YM_MISEQ_D707 CAAGCAGAAGACGGCATACGAGAT AGCTTCAG GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT CGA AGAGTTTGATYMTGGCTCAG 
27F_YM_MISEQ_D708 CAAGCAGAAGACGGCATACGAGAT GCGCATTA GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT CGA AGAGTTTGATYMTGGCTCAG 
27F_Bif_MISEQ_D701 CAAGCAGAAGACGGCATACGAGAT CGAGTAAT GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT  AGGGTTCGATTCTGGCTCAG 
27F_Bif_MISEQ_D702 CAAGCAGAAGACGGCATACGAGAT TCTCCGGA GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT  AGGGTTCGATTCTGGCTCAG 
27F_Bif_MISEQ_D703 CAAGCAGAAGACGGCATACGAGAT AATGAGCG GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT T AGGGTTCGATTCTGGCTCAG 
27F_Bif_MISEQ_D704 CAAGCAGAAGACGGCATACGAGAT GGAATCTC GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT T AGGGTTCGATTCTGGCTCAG 
27F_Bif_MISEQ_D705 CAAGCAGAAGACGGCATACGAGAT TTCTGAAT GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT GT AGGGTTCGATTCTGGCTCAG 
27F_Bif_MISEQ_D706 CAAGCAGAAGACGGCATACGAGAT ACGAATTC GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT GT AGGGTTCGATTCTGGCTCAG 
27F_Bif_MISEQ_D707 CAAGCAGAAGACGGCATACGAGAT AGCTTCAG GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT CGA AGGGTTCGATTCTGGCTCAG 
27F_Bif_MISEQ_D708 CAAGCAGAAGACGGCATACGAGAT GCGCATTA GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT CGA AGGGTTCGATTCTGGCTCAG 
27F_Bor_MISEQ_D701 CAAGCAGAAGACGGCATACGAGAT CGAGTAAT GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT  AGAGTTTGATCCTGGCTTAG 
27F_Bor_MISEQ_D702 CAAGCAGAAGACGGCATACGAGAT TCTCCGGA GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT  AGAGTTTGATCCTGGCTTAG 
27F_Bor_MISEQ_D703 CAAGCAGAAGACGGCATACGAGAT AATGAGCG GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT T AGAGTTTGATCCTGGCTTAG 
27F_Bor_MISEQ_D704 CAAGCAGAAGACGGCATACGAGAT GGAATCTC GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT T AGAGTTTGATCCTGGCTTAG 
27F_Bor_MISEQ_D705 CAAGCAGAAGACGGCATACGAGAT TTCTGAAT GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT GT AGAGTTTGATCCTGGCTTAG 
27F_Bor_MISEQ_D706 CAAGCAGAAGACGGCATACGAGAT ACGAATTC GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT GT AGAGTTTGATCCTGGCTTAG 
27F_Bor_MISEQ_D707 CAAGCAGAAGACGGCATACGAGAT AGCTTCAG GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT CGA AGAGTTTGATCCTGGCTTAG 
27F_Bor_MISEQ_D708 CAAGCAGAAGACGGCATACGAGAT GCGCATTA GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT CGA AGAGTTTGATCCTGGCTTAG 
27F_Chl_MISEQ_D701 CAAGCAGAAGACGGCATACGAGAT CGAGTAAT GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT  AGAATTTGATCTTGGTTCAG 
27F_Chl_MISEQ_D702 CAAGCAGAAGACGGCATACGAGAT TCTCCGGA GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT  AGAATTTGATCTTGGTTCAG 
27F_Chl_MISEQ_D703 CAAGCAGAAGACGGCATACGAGAT AATGAGCG GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT T AGAATTTGATCTTGGTTCAG 
27F_Chl_MISEQ_D704 CAAGCAGAAGACGGCATACGAGAT GGAATCTC GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT T AGAATTTGATCTTGGTTCAG 
27F_Chl_MISEQ_D705 CAAGCAGAAGACGGCATACGAGAT TTCTGAAT GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT GT AGAATTTGATCTTGGTTCAG 
27F_Chl_MISEQ_D706 CAAGCAGAAGACGGCATACGAGAT ACGAATTC GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT GT AGAATTTGATCTTGGTTCAG 
27F_Chl_MISEQ_D707 CAAGCAGAAGACGGCATACGAGAT AGCTTCAG GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT CGA AGAATTTGATCTTGGTTCAG 







Table 4.8 MiSeq Reverse Primer Sequences 
Primers are split into components for ease of visualisation. All Primers shown 5’-3’ across the row left to right. 
Table 4.9 Ion Torrent Forward and Reverse Primer Sequences 
Primers are split into components for ease of visualisation. All Primers shown 5’-3’ across the row left to right. 
Reverse Primer Name P5 Grafting Sequence: Index (i5): P5 Sequencing primer: Heterogeneity 
Spacer: 
16S rRNA Complementary Region 
(V2): 
338R_MISEQ_D501 AATGATACGGCGACCACCGAGATCTACAC TATAGCCT ACACTCTTTCCCTACACGACGCTCTTCCGATCT  TGCTGCCTYCCGTAGGAGT 
338R_MISEQ_D502 AATGATACGGCGACCACCGAGATCTACAC ATAGAGGC ACACTCTTTCCCTACACGACGCTCTTCCGATCT  TGCTGCCTYCCGTAGGAGT 
338R_MISEQ_D503 AATGATACGGCGACCACCGAGATCTACAC CCTATCCT ACACTCTTTCCCTACACGACGCTCTTCCGATCT A TGCTGCCTYCCGTAGGAGT 
338R_MISEQ_D504 AATGATACGGCGACCACCGAGATCTACAC GGCTCTGA ACACTCTTTCCCTACACGACGCTCTTCCGATCT A TGCTGCCTYCCGTAGGAGT 
338R_MISEQ_D505 AATGATACGGCGACCACCGAGATCTACAC AGGCGAAG ACACTCTTTCCCTACACGACGCTCTTCCGATCT TC TGCTGCCTYCCGTAGGAGT 
338R_MISEQ_D506 AATGATACGGCGACCACCGAGATCTACAC TAATCTTA ACACTCTTTCCCTACACGACGCTCTTCCGATCT TC TGCTGCCTYCCGTAGGAGT 
338R_MISEQ_D507 AATGATACGGCGACCACCGAGATCTACAC CAGGACGT ACACTCTTTCCCTACACGACGCTCTTCCGATCT CTA TGCTGCCTYCCGTAGGAGT 
338R_MISEQ_D508 AATGATACGGCGACCACCGAGATCTACAC GTACTGAC ACACTCTTTCCCTACACGACGCTCTTCCGATCT CTA TGCTGCCTYCCGTAGGAGT 
Forward Primer Name Ion Torrent Adapter: A/trP1 KEY IonXpressBarcode Barcode Adapter 16S rRNA Complementary Region (V1/V2) 
IT_27F_YM_Index_1 CCATCTCATCCCTGCGTGTCTCCGAC TCAG CTAAGGTAAC GAT AGTTTGATYMTGGCTCAG 
IT_27F_YM_Index_2 CCATCTCATCCCTGCGTGTCTCCGAC TCAG TAAGGAGAAC GAT AGTTTGATYMTGGCTCAG 
IT_27F_YM_Index_3 CCATCTCATCCCTGCGTGTCTCCGAC TCAG AAGAGGATTC GAT AGTTTGATYMTGGCTCAG 
IT_27F_YM_Index_4 CCATCTCATCCCTGCGTGTCTCCGAC TCAG TACCAAGATC GAT AGTTTGATYMTGGCTCAG 
IT_27F_YM_Index_5 CCATCTCATCCCTGCGTGTCTCCGAC TCAG CAGAAGGAAC GAT AGTTTGATYMTGGCTCAG 
IT_27F_YM_Index_6 CCATCTCATCCCTGCGTGTCTCCGAC TCAG CTGCAAGTTC GAT AGTTTGATYMTGGCTCAG 
IT_27F_YM_Index_7 CCATCTCATCCCTGCGTGTCTCCGAC TCAG TTCGTGATTC GAT AGTTTGATYMTGGCTCAG 
IT_27F_YM_Index_8 CCATCTCATCCCTGCGTGTCTCCGAC TCAG TTCCGATAAC GAT AGTTTGATYMTGGCTCAG 
IT_27F_YM_Index_9 CCATCTCATCCCTGCGTGTCTCCGAC TCAG TGAGCGGAAC GAT AGTTTGATYMTGGCTCAG 
IT_27F_YM_Index_10 CCATCTCATCCCTGCGTGTCTCCGAC TCAG CTGACCGAAC GAT AGTTTGATYMTGGCTCAG 
IT_27F_YM_Index_11 CCATCTCATCCCTGCGTGTCTCCGAC TCAG TCCTCGAATC GAT AGTTTGATYMTGGCTCAG 
IT_27F_YM_Index_12 CCATCTCATCCCTGCGTGTCTCCGAC TCAG TAGGTGGTTC GAT AGTTTGATYMTGGCTCAG 
IT_27F_YM_Index_13 CCATCTCATCCCTGCGTGTCTCCGAC TCAG TCTAACGGAC GAT AGTTTGATYMTGGCTCAG 
IT_27F_YM_Index_14 CCATCTCATCCCTGCGTGTCTCCGAC TCAG TTGGAGTGTC GAT AGTTTGATYMTGGCTCAG 
IT_27F_YM_Index_15 CCATCTCATCCCTGCGTGTCTCCGAC TCAG TCTAGAGGTC GAT AGTTTGATYMTGGCTCAG 
IT_27F_YM_Index_16 CCATCTCATCCCTGCGTGTCTCCGAC TCAG TCTGGATGAC GAT AGTTTGATYMTGGCTCAG 




4.8.3 Gel Electrophoresis  
To qualitatively confirm products were of a desired size, PCR products were loaded 
on an agarose gel (2%; w/v) containing ethidium bromide and exposed to 
electrophoresis at 110 V for 1 hour in TBE buffer. Gels were visualised under UV 
light to determine the presence and size of PCR amplicons. For all samples, a 12µl 
volume was loaded into each well; 5µl of PCR product mixed with 5µl of sterile 
water and 2µl of loading dye. For size comparison PCR products were compared 
against 100bp ladder and/or PhiX.  
4.8.4 Sample clean-up 
Post-PCR samples were purified by one round of Agencourt AMPure XP (Beckman 
Coulter) DNA purification beads to remove primer dimers and short fragments. 
Manufacturer’s instructions were followed apart from the ratio of DNA to beads. A 
ratio of 1: 0.8 DNA to beads was used for better size selection of larger fragments. 
4.8.5 DNA Quantification, Quality Control, and Equimolar Pool 
The integrity of the clean-up PCR-product was subsequently analysed on the 2100 
Bioanalyzer Instrument using an Agilent DNA 1000 Chip Kit for size determination. 
Total dsDNA was measured on the Qubit™ 2 Fluorometer using Qubit dsDNA HS 
Assay Kit following the manufacturer’s instructions. For Illumina MiSeq samples 
only, an additional qPCR using KAPA Library Quantification Kit was performed 
following the manufacturer’s instructions. This qPCR is specific to the Illumina 
sequence primers and gives an accurate measure of copies of DNA amplicons with 
Illumina adapters. KAPA qPCR was conducted with three technical replicates at two 
dilutions per library; 1:1000 and 1:10000 as suggested by the manufacturer’s 
protocol. 
The concentration (determined by Qubit and/or KAPA qPCR) and average size 
(determined by Bioanalyzer) of each sample was used to make an equimolar 




concentration and average size of each sample was also used to highlight samples 
below threshold that were subsequently dropped from processing. Purity of the 
equimolar pool was determined as before using the KAPA Library Quantification kit 




4.9 Sequencing and Base Calling 
For MiSeq libraries, bridge amplification was supported on the MiSeq platform in 2 
x 300 Paired End (PE) mode using the 600-cycle MiSeq Reagent v3 kit, at Edinburgh 
Genomics; University of Edinburgh. After sequencing, the FASTQ reads were 
filtered by the Illumina software to remove TruSeq indexes and demultiplexed.  
For Ion Torrent libraries, emulsion PCR was supported on the Ion OneTouchTM 400 
Template Kit v2 according to the manufacturer’s instructions. Sequencing of the 
library was carried out on the 314 chip using the Ion Torrent Personal Genomic 
Machine (PGM) system and using the Ion Sequencing 400 kit at the MRC-Human 
Genetics Unit, Edinburgh. After sequencing, the FASTQ reads were filtered by the 
PGM software to remove sub-threshold and polyclonal sequences. 
4.10 QIIME and Mothur 
Quantitative Insights into Microbial Ecology (QIIME) is a Linux-based open source 
software package that aids analysis of microbial communities from high throughput 
sequencing (HTS) technologies (Caporaso et al., 2010b). QIIME packaged utilises 
many other open source tools including; FastTree 2.1.3 (Price et al., 2010), RDP 
Classifier (Wang et al., 2007), PyNAST algorithm (Caporaso et al., 2010a) and 
UCHIME (Edgar et al., 2011). QIIME allows for; demultiplexing, aligning, 
screening, assigning OTUs, calculating diversity, hypothesis testing, and data 
visualisation.  
Mothur is also an open-source software program for microbial bioinformatics 
(Schloss et al., 2009). Mothur has all the similar functions to QIIME for data 
processing with built in function for RDP Classifier (Wang et al., 2007), NAST 





4.11 Downstream Quality Filtering and Data Analysis; MiSeq 
Parameters for Processed Paired Reads 
FASTQ files were received from Edinburgh Genomics (University of Edinburgh) 
already demultiplexed based on sample specific TrueSeq index sequences that were 
incorporated into the fusion primers. To search and trim the degenerate 16S rRNA 
primer sequence and any excess heterogeneity spaces from the 5’ end, Cutadapt was 
used in paired-end mode (Martin, 2011). A maximum of 6% error was allowed in 
primer sequence and any untrimmed reads were discarded. On average 97% of raw 
read-pairs passed Cutadapt filtering. FASTQ files were then passed to Trimmomatic 
(Bolger et al., 2014) to remove read pairs where one or both reads have an average 
phred33 score of <Q20, and trim sequences that fall below <Q20 in a rolling window 
of 15nt. Low quality bases below phred33 Q6 were masked with an N, prior to 
generating contigs, using fastq_masker (FASTX-Toolkit). On average 98% of paired 
reads passed Trimmomatic filtering. Figure 4.6 shows a representative graphical 
display of FASTQ summary data from raw reads and processed reads generated from 
a randomly selected sample. Raw quality of each independent MiSeq lane was 
variable, however, profiles post processing were consistent with Figure 4.6.  
  
Figure 4.6 Overview of MiSeq Sequencing Quality Output; FASTQ 3D 
plots  
Read Position vs. Quality Score vs. Frequency (x, y, z respectively) (a) Raw paired 
reads (b) Processed paired reads. Representative data from one randomly selected 





Contigs, Chimera filtering, OTU Picking and Tree building 
Contigs from paired-end reads were generated in Mothur (Schloss et al., 2009). To 
ensure sequence reads are a true representation of 16S rRNA gene and not 
sequencing artifacts; sequences with ambiguous bases, homopolymers of >6, and a 
contig length above 350bp were removed. 
To ensure sequence reads are a true representation of 16S rRNA gene and not PCR 
artifacts, reads were screened for chimeras using Mothur (Schloss et al., 2011) which 
is based on UCHIME (Edgar et al., 2011) and USEARCH (Edgar, 2010). The 
operational taxonomic units (OTUs) were picked de novo and clustered at 97% 
sequence similarity using the Nearest Alignment Space Termination (NAST) 
algorithm for alignment (DeSantis et al., 2006a). The taxonomy of each OTU was 
assigned using naive Bayesian classification that is based on the RDP Classifier 8-
kmers method (Wang et al., 2007) which is integrated in Mothur (bootstrap threshold 
80%) using SILVA (v119) database. FastTree 2.1.3 (Price et al., 2010) intergraded in 
QIIME (Caporaso et al., 2010b), was used to build approximately-maximum-





4.12 Downstream Quality Filtering and Data Analysis; Ion 
Torrent  
Parameters for Processed Reads 
Ion Torrent raw FASTQ sequencing reads were first quality filtered using tools in 
Galaxy (web-based platform for biological data) then directed into QIIME (version 
1.8.0), for OTU calling, taxonomy identification and diversity measurements. To 
ensure sequence reads are a true representation of 16S rRNA gene and not 
sequencing artifacts reads were quality filtered and trimmed. The workflow I 
designed in Galaxy quality filters and trims the sequence reads based on the 
following criteria (see appendix for full details). 
i) Only reads with perfect match to a barcode sequence are kept; barcode is 
trimmed 
ii) Only reads with a maximum of 2 mismatches in the complementary primer 
sequence are kept; complementary primer trimmed 
iii) Reads are trimmed when the average quality score drops below Phred score 25 
in a sliding window of 6bp. 
iv) Reads outside the rage of 150–500bp post trimming are discarded. 
v) Reads containing homopolymers of more than 8bp are discarded. 
Sequences are then binned by sample (demultiplexed) and the remaining high quality 






Chimera filtering, OTU Picking and Tree building 
Before OTU picking, reference-based and de novo based chimera detection was 
carried out using USEARCH 6.1 (Edgar, 2010) against the full Greengenes database 
(13_8 release). OTUs were picked at 97% sequence similarity using an open-
reference approach. This approach first clusters the sequences against the 
Greengenes database using UCLUST (Edgar, 2010), those sequences which do not 
cluster are then sent for de novo OTU picking. Representative FASTA sequences for 
each OTU were aligned to the Greengenes database (13_8 release) using PyNAST 
(re-implemented NAST aligner (Caporaso et al., 2010a)). Taxonomy was assigned 
using the RDP Classifier (Wang et al., 2007) with a bootstrap threshold of 60%. 
FastTree 2.1.3 (Price et al., 2010) intergraded in QIIME, was used to build 
approximately-maximum-likelihood phylogenetic trees. 
 
4.13 R Package 
The resulting OTU tables were imported into R for filtering and statistical analysis 
using multiple R packages for data manipulation, such as; Phyloseq, ggplot2, and 
Hclust. Phyloseq is an R-Package which manipulates the raw OTU data generated 
elsewhere (such as in QIIME or Mothur), and together with analytical and graphical 
packages (such as vegan, ape, picante and ggplot2) provides a tool for analysis and 
visualisation of phylogenetic data. Phyloseq also has functions to rarefy data and 
calculate diversity, however, for the most part these functions were used in QIIME 
and phyloseq was primarily used in this study for data manipulation and generating 





4.14 Rarefaction Curves  
Sufficient sequencing depth is needed to capture the full representation of bacterial 
species in a sample. To establish whether the depth of sequencing truly captures the 
community, a method commonly called rarefaction can be employed. Rarefaction is 
a technique used in ecology to measure species richness as a function of sampling 
effort. Rarefaction can be thought of as a method for random resampling, whereby 
diversity measures are then calculated for each simulated sequencing effort. The rate 
of increase in diversity measure is an inherent property of the microbial community 
of that sample, whereby a plateau suggest the majority of the species in the 
community have been found.  
In this study multiple rarefactions are done for each sample, diversity measures 
calculated and shown graphically on rarefaction curve plots. The diversity measures 
calculated for rarefaction were; species richness (Sobs), Chao1 Estimate (Chao, 1987), 
Shannon Diversity (Shannon, 1948) and Inverse Simpsons Index (Simpson, 1949); 





4.15 Alpha Diversity Analysis 
Bacterial diversity at the community level is evaluated using two principle measures; 
alpha and beta diversity. Alpha diversity is a measure of diversity ‘within’ a sample 
and can be assessed using various metrics. Most measures take into account both 
species richness and evenness. Richness refers to how many different species 
(OTUs) there are present, whereas evenness describes their distribution. 
The alpha diversity measures used in this study are; Observed species (Sobs), Chao1 
Estimate, Shannon Diversity and Inverse Simpsons Index. Observed species is a 
measure of the unique OTUs in each sample and Chao1 is an estimate of species 
richness which uses the ratio of singletons to doubletons (Chao, 1987). Low 
abundant OTUs should therefore not be removed prior to analysis. Simpson’s index 
is a measure of the probability that upon randomly selecting an individual from a 
community, the individual has already been observed (Simpson, 1949). Shannon 
Diversity measure is more sensitive to species richness, giving higher weight to low 
abundant OTUs/species (Shannon, 1948). 
4.15.1 Statistical analysis of alpha diversity 
Where alpha diversity between two groups were compared (e.g. Fecal vs. Vaginal); a 
unpaired student t-test was performed. Continuous parametric data between more 
than two groups was compared using a one way analysis of variance (ANOVA). 
Longitudinal data within-subject across the 4 time-points was compared using 
repeated measures ANOVA (RM-ANOVA) and Tukey's post-test. Linear mixed 
regression was applied to the Alpha Diversity measures across collection time-points. 





4.16 Beta Diversity Analysis 
While Alpha Diversity is descriptive for inferring community structure, it represents 
only the dispersion pattern of the OTUs. Alpha Diversity will not tell us if the same 
bacteria are shared between samples. Beta diversity measures are used to describe the 
similarity or dissimilarity between two different samples. Beta diversity, like alpha 
diversity is dependent on the depth of sequencing and the metric used. A popular 
method which uses the phylogenetic tree as the measure for similarity is a technique 
called UniFrac (Lozupone and Knight, 2005). UniFrac takes into account the shared 
species between two samples, their abundance and their phylogenetic relationship. It 
measures pairwise distances and returns a value between 0, where two communities 
are identical, and 1, where communities are totally unrelated. The higher the beta 
diversity, the less similar the communities are. Unweighted UniFrac distance is a 
qualitative description of similarity whereas weighted UniFrac distance takes into 
account the quantitative occurrence of the OTUs/species. Weighted UniFrac distance 
therefore attributes more power to highly abundance OTUs/species than unweighted 
UniFrac measure.  
The UniFrac distances from all samples are approximated visually using Principle 
Co-ordinate Analysis (PCoA). PCoA is a method of dimensionality reduction that 
aims to recapture whatever patterns are in the data but reduce the number of 
dimensions using a new co-ordinate system. PCoA is related to the commonly used 
statistical method principle component analysis (PCA) which is analogous to 
Euclidian distance and not UniFrac measures. 2D PCoA plots in this thesis were 
created and visualised using phyloseq; an R package (McMurdie and Holmes, 2013). 
Ultimately ordination is a visualisation method, but any spatial separation seen in 2D 
PCoA plots can be tested for statistical significance using hypothesis testing on the 





4.16.1 Statistical analysis of beta diversity 
Where beta diversity between two groups was compared, a parametric two sample t-
test with Bonferroni correction was performed. This was supported with non-
parametric testing using 999 Monte Carlo permutations and Bonferroni-corrected. 
Adonis 
Adonis is a nonparametric statistical method that first identifies the central points in 
the data, centroids, and then radially calculates the squared deviations out from these 
points. This produces an effect size value (r
2
) which is the level of variance in the 
data that can be attributed to the specified category (e.g. genotype or gestation). In 
addition this method provides a P value from permutations of the raw data (999) 
using multiple F-tests (sequential sums of squares).  
ANOSIM 
ANOSIM is a test which determines whether two or more groups of samples (e.g. 
C57BL/6J vs. Camp-/-) are significantly different by relating the distances ‘between’ 
the groups, to the distances ‘within’ the groups, and providing an r value. A positive 
r value close to 1.0 signifies that the groups are highly dissimilar. Significance is 





4.16.2 Jack-knife and UPGMA bootstrapped trees  
A rooted dendrogram (tree) is constructed from the pairwise UniFrac distance matrix 
using Unweighted Pair Group Method with Arithmetic Means algorithm (UPGMA) 
to infer structure. Jack-knife replicates are used to estimate uncertainty in distance 
matrix and involves dropping one/many observations from a sample each time and 
recalculating the distance. Together with bootstrapped hierarchical clustering, 
UPGMA provides an estimate to the uncertainty of the points in PCoA plots. Jack-
knifing in this study was set at 100 replicates at 45,000 sequences (75% per sample 
sequences). Those nodes which are consistent across jack-knife replicates are robust 
for microbial inference. Bootstrap values on the branch indicate how much support is 
given to that branch on a phylogenetic tree.  
 
4.17 Significant Taxa (LEfSe) 
Linear Discriminant Analysis with Effect Size (LEfSe) is an all-against-all multi-
class comparison tool used to highlight biological consistency and estimate effect 
size (Segata et al., 2011). LEfSe was used to detect which taxa were enriched in 
different genotypes; C57BL/6J vs. Camp-/-. LEfSe first applies a nonparametric 
(Kruskal -Wallis) rank sum test to the OTU data to detect OTUs and classifications 
with significant differential abundances. Stringent alpha values of 0.01 for Kruskal-
Wallis were set in this study. This is then followed by a biological consistency 
estimate which involves pairwise rank sum tests (Wilcoxon). Linear Discriminant 
Analysis is then used to estimate an effect size of the differentially abundant taxa; 






4.18 Mock Community 
To measure the error rate of MiSeq microbial sequencing in this workflow, a mock 
community was co-sequenced along with samples detailed in Chapter 5. The mock 
community HM-278D was sourced from BEI (https://www.beiresources.org/) and 
contained an even mixture of 20 bacterial species listed in Table 4.10. Reference 
sequences of the 20 species contained 115 unique 16S RNA operons. These 115 
sequences were aligned and trimmed to the V1-V2 region for comparison to the 
sequenced ‘Mock’ sample. Using seq.error in Mothur the error rate was determined 
to be 0.00673%. This is very low and confirms the quality control and pre-processing 
parameters employed in this workflow are more than adequate for robust microbial 
species inference. 
Bacteria Strain NCBI 
Rhodobacter sphaeroides strain ATH 2.4.1  NC_007493 
Acinetobacter baumannii strain 5377  NC_009085 
Actinomyces odontolyticus strain 1A.21  NZ_AAYI02000000 
Bacillus cereus strain NRS 248 NC_003909 
Bacteroides vulgatus strain ATCC®8482 NC_009614 
Clostridium beijerinckii strain NCIMB 8052  NC_009617 
Deinococcus radiodurans strain R1 (smooth)  NC_001263, NC_001264 
Enterococcus faecalis strain OG1RF  NC_017316 
Escherichia coli strain K12 sub-strain MG1655 NC_000913 
Helicobacter pylori strain 26695  NC_000915 
Lactobacillus gasseri strain 63 AM  NC_008530 
Listeria monocytogenes strain EGDe  NC_003210 
Neisseria meningitidis strain MC58  NC_003112 
Propionibacterium acnes strain KPA171202  NC_006085 
Pseudomonas aeruginosa strain PAO1-LAC  NC_002516 
Staphylococcus aureus strain TCH1516  NC_010079 
Staphylococcus epidermidis FDA strain PCI 1200  NC_004461 
Streptococcus agalactiae strain 2603 V/R NC_004116 
Streptococcus mutans strain UA159  NC_004350 
Streptococcus pneumoniae strain TIGR4  NC_00302 
Table 4.10 Mock Community HM-278D Species List 
Genomic DNA from Microbial Mock Community A (Even, Low Concentration), 





Further investigation of the sequenced Mock community showed that there were 81 
unique OTUs generated from this sample. This was reduced to 50 OTUs once 
rarefied to 60,000 sequences (Table 4.11). As there are only 20 species in the mock 
community the number of OTUs returned in an ideal scenario should be 20. 
However, there are always some erroneous and chimeric sequences that pass even 
very stringent quality filtering. The spurious OTUs were found to make only a small 
contribution to the total number of sequences, whereby most are in fact singletons or 
doubletons that would be filtered out in subsequent downstream beta-diversity 
analysis (Table 4.11).  
Once taxonomy were assigned for the OTUs from the mock community, it was 
apparent that Rhodobacter sphaeroides had not amplified in either of the Mock 
samples. Three clusters of Streptococcus OTUs were distinguished, but taxonomy 
assignment did not attribute a genus classification at 97% sequence identity. At 97% 
sequence similarity, the OTU picking method failed to highlight two OTU clusters 
for the two Staphylococcus spp. in the mock community. After removal of single and 
double sequences, the only spurious taxonomic classification of bacteria not in the 
mock community was Ralstonia spp.. However, only 15 out of 150,023 total 
sequences in the mock sample were assigned to this taxonomy. 
The mock sample that underwent the nested PCR protocol ‘Mock_Nested’ has a 
greater number of OTUs, singlets, and doublets (Table 4.11). This was expected as 
combined increase of PCR cycle number can amplify chimeric reads. The nested 
mock community proportions of the 19 taxonomic groups identified are also more 
varied, which highlights the primer bias in the first round of PCR, especially in 
favour of Helicobacter (Figure 4.7)  
 
 MOCK OTU Count MOCK_NESTED OTU Count 
All Reads 150,000 81 (48) 182 (108) 
Rarefied to 60,000 50 (26) 104 (60) 
Table 4.11 Sequenced Mock Community OTU Counts 






Figure 4.7 Mock Community Relative Abundance  
Bar plot of relative bacterial abundance determined by OTUs and grouped at the 
genus level. The expected proportions of HM-278D are shown in the left bar, the 
middle bar describes the actual proportions seen in the mock community sample that 
underwent x20 PCR cycles (method for fecal samples). The right bar shows the 
actual proportion from the mock community sample which underwent nested PCR 




Further analysis of the mock sample sequenced highlighted which taxa had positive 
and negative bias for amplification (Figure 4.8). In an ideal scenario each taxa’s 
contribution to the total number of sequence reads would be 5%. Helicobacter shows 
the most positive bias having nearly 8% of the sequence reads attributed to this 
genus. After Rhodobacter, which is not amplified, one of the Streptococcus spp. 
shows the greatest negative bias. 
 
Figure 4.8 Percentage Bias in Sequenced Mock Community 
Positive and negative amplification bias of each genus compared to an expected 5% 
contribution in HM-278D. #Analysis was unable to differentiate OTUs between the 







This chapter details a method for looking at the microbiome across body sites and 
has been optimised to consider the murine fecal and vaginal bacterial community. 
After review of the literature and in-silico work I deduced the V1-V2 region would 
provide the highest discrimination potential for species identification in the murine 
vagina and gastrointestinal tract. In this chapter I conducted in-silico primer 
evaluation to generate and confirm the suitability of universal sequencing primers to 
amplify the V1-V2 region of the 16S rRNA gene.  
As the murine vagina has a low bacteria burden, different sampling methods were 
evaluated for 16S rRNA gene recovery, this highlighted that whole vaginal tissue 
provides the most consistent bacterial yield. 
Different extraction methods used to isolate and extract bacterial DNA from 
ecological samples can give a varied representation of species diversity and 
abundance (Milani et al., 2013). Milani et al., (2013) found large variations in 
proportions of the contributing bacteria depending on the extraction method used; 
mechanical and/or enzymatic. Milani et al., (2013) concluded that Faecalibacterium 
and Bacteroides (gut microbial taxa), might be over-represented in human gut 
metagenomic studies as a result of this bias. Although I did not directly compare the 
bias in extraction methods in this study, I favoured the FastDNA® SPIN Kit with 
bead-beating over the PowerSoil® DNA Isolation Kit due to this reported reduction 
in bias towards Bacteroidetes phylum.  
Reagent contamination is emerging as a key factor in microbiome studies especially 
in low-biomass sites. Salter et al., (2014) demonstrated this using low concentrations 
of Salmonella DNA, where low biomass was associated with inflated spurious 
sequences of various taxonomic assignments. Ultra-pure polymerases and ultra-pure 
molecular grade water were used in this study with the aim of reducing potential 
contaminants. 
Co-sequencing of a mock community on the MiSeq platform highlighted that the 




extremely low, only 0.00673%. The mock community also highlights Ralstonia as a 
species for possible PCR reagent contamination, although only 15 out of 150,023 
total sequences in the mock sample were attributed to this clade. Molecular grade 
water is a common source of this bacterium (Grahn et al., 2003, Barton et al., 2006, 
Laurence et al., 2014). The mock community also highlights that the primers in this 
study are not suitable for picking up bacteria in the Rhodobacter genus as no OTUs 
were assigned to this taxonomy.  
Consideration was given in this study to keep the number of PCR cycles to a 
minimum as to reduce the affliction of PCR artifacts, such as chimeras, inflating 
OTU clusters (Acinas et al., 2005). A study comparing 15x and 30x PCR cycles 
showed a 30% inflation of chimeric amplicons with increased cycle number (Ahn et 
al., 2012).  
In this study, for the low biomass vaginal samples, a nested PCR approach was 
adopted. This approach was a compromise of controlling the number of chimeric 
reads while allowing for workable concentrations of PCR product to be obtained. 
Sequencing artifacts are also kept to a minimum by doing paired end sequencing 
(MiSeq only) and employing stringent downstream chimera checking. Using the 
most current database for taxonomic assignment is essential but there are still 
sequences that are poorly annotated.  
A limitation in this study was in the optimisation required to get strong amplification 
results using fusion-primers; which are known to be difficult due to the extended 
primer length and off target amplification. There are similar low cost methods of 
multiplexing that allow barcodes and sequencing adaptors to be added without 
having to incorporate target-specific sequences for each fusion primer. These 
methods employ a two-step PCR protocol, where shorter ‘tail’ sequences are 
incorporated in the first universal 16S rRNA amplification. The second PCR is then 
specific to the tail sequence allowing for barcodes and sequencing adapters to be 
added at this stage. Any processes involving two PCR steps, as I have shown in this 




bias. A robust study comparing multiplexing approaches for 16S rRNA sequences 
has yet to determine the associated bias in the various approaches. 
OTUs were clustered using a cut-off of 97% sequence identity to seed in database, 
which is generally accepted to represent species level. There is however some debate 
whether this cut-off is too conservative (Mizrahi-Man et al., 2013). Collectively, for 
the MiSeq data-set, only 0.01630% of the sequences did not align with the V1-V2 
region of the 16S rRNA gene, of all those sequences that did align, only 0.09143% 
were identified as non-bacterial (e.g. chloroplast, mitochondria and Archaea and 
unknown) with a cut off of 80% to bacteria kingdom. Collectively this means that 
only 0.5418% of total sequences passing quality filtering were not identifiable as 
bacterial. This low value is evidence of the specificity of the primers used in this 
study and appropriate quality filtering. 
Low nucleotide diversity in the first few cycles of sequencing on the Illumina 
platform is known to cause problems with base calling and the cluster identification 
algorithms, which impacts greatly on sequence quality (Krueger et al., 2011). To 
bypass/rectify this problem researchers often “spike-in” a PhiX shotgun library to 
increase diversity and gain better sequence quality. The amount of PhiX spike can 
range for 10% but some times as high as 50-80% depending on the complexity of 
targeted library (Mitra et al., 2015). This obviously has enormous impact on the per 
sample cost, as the majority of sequences are being assigned to PhiX and not the 16S 
rRNA gene of interest. In this study I attempt to reduce this problem by the 
incorporation of random nucleotides of varying lengths into the forward and reverse 
fusion-primers, known as ‘heterogeneity’ spacers. Cluster density of all MiSeq runs 
in this study was respectable, and raw sequence quality was above threshold; with 
>78% raw reads having an average quality of >Q20. This is suggestive that the 
heterogeneity spacers employed have reduced possible issues with low complexity 
and improved sequence quality. 
Cross-study comparisons with regards to 16S rRNA gene studies should be 
approached with some caution. Although the discussed factors in 16S rRNA 




method and variable regions were still shown to be less than the variation attributed 
to differences between individual samples and body sites (Wesolowska-Andersen et 
al., 2014, Lozupone et al., 2013). There is however still a need for a gold standard 
library preparation and bioinformatic protocol for looking at microbial communities.  
 
4.20 Summary 
In this chapter I have detailed a method for looking at the microbiome across body 
sites; specifically optimising protocols to consider the murine fecal and vaginal 
bacterial communities. Co-sequencing of a mock community highlights this 
workflow is robust for broad taxonomic classification, but is not suitable for picking 
up bacteria in the Rhodobacter genus. The mock community also highlights 




Chapter 5  




Chapter 5 Modulation of the Microbiome  
5.1 Introduction 
Animals offer researchers a vital tool by providing a model to test out host-
microbiome interactions under controlled environmental conditions. They also allow 
for infectious models that help understand pathogenicity. Gastrointestinal bacteria 
have an important role in maintaining multiple physiological processes. LL-37/Camp 
is upregulated during ileitis/colitis dependent on the level of inflammation (Schauber 
et al., 2006), and Camp null mice have more severe phenotype in a DSS induced 
colitis model (Koon et al., 2011). Addition of exogenous Camp could reverse some 
of the phenotypic severity of DSS treatment in Camp-/- animals, such as cytokine 
production, apoptosis and mucus production (Tai et al., 2013). In this chapter I look 
at the direct consequences of the cathelicidin gene on gut microbial diversity and 
structure, by interrogating the microbiome of Camp-/- animals. 
There are vast metabolic changes that occur during pregnancy, especially in late 
gestation, which could impact on microbial communities. Indeed, alterations in the 
maternal gastrointestinal bacteria have been implicated in metabolic adaptations to 
pregnancy (Koren et al., 2012, Collado et al., 2008). However, there are conflicting 
reports with regards to whether pregnancy causes the modulation of gut bacterial 
composition, with a large longitudinal study failing to show significant remodelling 
of the gut microbiota in pregnant women (DiGiulio et al., 2015). This study 
investigates whether there is remodelling in the diversity and composition of the 





The aims of this study were;  
1) To establish whether the microbiome of animals lacking cathelicidin are altered 
across body sites. 
2) To investigate whether there are gestational related changes in the female murine 
gut microbiome.  
3) To establish whether the vaginal microbiome is affected by pregnancy, results and 





5.2 Experimental Methods 
5.2.1 Camp-/- Microbiome and Pregnancy Microbiome Study  
Virgin female and male mice of either wildtype C56BL6/J Ola Hsd (n=10♀/10♂) or 
Camp-/- (n=8♀/♂8) genotype (congenic on C57BL/6J Ola Hsd) had fecal samples 
collected on day 0. Within genotype, these animals were set-up in mating pairs and 
females were checked for a copulatory plug over 4 consecutive days. On day 4 
female animals were removed from the mating and singly housed for the remainder 
of the experiment. Subsequently, the majority of the female animals became 
pregnant; with the remainder providing the non-pregnant control group. In parallel, 
littermate female virgin mice, not exposed to any males, were singly housed on Day 
0 providing the non-plug control group. Fecal samples were collected from females 
on day 4, day 10 and day 17, when animals were culled on day 17 vaginal tissue was 
also collected. A subset of pregnant wildtype mice continued to term, where fecal 
and vaginal samples were collected postpartum on day 22. 
All fecal and vaginal tissue samples were stored at -20°C within 2 hours of collection 
and DNA was extracted within 3 weeks. Sample extraction, multiplexing and library 
preparation was conducted as described in Chapter 4 using the MiSeq protocols. 
 
Figure 5.1 Experimental Timeline for Camp-/- Microbiome Study 
Fecal samples were taken from male and female mice on Day 0 at the start of the 
experiment. Female animals were longitudinally sampled on Day 4, Day 10, Day 17 
and a subset on Day 22. Non-plug female control animals were also longitudinally 
sampled on Day 4, Day 10, and Day 17. Animals were culled on Day 17 or Day 22 






Table 5.1 Experimental Sample Number for Camp-/- Microbiome Study 
Table displaying the number and genotypes of animals at each collection time-point 
in this study. Numbers given are for fecal sampling; vagina sample numbers are 











Day 0 8 2 2 10 6 2 2 8
Day 4 8 2 2 6 2 2
Day 10 8 2 2 6 2 2
Day 17 8 (5) 2 (2) 2 (2) 6 (6) 2 (2) 2 (2)






5.3.1 Data Summary 
The full 16S rRNA gene sequencing performed on the Illumina MiSeq platform 
consisted of 139 samples; two mock communities, 114 murine fecal samples and 22 
murine vaginal samples. Amplicon libraries were sequenced on 6 independent MiSeq 
lanes. Bioinformatic and quality filtering done on the raw data are described in 
section 4.11, but in brief; runs were demultiplexed and barcodes and indexes 
removed using Illumina software. Raw sequence read quality filtering and primer 
trimming was done using Cutadapt and Trimmomatic. The total number of raw reads 
prior and post data processing is given in Table 5.2. Quality filtering the raw reads 
reduced the number of paired end reads from 31,640,538 (raw paired reads) to 
30,279,366 reads (processed paired reads) (Figure 5.2). 
Contigs were made in Mothur and screened as detailed in section 4.11. Chimeras 
were removed by UCHIME and operational taxonomic units (OTUs) were picked de 
novo and clustered at 97% sequence similarity using the NAST algorithm. The 
taxonomy was assigned by RDP classifier (Bootstrap threshold 80%) using SILVA 
(v119) as the reference database. This further quality screening reduced the number 
of processed paired end reads from 30,279,366 (processed paired reads) to 











Paired read #: 31,640,538 (100%) 30,279,366 (100%) 24,306,711 (100%) 
Number of 
Q>=20 reads: 
31,083,664 (98.24%) 30,279,366 (100%) NA 
Number of 
Q>=30 reads: 
24,869,462 (77.86%) 23,287,860 (76.91%) N/A 
Read Length: 300 ± 0.00 279 ± 1.18 316 (Contig length) 
GC Content 55.80% ± 4.64 55.89% ± 4.69 N/A 
N base Count 691,892 218,510 0 
Table 5.2 MiSeq Sequence Quality Summary 
Summary data for raw paired reads, processed paired reads, and filtered contigs for 
n=139 samples on 6 MiSeq lanes. A Phred +33 quality score of Q20 is predicted 




Figure 5.2 MiSeq Processed Paired Reads and Filtered Contigs  
Processed paired reads and quality filtered contig counts of all n=139 samples. Grey 
dotted line represents mean processed paired read count at 217,837 sequences. Green 





5.3.2 Taxa Summary 
In this study 2,257 OTUs were identified collectively in the full data-set, many of 
these were low abundant OTUs. Sub-sampling each sample to 60,000 sequences 
(discussed in section 5.3.5) reduced the number of OTUs to 915 across the data-set. 
Removal of singletons and doubletons further pruned the OTU count to 908. These 
908 OTUs represent 143 unique genera, 82 unique family level classifications, 50 
unique orders, 29 unique classes and 15 different phyla (Figure 5.3). 
 
 
Figure 5.3 Taxonomic Classification Hierarchy 
(a) Schematic view of taxonomic classification hierarchy. (b) Distribution of 















Subset 1 - Fecal vs. Vaginal 
To examine the murine fecal microbiome in relation to vaginal bacterial 
communities, Subset 1 consisted of the full data-set minus the two mock community 
samples, which are evaluated in section 4.18. This subset includes the full data of 
vaginal (n=22) and fecal samples (n=115).  
Subset 2 - Camp-/- vs. C57BL/6J 
To determine whether there is any genotypic difference in the fecal microbiome in 
Camp-/- compared to wildtype C57BL/6J animals, the data was further partitioned to 
only include fecal samples from the Camp-/- pregnancy microbiome study (n=99; 42 
Camp-/- , 57 C57BL/6J). 
Subset 3 - C57BL/6J; Gestational effect 
To examine whether the fecal microbiome varied longitudinally both in a non-
pregnant and pregnant state, fecal samples were further partitioned to only include 
the wildtype C57BL/6J animals which were longitudinally sampled at 4 time-points 
over 17 days (n=44 samples; 16 non-pregnant, 28 pregnant). 
Subset 4 - Vaginal Microbiome; Camp-/- vs. C57BL/6J, Pregnant vs. 
Non-pregnant 
This subset included only the vaginal samples (n=22), and is detailed and discussed 





5.3.4 Rarefaction Curves  
As deep sequencing was performed in this study, it would be assumed that the depth 
of sequencing is sufficient for robust conclusions to be made. However, this needs to 
be empirically established as a true representation is dependent on community 
complexity. To establish whether the depth of sequencing truly captures the 
community, a method commonly called rarefaction was employed (discussed in 
section 4.14). 
Multiple rarefactions to a maximum sampling depth of 60,000 sequences were 
calculated for each sample and species richness (Sobs), Chao1 Estimate, Shannon 
Diversity, and Inverse Simpsons Index, were computed for each simulated 
sequencing effort (Figure 5.4). Specifically, 10 rarefactions at 10 increasing depths 
(6,000 integers) were conducted on the data. Maximum rarefaction at 60,000 was 
chosen as this is the number of sequences from the lowest sample. 
Visual assessment of the rarefaction plots reveal that the diversity and complexity of 
the vaginal community is considerably lower than the fecal samples, as expected, 
displayed by lower amplitude on the rarefaction curves (Figure 5.4). A common 
trend was seen in all mean diversity measures in both fecal and vaginal samples, 
whereby a steep increase up-to 6,000 is observed followed by a plateau to varying 
degrees (Figure 5.4). The number of observed OTUs (Sobs) can sometimes never 
reach a true plateau, as this is often a factor of sequencing chemistry error and 
stringency of OTU alignment. Chao1 estimates species richness based on the ratio of 
singletons to doubletons in the sample and is therefore also a factor of Sobs. Chao1 
and Sobs show a steady increase with sampling effort after 6,000 sequences but this is 
not adding to the complexity of community structure. This can be seen by the 
Shannon Diversity and Inverse Simpson Index, which are stable past 6,000 
sequences. This suggests that many OTUs are present in low abundance. Overall the 
curves reach an acceptable plateau somewhere before 6,000, highlighting that 
sequence depth >6,000 is more than adequate to capture a true representation of the 
community. Subsequent beta-diversity measures were calculated on a single 





Figure 5.4 Rarefaction Curves - Fecal and Vaginal 
Rarefaction curves created for (a) Observed OTUs (Sobs) (b) Chao1 Estimate (c) 
Shannon Diversity (d) Inverse Simpsons Index of fecal (n=122) and vaginal (n=22) 
samples. Rarefaction plots are displayed as diversity measure versus simulated 
sequencing effort at 10 iterations per depth, to maximum depth of 60,000 sequences. 






5.3.5 Subsampling; Single Rarefaction 
Although library quantification steps, such as KAPA qPCR (detailed in section 
4.8.5), were used in this study, there was still a degree of unequal contribution of 
each library to the sequencing reads (Figure 5.2). In addition, as sequencing in this 
chapter was conducted over 6 independent MiSeq lanes, there is additional 
variability in depth due to lane specific characteristics. Although there is some debate 
about whether subsampling (single rarefaction) to normalise 16S rRNA amplicons is 
essential (McMurdie and Holmes, 2014); to minimise artificial inflation of diversity 
from samples with greater coverage I performed subsampling to a depth of 60,000. 
This was done as the biological questions I will be asking are based on beta-diversity 
measures, which have sensitivity to sample size. This subsampling depth was chosen 
as it is the number of sequences of the lowest sample. 
5.3.6 The Murine Fecal Microbiome in Relation to Vaginal 
Bacterial Communities (Subset 1) 
5.3.6.1 Alpha Diversity 
Alpha diversity is a measure of diversity ‘within’ a sample and can be assessed using 
various metrics. Observed species (Sobs), Shannon Diversity, and Inverse Simpson 
Index were calculated for each sample on the rarefied but unfiltered OTU data 
(Figure 5.5). As expected the vaginal community has a significantly lower number of 
observed species, lower Shannon Diversity and lower Inverse Simpsons Index than 
the fecal samples (P<0.0001 for all). The mean Shannon Diversity measure for fecal 
sample is 5.98 ± 0.06, whereas the mean value for vaginal samples is 1.06 ± 0.1. This 
indicates that the fecal microbiome is significantly more complex than the vaginal 
community. This is a result of the vaginal microbiome being dominated by just a few 
high abundant OTUs. The most abundant genera found in the vaginal samples are 






Figure 5.5 Alpha Diversity Fecal vs. Vaginal 
Boxplots representing median, IQR, whisker length represents 1.5x IQR of the (a) 
Observed species, (b) Shannon Diversity and (c) Inverse Simpson Index measures 
calculated for all samples and grouped by sample site; vagina (n=22) or fecal 
(n=115). All measures indicate that the fecal community is statistically more 












5.3.6.2 Beta Diversity 
While Alpha Diversity is descriptive for inferring community structure, the identity 
of each species is not considered; therefore it will not tell us if the same bacteria are 
shared between samples. Beta diversity, specifically weighted and unweighted 
UniFrac distance, was calculated between the vaginal and fecal samples and 
visualised using Principle co-ordinate Analysis (PCoA). As expected, these pairwise 
comparisons show substantial variation in bacteria community membership 
(unweighted UniFrac) and substantial variation in community structure (weighted 
UniFrac) between the two body sites (Figure 5.6). 
 
 
Figure 5.6 UniFrac Distance 2D PCoA plots of Vagina and Fecal 
Community 
(a) Unweighted and (b) weighted UniFrac 2D PCoA plots illustrating the relationship 
between the bacterial diversity of fecal (n=115) samples compared to vaginal (n=22) 
samples. Points are coloured by sample group and shape by sample sex. Each point 









5.3.6.3 Sample Cross Contamination 
Due to the close proximity of the murine vagina and anus it is possible that cross-
contamination during sampling can occur. To determine whether this is a common 
occurrence the shared taxa between the two sites were compared. There were 188 
overlapping OTUs between the vaginal and fecal samples (Figure 5.7.a). This portion 
is higher than expected, inferred from what Barfod et al., (2013) had detailed 
comparing the cecum and vagina. Due to the high depth of sequencing I conducted in 
this study, many of these shared OTUs are low abundant; less than 100 sequences. If 
only OTUs with an abundance of >0.1% are considered, the number of shared OTUs 
is reduced to 50 (data not shown), these shared OTUs represent only 4 different 
genus level classifications (Figure 5.7.b); Staphylococcus, Lactobacillus, S24-7-
Family, and Pseudomonas. This is more in keeping with the proportions of shared 
taxa detailed in Barfod et al., (2013).  
The contribution of Pseudomonas to the fecal community is highly skewed by one 
animal that had predominately Pseudomonas sequences. Pseudomonas should 
therefore not be defined as a common fecal bacterium in this study. Staphylococcus, 
Lactobacillus, and Pseudomonas have previously been reported in the vagina of 
laboratory and wild mice (MacManes, 2011, Barfod et al., 2013). S24-7 is mostly a 
mouse gut associated bacteria, sequences from this genus are most likely due to low 
level contamination from fecal material. The contribution of S24-7 sequences in the 
vagina is 0.22% compared to fecal sample where 44.6% of sequences are from this 
clade. To conclude there is very little overlap between fecal and vaginal microbiota, 





Figure 5.7 Venn diagram of Shared Taxa between Fecal and Vaginal 
Samples 
(a) Displays the number of shared OTUs between fecal and vaginal samples in 
Subset 1. (b) Shared genus between fecal and vaginal samples from Subset 1 where 








5.3.7 Fecal Microbiome of Camp-/- Animals (Subset 2) 
To establish whether Camp-/- animals have altered diversity and composition of the 
fecal microbial community compared to wildtype animals, 16S rRNA sequences 
from Camp-/- samples (n=42) and C57BL/6J samples (n=57) were compared. Alpha 
diversity measures were compared between these sample populations, in addition, 
the UniFrac distances were also recomputed on this subset. 
5.3.7.1 Phylum Level Classification 
The 648 unique OTUs in Subset 2 represented 9 phylum level classifications (Figure 
5.8). The murine fecal samples were dominated by two main phyla, Bacteroidetes 
(gram negative) and Firmicutes (gram positive), contributing on average 56.78% and 
39.57% of the sequences respectively. Seven other phyla were represented but only 
at very low levels of less than 1%. Bacteroidetes and Firmicutes collectively made 
up around 96% of the sequences; this is slightly inflated over other studies that have 
shown 70–80% contribution of these two phyla (Salzman et al., 2003, Salzman et al., 
2007). In this study the relative abundance of Tenericutes (0.52% ± 0.02%) and 
Deferribacteres (0.51%  ± 0.01%) are lower than seen in other 16S rRNA studies 
(Turnbaugh et al., 2008, Nagalingam et al., 2011). Tenericutes have commonly been 
shown to contribute around 3-5% of sequences in other 16S rRNA investigations. 
This clade is highly sensitive to diet, where increases in Mollicute, a subclass of 
Tenericutes, have been observed in obese animals (Turnbaugh et al., 2008). In 
contrast Mollicute spp. are decreased in animals as a result of DSS treatment 
(Nagalingam et al., 2011).  
At the phylum level, C57BL/6J and Camp-/- samples have a very similar 
contribution of sequences to the 9 phyla. C57BL/6J have on average 54.63% ± 
6.99% sequences classified as Bacteroidetes, whereas in the Camp-/- samples the 
average contribution is 58.24% ± 9.48%. For Firmicutes, the average contribution in 
C57BL/6J samples is 41.88% ± 5.36% and 38.01% ± 6.19% in Camp-/- samples.  
The significance of these differences is estimated using Linear Discriminant Analysis 





Figure 5.8 Phylum Level Classification in Camp-/- vs. C57BL/6J Fecal 
Samples 
Average relative abundance of sequences at the phylum level of C57BL/6J (n=57) 










Phylum C57BL/6J  C57BL/6J SD Camp-/- Camp-/- SD 
Bacteria;Actinobacteria 0.21% 0.03% 0.26% 0.04% 
Bacteria;Bacteroidetes 54.63% 6.99% 58.24% 9.48% 
Bacteria;Candidate_division_TM7 0.08% 0.01% 0.08% 0.01% 
Bacteria;Cyanobacteria 0.25% 0.03% 0.28% 0.05% 
Bacteria;Deferribacteres 0.57% 0.07% 0.47% 0.08% 
Bacteria;Firmicutes 41.88% 5.36% 38.01% 6.19% 
Bacteria;Proteobacteria 0.85% 0.11% 0.82% 0.13% 
Bacteria;Tenericutes 0.35% 0.04% 0.64% 0.10% 
Bacteria;Verrucomicrobia 0.00% 0.00% 0.02% 0.00% 
Bacteria;unclassified 1.18% 0.15% 1.18% 0.19% 
Table 5.3 Phylum Level Classification in Camp-/- vs. C57BL/6J Fecal Samples 





5.3.7.2 Genus Level Classification 
The 648 unique OTUs in Subset 2 represented 78 genus level classifications. Figure 
5.9.a and Table 5.4 show the relative abundance of these genera in each sample 
(n=99). Genera with a contribution of <0.5% sequences have been grouped and 
represented as ‘low OTUs’ for ease of visualisation.  
Bacteroidetes 
Ten Bacteroidetes genera were identified which represent six different families. The 
most dominant Bacteroidetes in the fecal samples were found to be S24-7 family of 
bacteria, contributing on average 44.98% of the sequences. The next abundant genera 
of Bacteroidetes were, Alistipes, Bacteroides and RC9 gut group, contributing 
3.65%, 2.74% and 1.29% average sequences respectively.  
S24-7 family, a butyrate-producing bacterium predominantly only seen in rodents, 
covers the largest component of mouse fecal sequences assigned in the Bacteroidetes 
phylum. Alistipes spp. are found in the gastrointestinal tract of both humans and 
mouse. It has been reported to be the most significantly overrepresented taxa in older 
mice (Langille et al., 2014), which is consistent to what has been shown in humans, 
suggesting parallel age related microbial shifts in this taxa (Claesson et al., 2012). 
Gastrointestinal Bacteroides are an abundant and well-studied member of the 
mammalian commensal microbiota providing many beneficial activities, including 
the metabolism of complex carbohydrates and glycosylation (Comstock, 2009, 
Hooper et al., 2001). 
Firmicutes 
Forty Firmicutes genera were identified, representing nineteen different families. The 
most dominant Firmicutes were Lactobacillus with 11.23% contribution, followed by 
Blautia, an unclassified Lachnospiraceae, and an unclassified Ruminococcaceae, 




Lactobacillus spp. colonise the gut and mucosal sites of most mammals where they 
can adhere to the non-secreting stomach epithelium, continuously seeding the content 
of the stomach. Interestingly the absence of Lactobacillus reuteri in the gut of mice 
causes autism-like behaviours, which can be reversed by probiotic inoculation of this 
bacterium (Buffington et al., 2016). The mechanisms of this are still unclear but 
Lactobacillus reuteri has been shown to increase the levels of the oxytocin hormone 
(Buffington et al., 2016). Other Lactobacillus species have also been found to have 
cognitive effects in mice (Bravo et al., 2011). 
Blautia is a genera often associated with the production of beneficial Short-chain 
fatty acids (SCFAs), which are also thought to work in helping suppress 
inflammation. Interestingly giving Blautia spp. to mice could protect them from graft 
versus host disease (Jenq et al., 2015). 
Lachnospiraceae family is abundant in the digestive tracts of many mammals but is 
rarely found at other sites, it is also a group often associated with the production of 
SCFAs. Members of this family in humans have been linked to obesity and colon 
cancer, mainly due to the association with the production of Butyric acid. Although 
this property is not conserved as not all species of Lachnospiraceae have genes 
related to Butyric acid production (Meehan and Beiko, 2014).  
Ruminococcaceae is a family normally found just in the ruminant gut, although 
species within this family have also been seen in human gastrointestinal samples 
(Wang et al., 2004a). 
Shared Taxa  
77 of the 78 genera were common to C57BL/6J and Camp-/- samples. The only 
genera not shared were the low abundant Akkermansia. C57BL/6J samples 
collectively had no sequences from this clade; Camp-/- animals had 0.02% average 
Akkermansia contribution. Although, this clade was not consistently seen in all 
Camp-/- animals; only 11/42 had Akkermansia sequences. The most abundant 
genera, S24-7 family, are higher in the Camp-/- samples; 47.32% compared to 




wildtypes displaying 11.82% compared to Camp-/- samples which had 10.43% 
average contribution. Lower abundant genera also show differences such as 
Allobaculum, which is 2.02% in C57BL/6J and 0.95% in Camp-/-mice. The 
significance of these differences, and all other OTUs, is estimated using Linear 
















Figure 5.9 Genus Level Classification in Camp-/- vs. C57BL/6J Fecal Samples  
(a) Relative abundance of each genus level sequence contribution in n=99 fecal samples. (b) Average relative abundance of C57BL/6J 
(n=57), Camp-/- (n=42) fecal samples. For visual clarity, only the 23 most abundant genera are displayed. Those genera with an abundance 








Taxon C57BL/6J Camp-/- 
Bacteria;Bacteroidetes;Bacteroidia;Bacteroidales;S24-7;unclassified 43.25% 47.32% 
Bacteria;Firmicutes;Bacilli;Lactobacillales;Lactobacillaceae;Lactobacillus 11.82% 10.43% 
Bacteria;Firmicutes;Clostridia;Clostridiales;Lachnospiraceae;Blautia 9.34% 8.52% 
Bacteria;Firmicutes;Clostridia;Clostridiales;Lachnospiraceae;unclassified 6.10% 6.58% 
Bacteria;Bacteroidetes;Bacteroidia;Bacteroidales;Rikenellaceae;Alistipes 3.70% 3.57% 
Bacteria;Firmicutes;Clostridia;Clostridiales;Ruminococcaceae;unclassified 3.38% 3.12% 
Bacteria;Bacteroidetes;Bacteroidia;Bacteroidales;Bacteroidaceae;Bacteroides 3.05% 2.33% 
Bacteria;Firmicutes;Erysipelotrichia;Erysipelotrichales;Erysipelotrichaceae;Allobaculum 2.02% 0.95% 
Bacteria;Firmicutes;Clostridia;Clostridiales;Lachnospiraceae;Incertae_Sedis 1.60% 1.32% 
Bacteria;Firmicutes;Clostridia;Clostridiales;unclassified;unclassified 1.49% 1.45% 
Bacteria;Bacteroidetes;Bacteroidia;Bacteroidales;Rikenellaceae;RC9_gut_group 1.22% 1.37% 
Bacteria;Bacteroidetes;Bacteroidia;Bacteroidales;Porphyromonadaceae;Odoribacter 1.14% 1.35% 
Bacteria;unclassified;unclassified;unclassified;unclassified;unclassified 1.18% 1.18% 
Bacteria;Firmicutes;Clostridia;Clostridiales;Lachnospiraceae;Roseburia 1.06% 0.76% 
Bacteria;Bacteroidetes;Bacteroidia;Bacteroidales;unclassified;unclassified 0.34% 1.64% 
Bacteria;Bacteroidetes;Bacteroidia;Bacteroidales;Prevotellaceae;Prevotella 1.32% 0.22% 
Bacteria;Firmicutes;Clostridia;Clostridiales;Ruminococcaceae;Oscillibacter 0.85% 0.76% 
Bacteria;Firmicutes;Clostridia;Clostridiales;Defluviitaleaceae;unclassified 0.71% 0.54% 
Bacteria;Firmicutes;unclassified;unclassified;unclassified;unclassified 0.49% 0.73% 
Bacteria;Firmicutes;Clostridia;Clostridiales;vadinBB60;unclassified 0.51% 0.65% 
Bacteria;Deferribacteres;Deferribacteres;Deferribacterales;Deferribacteraceae;Mucispirillum 0.57% 0.47% 
Bacteria;Firmicutes;Clostridia;Clostridiales;Ruminococcaceae;Anaerotruncus 0.56% 0.47% 
Bacteria;low OTUs (<0.5%) 4.29% 4.27% 
Table 5.4 Genus Level Classification Camp-/- vs. C57BL/6J Fecal Samples 
Average percentage contribution of sequences to each genera in C57BL/6J (n=57) and Camp-/- (n=42) samples. Those genera with an 
abundance <0.5% have been combined and displayed as ‘Low OTUs’. The significance of any differences including samples of low 




5.3.7.3 Alpha Diversity 
The alpha diversity measures; Sobs, Shannon Diversity and Inverse Simpsons Index 
were calculated for each sample on the rarefied but unfiltered OTU data (Figure 
5.10). There was no significant difference in any alpha diversity metric between the 
C57BL/6J and the Camp-/- samples (two sample t-test). All measures indicate that 




Figure 5.10 Comparison of Alpha diversity for C57BL/6J vs. Camp-/- 
Boxplots representing median, IQR, whisker length represents 1.5x IQR of the (a) 
observed species Sobs (b) Shannon Diversity (c) and Inverse Simpsons Index 
calculated for all samples and grouped by genotype; C57BL/6J (n=57) and Camp-/- 
(n=42). All measures indicate that the fecal communities are equally complex (NS: 









5.3.7.4 Beta Diversity 
The pairwise qualitative difference between sample diversities (unweighted UniFrac) 
distances reveals there is a highly significant difference in the diversity within 
genotypes compared to between genotypes (P<0.0001), whereby Camp-/- knockout 
animals are significantly more diverse than the wildtype controls (P<0.0001) (Figure 
5.11). The diversity between genotypes is also significantly more than the diversity 
within each genotype respectively (P <0.0001 for both). Nonparametric p-values 
were also calculated using 999 Monte Carlo permutations and Bonferroni-corrected, 
all tested pairs give P <0.01. 
That is to say animals are more similar to other animals of the same genotype than 
they are to another animal of the opposite genotype. In addition the Camp-/- animals 





Figure 5.11 Unweighted UniFrac Distance Boxplots comparing 
C57BL/6J vs. Camp-/- 
Boxplots representing median, IQR with min, max whisker of pairwise unweighted 
UniFrac distance within genotypes and between genotypes. (Parametric two sample 
t-test, Bonferroni-corrected P<0.0001;****) (Nonparametric p-value using 999 
Monte Carlo permutations and Bonferroni-corrected P<0.01; ##) C57BL/6J (n=57) 






The pairwise UniFrac distances were visualised using Principle co-ordinate Analysis 
(PCoA) (Figure 5.12). Principal coordinate 1 (Axis 1; percent variation explained: 
19.6%) of the unweighted UniFrac distances separates the two genotypes, while 
Principal coordinate 2 (Axis 2; percent variation explained: 9.7%) intercepts the 
genotypes and appears to be driven partly by cage variation, especially for the 
wildtype cluster (Figure 5.13). In the weighted UniFrac plot, there is no apparent 
separation of the samples by genotype or cage, and therefore does not highlight 
substantial variation in community structure. The clustering of samples by genotype 
in the unweighted UniFrac suggests a strong relationship in terms of qualitative 
community membership.  
In other terms, it is the presence or absence of certain OTUs that is driving the 







Figure 5.12 UniFrac Distance 2D PCoA plots - Coloured by Genotype  
(a) Weighted and (b) Unweighted UniFrac 2D PCoA plots illustrating the 
relationship between the bacterial diversity of fecal samples from C57BL/6J (n=57) 
and Camp-/- mice (n=42). Points are coloured by genotype and shape by sample sex. 
Each point represents an individual sample. PCoA axis 1; horizontal separation 










Figure 5.13 UniFrac Distance 2D PCoA plots - Coloured by Cage 
(a) Weighted and (b) Unweighted UniFrac 2D PCoA plots illustrating the 
relationship between the bacterial diversity of fecal samples from C57BL/6J (n=57) 
and Camp-/- (n=42) samples. Points are coloured by breeding cage and shape by 








To determine whether the spatial separations in the PCoA plots associated with 
genotype were significant, two methods of hypothesis testing were conducted; 
ANOSIM and Adonis. ANOSIM was conducted on the unweighted UniFrac distance 
matrix and compared C57BL/6J and Camp-/- samples. The difference between 
genotypes is significant with an r-statistic of 0.6345 (P <0.001). Adonis, a 
permutation approach, gave an r
2
 value of 0.16781 (P <0.001). The concordant result 
of these two hypothesis methods gives weight to the conclusion that the grouping of 
samples based on genotype is significant. The same hypothesis tests on the weighted 
UniFrac distances did not show any significant values which backs up the lack of 










 Pr(>F)  
Unweighted Genotype 1 0.2564 0.2564 19.5600 0.1678 0.001 *** 




Test Factor  
Number of 
permutations 
r statistic p-value  
Unweighted Genotype 999 0.63450 0.00100 *** 
Weighted Genotype 999 0.00180 0.35700  
Table 5.5 Hypothesis testing comparing C57BL/6J vs. Camp-/- Samples 
Adonis (top) and ANOSIM (bottom) summary statistics comparing C57BL/6J 
(n=57) and Camp-/- (n=42) samples. Both tests on unweighted UniFrac distance 







As a portion of samples in this study were taken from the same mouse across 4 time-
points, this raises the question of whether intra-mouse correlations are artificially 
increasing the similarity within genotype. To address this question, I examined the 
average beta-diversity from the same mouse and compared to the beta-diversity 
between mice, within the same genotype (Figure 5.14). The mean unweighted 
UniFrac distance within animals is statistically lower than the mean UniFrac distance 
between animals in both genotypes (P; <0.0001; parametric two sample t-test, 
Bonferroni-corrected). Overall this suggests the phylogenetic diversity within the 
same-animal at the different time-points is more similar than between samples at the 
various time-points. That is to say animals are more similar to themselves than they 
are to another animal within genotype. This difference suggests no substantial intra-
mouse changes in the microbiome composition over the short period of time (17 
days). This will however inflate the apparent similarity within genotype; therefore a 
further subset of the data is required to only include mice that have been sampled 
once to confirm this separation by genotype is significant. Sub-setting to only include 






Figure 5.14 Unweighted UniFrac Distance Boxplots - Inter and Intra 
Animal Variation  
Boxplots representing median, IQR with min, max whisker of pairwise unweighted 
UniFrac distance within genotypes and between genotypes. (Parametric two sample 
t-test, Bonferroni-corrected P<0.0001;****) (Nonparametric p-value using 999 
Monte Carlo permutations and Bonferroni-corrected P<0.01; ##) C57BL/6J (n=57) 






The pairwise UniFrac distances were recalculated to only include samples from Day 
0 and visualised using Principle co-ordinate Analysis (PCoA) as before (Figure 5.15 
& Figure 5.16). Axis 1 of the unweighted UniFrac distances separates the two 
genotypes as was shown previously. In the weighted UniFrac plot, there is no 
apparent separation of the samples by genotype or cage, and therefore does not 
highlight substantial variation in community structure, as previous. The clustering of 
samples by genotype by unweighted UniFrac in the reduced subset suggests the 
strong relationship in community membership is upheld.  
To determine whether the spatial separations in the PCoA plots associated with 
genotype were still significant after reducing the subset to just Day 0; ANOSIM and 
Adonis were applied. ANOSIM suggested the difference between genotypes is 
significant with an r-statistic of 0.5856 (P <0.001). Adonis gave an r
2
 value of 0.1725 
(P <0.001). The concordant result of these two hypothesis methods gives weight to 
the conclusion that the grouping of samples based on genotype is significant. The 
same hypothesis tests on the weighted UniFrac distances did not show any 








Figure 5.15 UniFrac Distance 2D PCoA plots - Coloured by Genotype; 
Day 0 Subset 
(a) Weighted and (b) Unweighted UniFrac 2D PCoA plots illustrating the 
relationship between the bacterial diversity of fecal samples from C57BL/6J (n=22) 
and Camp-/- (n=17) animals. Points are coloured by genotype and shape by sample 











Figure 5.16 UniFrac Distance 2D PCoA plots - Coloured by Cage; Day 0 
Subset  
(a) Weighted and (b) Unweighted UniFrac 2D PCoA plots illustrating the 
relationship between the bacterial diversity of fecal samples from C57BL/6J (n=22) 
and Camp-/- (n=17) animals. Points are coloured by breeding cage and shape by 

















 Pr(>F)  
Unweighted 
Genotype 
1 (38) 0.0983 0.09836 7.9216 0.1725 0.001 *** 
Weighted 
Genotype 







r statistic p-value  
Unweighted Genotype 999 0.5856 0.001 *** 
Weighted Genotype 999 0.0056 0.310  
 
Table 5.6 Hypothesis testing comparing C57BL/6J vs. Camp-/- Animals; 
Day 0 subset 
Adonis (top) and ANOSIM (bottom) summary statistics comparing C57BL/6J 
(n=22) and Camp-/- (n=17) animals. Both tests on unweighted UniFrac distance 
show significant grouping. The weighted UniFrac distance shows no significant 






5.3.7.5 Jack-knife Support; UPMGA bootstrapping 
To estimate the uncertainty in the PCoA plots, Jack-knife bootstrapping was 
performed, whereby samples are hierarchically clustered based on inter-sample 
variation in UniFrac distances. Specifically, 100 jack-knife replicates at 45,000 
sequences were used to generate a bootstrapped Unweighted-Pair Group Method 
with Arithmetic mean (UPGMA) tree for the unweighted distance matrix (Figure 
5.17). Tree generally supports the clustering seen in the PCoA plots; phylogenetic 
clustering of samples by genotype with the exception of one outlier and root. 
 
Figure 5.17 Jack-knife Unweighted UniFrac UPGMA Bootstrapped Tree 
Unweighted UniFrac pair group method with arithmetic mean (UPGMA) of Jack-
knife distance, re-sampling 100 times at 45,000 sequences. Fecal Samples are 




5.3.7.6 Significant Taxa (LEfSe) 
Using Linear Discriminant Analysis with Effect Size (LEfSe), an all-against-all 
multi-class comparison of C57BL/6J and Camp-/- fecal samples was performed 
(Figure 5.18). This highlighted several taxa were specifically modulated by 
genotype. 
A total of three core microbial groups at the family level were identified with 
enrichment; Erysipelotrichaceae, Anaeroplasmataceae and Prevotellaceae. The most 
notable OTU assigned to be enriched in Camp-/- samples was OTU0003, which was 
classified as S24-7 family of bacteria, having an LDA score of 4.12. At the family 
level this bacterium is not shown to have significant enrichment in Camp-/- samples. 
OTUs within Lachnospiraceae and Blautia genera were also enriched in Camp-/- 
animals.  
C57BL/6J samples show an enrichment of Prevotella, this is very interesting as the 
Camp-/- samples are nearly devoid of Prevotella clade. Certain Blautia OTUs and 
Allobaculum are also enriched in the C57BL/6J samples. 
The only enriched ‘class’-level taxa was Erysipelotrichia (p.Firmicutes), which was 
mainly attributed to the genera Allobaculum. Allobaculum was significantly enriched 
in C57BL/6J compared to Camp-/- samples. The other main genera showing multi-
level enrichment were Anaeroplasma, which were enriched in Camp-/- samples. As 
one of the few Tenericutes observed in this study, Anaeroplasma contributed to the 
enrichment back to the ‘order’-level of classification. Prevotella was highlighted as 
an enriched genera in the C57BL/6J animals, this genus (and family) were also 







Figure 5.18 Significant Differential Abundant Taxa in C57BL/6J vs. 
Camp-/- Fecal samples 
Differential abundant taxa with and LDA cut-off score of >3.0. Enriched taxa in 
C57BL/6J samples (n=57) are indicated with positive LDA score, while taxa 
enriched in Camp-/- (n=42) have a negative LDA score. ‘p’, phylum; ‘c’, class; ‘o’, 
order; ‘f’, family; ‘g’, genus. For visual clarity, the full classifications of the 
significant taxa are not annotated. Only the phylum and the significant domain are 
annotated. Where the significant domain is ‘unclassified’ the next hierarchical 





Figure 5.19 Top 6 Differential abundant OTUs 
Comparison of relative abundance of top OTUs highlighted as enriched in C57BL/6J 
(a-c) or Camp-/- (d-f) samples. Each bar represents a sample and the mean value 
within genotype is represented by the dotted line. (P value for each OTU group is 
reported using Wilcoxon rank sum test). Taxa names are previously described in 




5.3.8 Pregnancy Modulation of the Microbiome (Subset 3) 
To examine whether the fecal microbiome varied longitudinally both in a non-
pregnant and pregnant state, samples were partitioned to only include the wildtype 
C57BL/6J animals which were sampled at 4 time-points over 17 days (n=44 samples; 
16 non-pregnant, 28 pregnant). 
 
5.3.8.1 The Stability of the Fecal Microbiome- Non Pregnant 
Establishing baseline instability in a population is important when trying to infer 
microbial shifts that are truly related to pregnancy. It is therefore important to 
establish the diversity and composition of the bacterial community in a steady sate. 
To determine the stability of the fecal microbiome over 17 days, longitudinal 
samples of female C57BL/6J animals (n=4 animals, n=16 samples) were analysed for 
alpha and beta diversity measures. The 4 mice investigated here (Animal ID: F01, 
F04, F05, and F12) had very similar bacterial communities, mostly dominated by 









Figure 5.20 Stability of the non-pregnant Fecal Microbiome; Relative 
Abundance of Genera 
Area charts of the relative abundance of taxa at the genus level in n=4 C57BL/6J 
animals sampled across 4 time-points (Day 0, 4, 10, and 17). For visual clarity, only 
the 16 most abundant genera are displayed in the key. Animal ID - F01 top left; F04 







Alpha diversity measures in the longitudinally sampled C57BL/6J animals showed 
that at day 10 the mean number of observed species (Sobs) were significantly lower 
than that at Day 0 (P <0.05) (Figure 5.21). Although there was a trend for the 
Shannon Diversity and Inverse Simpson Index to be lower at Day 10, and dispersed 
at Day 17, neither linear regression analysis nor matched one-way ANOVA suggest 
this trend was significant. I can therefore conclude that at the community level there 
is no great difference in bacterial complexity within a mouse across a 17 day period. 
 
 
Figure 5.21 Stability of the non-pregnant Fecal Microbiome; Alpha 
Diversity Measures 
(a) Observed species (Sobs), (b) Shannon Diversity and (c) Inverse Simpson Index 
measures of samples from C57BL/6J (n=4) animals collected over 4 time-points 
(n=16 total samples). Animal ID at each time-point can be identified by the shape of 
the point. There was no significant linear fit to any of the alpha metrics using a linear 
regression model. One-way matched ANOVA with Dunnett's post-test compared to 






No significant trend (P =0.5173) over collection day was observed in the unweighted 
UniFrac distance between same-animal fecal samples comparing progressive time-
points (Figure 5.22). Although the numbers here are low, this suggests the beta 
diversity across 4 time-points within-animal is mostly stable.  
There was no significant difference (P=1.0) in the mean unweighted UniFrac 
distance within collection day (0.150 ± 0.006) compared to between collection day 
(0.149 ± 0.0027) (parametric two sample t-test, Bonferroni-corrected), suggesting the 
between-animal composition of the bacterial species across 17 days is not 
significantly different (Figure 5.23). 
The mean unweighted UniFrac distance within animal is statistically lower than the 
mean distance between different animals (P; <0.0001; parametric two sample t-test, 
Bonferroni-corrected) (Figure 5.23). Nonparametric p-values were also calculated 
using 999 Monte Carlo permutations, (P; < 0.0001) although this significance did not 
hold once Bonferroni-corrected (P = 0.66). Overall this suggests the phylogenetic 
diversity within the same-animal at the different time-points is more similar than 
between samples from different animals at the various time-points. That is to say 
animals are more similar to themselves than they are to another animal, which is not 






Figure 5.22 Stability of the non-pregnant Fecal Microbiome; Beta 
Diversity 
Unweighted UniFrac distance between same-animal samples comparing progressive 
time-points. For reference each Animal ID is given and coloured accordingly (NS; 




Figure 5.23 Unweighted UniFrac Distance Boxplots - Inter-animal and 
collection day 
Boxplots representing median, IQR with min, max whisker of pairwise unweighted 
UniFrac distance within genotypes and between genotypes (left) and within and 





5.3.8.2 Pregnancy Related Microbial Change; Alpha Diversity 
To examine whether the fecal microbiome varied longitudinally with gestation, I 
applied a linear regression to the Observed species, Shannon Diversity and Inverse 
Simpson Index (Figure 5.24) both in a non-pregnant and pregnant state. The only 
linear trend was seen in the pregnant Inverse Simpson index (P =0.024, r = 0.180) 
(Figure 5.24.b). However, there is no significant difference in this regression 
compared to the non-pregnant control slope (P =0.192). In a similar regard, there was 
no significant difference between the slopes from pregnant and non-pregnant mice in 
either the Sobs (P =0.525; Figure 5.24.a) or Inverse Simpson Index (P=0.798; Figure 
5.24.c). This indicates the diversity in microbial community did not progressively 
change in terms of complexity throughout gestation.  
The prior tested hypothesis is that microbial changes in pregnancy are accumulative 
and progressive with gestation. However this need not be the case; many of the 
metabolic and immunological changes that could impact the microbiome are 
temporal during pregnancy. To test a non-linear association between alpha diversity 
and gestation, a two-way ANOVA was also conducted. The two-way ANOVA 
showed no significant association with time-point in either the pregnant (i.e. 
gestation) or non-pregnant samples (i.e. time-point). This gives further support to the 
conclusion that the complexity of the microbial communities is similar in a pregnant 






Figure 5.24 Pregnancy Influence on Alpha Diversity Measures 
Observed species (a) Shannon Diversity (b) and Inverse Simpson Index (c) measures 
in samples collected over 4 time-points in pregnant and non-pregnant animals. P-
values displayed are for the difference between the Non-Pregnant vs. Pregnant 
slopes. The only linear trend was seen in the pregnant Inverse Simpson index (b), P-
value and slope are given in parentheses. A two-way ANOVA did not highlight any 
significant association of gestation or pregnancy status with alpha diversity 




5.3.8.3 Pregnancy Related Microbial Change; Genera Associated with 
Progressing Gestation 
To determine whether any genera are associated with progressing gestation, linear 
regression was applied to the absolute abundance of all of the 78 genera classified. 
Those genera which have a significant (<0.02) linear regression are shown in Figure 
5.25. Four genera were increased during pregnancy, Candidatus saccharimonas, 
Lactobacillus, Candidatus arthromitus, and Ralstonia. Ralstonia and Candidatus 
saccharimonas were present at low abundance (<0.5%). Two genera were reduced 
during pregnancy; Parabacteroides and Bacteroides.  
Linear regression analysis was also applied to the control non-pregnant group to 
determine differences in abundance that are not due to pregnancy. This group 
highlighted two of the same genera; Lactobacillus and Parabacteroides as having a 
significant linear regression to time-point (Figure 5.26).  
As previously suggested, it is important to establish baseline flux in microbial 
diversity, for this reason, the linear regression slopes of the significant genera 
between non-pregnant and pregnant samples were compared (Figure 5.27). The 
majority of the trends seen in pregnancy were also seen in those animals not pregnant 
collected at the same time-point, with the exception of Candidatus arthromitus 
which significantly increases with gestation compared to non-pregnancy (p =0.020). 
This is a clear indication that in murine pregnancy there are very little global 







Figure 5.25 Linear Regression of Genera Abundance to Gestation 
Linear regression was applied to the absolute abundance of all 78 genera progressive 
to gestation in pregnant C57BL/6J animals (n=8). Only those linear regressions with 
a P value of <0.02 are shown. Blue line indicates linear regression with 95% 
confidence in grey. Animal ID at each time-point can be identified by colour and 
connecting lines. 
 p =0.0180 




r =0.3136  
 p =0.0004 
r =0.3862 
 p =0.0068 
r =0.2495  







Figure 5.26 Linear Regression of Genera Abundance to Time-point 
Linear regression was applied to the absolute abundance of all 78 genera progressive 
to time-point in non-pregnant C57BL/6J animals (n=4). Only those linear regressions 
with a P value of <0.05 are shown. Red line indicates linear regression with 95% 
confidence in grey. Animal ID at each time-point can be identified by colour and 
connecting lines. 
 
 p =0.0482 
r =0.2506  
 p =0.0137 





Figure 5.27 Linear Regression of Genera Abundance; Pregnant vs. Non-
Pregnant 
Linear regression comparison of genera progressive to gestation/time-point in non-
pregnant (n=4) and pregnant (n=8) C57BL/6J animals. Only those linear regressions 
with a P value of <0.05 in either pregnant or non-pregnant group are shown. Red line 
indicates linear regression in non-pregnant (NP) samples. Blue line indicates linear 
regression in pregnant samples (PR). Animal ID at each time-point can be identified 
by colour of point and the shape of point corresponds to pregnancy status. 
 p =0.463   p =0.020 *  
 p =0.261   p =0.487  




Candidatus arthromitus significantly increases with gestation compared to non-
pregnancy (p =0.020) (Figure 5.27). Furthermore, data from the n=3 mice sampled at 
1 day postpartum suggest the maternal increase seen during pregnancy is indeed 
maintained in to the postpartum period, showing a highly significant linear trend to 
gestation (P <0.0001) (Figure 5.28). 
 
 
Figure 5.28 Linear Regression of Candidatus arthromitus; Pregnant vs. 
Non-Pregnant 
Linear regression comparison of Candidatus arthromitus progressive to 
gestation/time-point in non-pregnant (n=4) and pregnant (n=8) C57BL/6J animals. 
Red line indicates linear regression in non-pregnant samples. Blue line indicates 
linear regression in pregnant samples. Postpartum Day 22 samples have been added 
to the linear fit, in addition a box plot (min-max whiskers) from male fecal samples 
(n=10) collected on Day 0 is added for reference. Shape and colour of point 






As mentioned previously the hypothesis for linear regression analysis is that the 
community is driven by progressive and accumulative microbial shifts as pregnancy 
progresses. To test for non-linear association of the gestation/time-point on 
abundance of genera, a non-parametric Kurskal-Wallis test was used to identify 
significant genera associated with gestation/time-point in pregnant and non-pregnant 
animals respectively. 
Several genera were highlighted as having a significant association to gestation/time-
point, including; Anaeroplasma, Bacteroides, Blautia, Candidatus arthromitus, 
Candidatus saccharimonas, Parabacteroides, Prevotella, and Oscillibacter (Figure 
5.29). However, when adjusted for multiple comparisons none of these genera were 
statistically significant. Moreover, an ANOVA did not show any significant 
differences between pregnant and non-pregnant abundance of any of these genera 
across all time-points. This suggests that although there is variation in the relative 
abundance of genera over time, the majority is not attributed to pregnancy and is 







Figure 5.29 Boxplots of Significant Genera Associated with Pregnancy  
Boxplots representing median, IQR, whisker length represents 1.5x IQR of the 
observed sequences for significant genera grouped by genotype. Displaying 
significant (P <0.05) genera associated with gestation/time-point using non-







Fecal Microbiome of Camp-/- Animals 
Microbes in the gut are essential for the break down of complex carbohydrates where 
they can manipulate host metabolism by altering nutrient availability. The presence 
and abundance of each bacterial group is fundamental since different species 
differentially metabolise these nutrients. The host antimicrobial defence system has 
co-evolved with complex communities of bacteria that have sought to create an 
environment for commensal and mutualistic cohabitation. The mammalian 
gastrointestinal tract is dominated by two main phyla, Firmicutes and Bacteroidetes. 
Shifts in the ratio of these two phyla have been observed in many conditions such as 
obesity (Ley et al., 2006) and diabetes (Wen et al., 2008). Diet and host genetics can 
also influence on microbial community composition (Blanton et al., 2016, Ussar et 
al., 2015). Host Defence Peptides provide the first line of defence against infectious 
pathogens in the gastrointestinal tract. In the mouse and human colon, cathelicidin is 
expressed in epithelial cells and immune cells such as macrophages. 
In this chapter, I evaluate the direct influence of Cathelicidin on the fecal 
microbiome by utilising Camp-/- knockout animals. The microbiome was 
interrogated by 16S rRNA gene sequencing for bacterial classification. After 
subsampling and removal of rare sequences, 908 OTUs were identified, which 
represent 143 unique genera, 82 unique family level classifications, 50 unique orders, 
29 unique classes and 15 different phyla (Figure 5.3). 
Direct comparison of the phyla classifications for the Camp-/- and C57BL/6J 
samples showed similar overall compositions; there were no differences in relative 
abundance at the phylum level (Figure 5.8). As CAMP is a potent broad range 
antimicrobial which has been shown to modulate mucosal immune responsiveness, it 
was unexpected that knocking out this gene in mice would not confer shifts in 
bacteria at the phylum level. Although, cathelicidin is only expressed at moderate 




for pathogenic species; these factors might be responsible for the lack of huge shifts 
at the phylum level.  
At the genera and OTU level of classification, Camp-/- and C57BL/6J mice 
demonstrated disparate gut microbiota as indicated by statistically significant 
taxonomic differences (Figure 5.18). At the genus level Allobaculum (p.Firmicutes 
o.Erysipelotrichales), was significantly enriched in C57BL/6J samples, whereas 
Anaeroplasma (p.Tenericutes o.Anaeroplasmatales) was enriched in samples from 
Camp-/- animals. The most notable OTU assigned to be enriched in Camp-/- samples 
was OTU0003, which was classified as S24-7 family of bacteria. C57BL/6J animals 
show an enrichment of Prevotella, which is interesting as the Camp-/- samples are 
nearly totally devoid of this clade (Figure 5.19).  
Allobaculum is a low abundant genera significantly enriched in C57BL/6J animals. 
On average the sequence contribution of this genus in C57BL/6J samples was 2.02% 
compared to 0.95% in Camp-/- mice. Allobaculum is considered beneficial to host 
physiology; low fat intake has been associated with increases in this genus, compared 
to high-fat intake where this genus is reduced (Cani et al., 2008, Ravussin et al., 
2012). In this study, diet was kept consistent; indicating that innate immune genotype 
is also able to confer changes in relative abundance of this genus.  
As one of the few Tenericutes observed in this study, Anaeroplasma, an anaerobic 
Mycoplasmatales, contributed to the enrichment back to the ‘order’-level of 
classification in Camp-/- samples. 
S24-7 family, a butyrate-producing bacterium only normally seen in rodents covers 
the largest component of mouse fecal sequences assigned in the Bacteroidetes 
phylum in this study. Many of the Bacteroidetes species in mice do-not fit into 
existing genera well. The strain reference for S24-7 family (AJ400263), deposited by 
Salzman et al., (2002a) is distinct but closely related to Prevotella, Bacteroides, and 
Porphyromonas. Exercise has been shown to significantly increase the relative 
proportion of S24-7 in mice, whereas sedentary mice on a high-fat diet had lower 
levels of S24-7 (Evans et al., 2014). Interestingly antibiotics, and antibiotic prodrug 




al., 2015). Only one study has found S24-7 in humans (Clemente et al., 2015), S24-7 
is however closely related to Bacteroidetes which are abundant in humans. 
Interestingly in humans, Bacteroidetes levels in the gut are lower in obese 
individuals then those of healthy weight (Turnbaugh et al., 2008, Turnbaugh et al., 
2009).  
The increase in S24-7 in the Camp-/- mice could be due to the direct microbicidal 
activity of CAMP targeted to this genus. As mostly commensals, Bacteroidetes have 
adopted mechanisms of increased resistance to bacterial killing to LL-37 and CAMP 
(Cullen et al., 2015).  
Prevotella was highlighted as an enriched genus in the C57BL/6J animals, this genus 
(and family) were also notably absent from the Camp-/- samples with the exception 
of one sample. The one outlier sample clusters with the C57BL/6J samples in the 
PCoA plots (Figure 5.12). This mouse has been sampled multiple times, as all other 
samples from this animal cluster with the Camp-/- samples I would suggest this is a 
sampling or processing error and can be excluded. 
Prevotella spp. have mainly been isolated from the mammalian oral cavity but are 
also present in the gut, where Prevotella copri is generally the more abundant species 
(Gupta et al., 2015). Prevotella has been associated with some beneficial activities 
but has also been linked with inflammatory conditions (Scher et al., 2013, Dillon et 
al., 2016). Most Prevotella spp. produce succinate and this genus has been positively 
associated with a Mediterranean diet (De Filippis et al., 2015). This bacterium has 
also been described to improve glucose metabolism in healthy human individuals 
(Kovatcheva-Datchary et al., 2015). However, Prevotella in the gut has been 
positively associated with HIV, where exposure of key dendritic cells to Prevotella 
copri boosted cytokine production in-vitro (Dillon et al., 2016). Dillon et al., (2016) 
suggested that increased levels of Prevotella copri might contribute to driving the 
chronic inflammation seen in individuals infected with HIV. 
Prevotella copri has been used in many in-vivo studies looking at host-microbe 
interactions. Mice treated with Prevotella copri had increased hepatic glycogen 




post-antibiotic treatment has been shown to increase murine susceptibility to colitis 
induced by dextran sulfate sodium (DSS). Camp-/- animals are also shown to have 
increased susceptibility to DSS colitis (Tai et al., 2013, Koon et al., 2011), which is 
interesting as in this study I have shown they have reduced levels of Prevotella. This 
is contradictory to the observation that Prevotella increases the host susceptibility to 
colitis. Prevotella is however a very large diverse genus with large genomic diversity 
between strains. It is most probable that the species of Prevotella in this study is not 
the highly used in-vivo strain Prevotella copri and therefore can have very different 
properties. It is also possible that these specific members of the Prevotella genus 
have important anti-inflammatory functions in the gastrointestinal tract; loss of such 
anti-inflammatory genera could result in exacerbated inflammation during exposure 
to DSS, conferring the amplified phenotype.  
It is not known why removing Camp results in a lack of Prevotella, it is possible that 
this decrease is a result of another species inhibiting or out competing for space. As 
OTUs from the S24-7 family of bacteria are enriched in Camp-/- mice I would 
suggest this genera is an ideal candidate. Another possible reason for the differences 
in gut microbiome of the Camp-/- mice compared to wildtype mice, is the influence 
of gut architecture.  
There are two reports that confer a low-level change in steady state gut morphology 
in Camp-/- mice. While investigating induced inflammation via TLR-9 signalling, 
Koon et al., (2011) demonstrated that Camp-/- mice developed very mild 
inflammation when given just water. Another study suggested that Camp-/- mice 
have a 32% thinner mucus layer in the colon (Chromek et al., 2012). This is 
supported by in-vitro work on human colon cells which showed LL-37 can directly 
stimulate mucus synthesis by the increased expression of mucins, MUC1 and MUC2 
(Tai et al., 2008). By use of Muc2 knockout mice, this mucin was shown to be 
essential for limiting the number of pathogenic but also commensal bacteria that can 
interact with the colonic mucus layer (Bergstrom et al., 2010). The mucus layer is a 
very dynamic environment, which is rapidly renewing, therefore bacteria need to be 




The mucus layer development of the Camp-/- animals was not investigated in this 
study. As it has been reported that different animal facilities and background strain 
can influence mucus development (Jakobsson et al., 2015), it would be essential to 
establish whether the Camp-/- mice which I have shown have an altered microbiome, 
also have the mucus layer phenotype as described by Chromek et al., (2012). 
Jakobsson et al., (2015) showed that two mice colonies within the same animal unit 
can display different mucus permeability to bacteria. Interestingly, although the 
authors did not conclude a specific bacteria was responsible for normal mucus 
development; higher relative abundances of Bacteroides were found in mice with 
less developed mucus. In addition, the authors found that Erysipelotrichia was 
increased in those animals with normal impenetrable mucus. I have shown wildtype 
mice in this study have enrichment for Erysipelotrichia and the Camp-/- mice are 
enriched in S24-7, closely relate to Bacteroides, this could be inducing or a result of 
Camp-/- mice having a under developed mucus layer. In addition to histological 
evidence for mucus layer thickness, it would be of interest to quantify secreted 
mucus glycoprotein and also transcript levels of key mucins in Camp-/- mice to 
support this theory. Definitive proof of the involvement of these mechanisms would 
aid understanding of how cathelicidin maintains gut homeostasis by the maintenance 
of mucus integrity.  
It would also be interesting to see whether giving Camp-/- mice exogenous CAMP 
peptide could restore the levels of Prevotella and Erysipelotrichia in the gut. One 
study has given exogenous LL-37 treatment to wildtype rats and explored gut 
microbial populations (Pound et al., 2015). Although the authors did not find global 
alterations in gastrointestinal bacterial communities in response to LL-37 peptide, 
there were increases in select lineages, including Adlercreutzia (p. Actinobacteria), 
but also Lactobacillus spp.. These species were not consistently increased in another 
rat strain suggesting there are possible additional genotypic interactions of LL-37 and 
the microbiome (Pound et al., 2015). 
In this chapter, I compared the alpha diversity (the diversity within samples) and beta 




There was no significant difference in any alpha diversity metric between these two 
genotypes. These alpha diversity measures assume all species are equally related to 
each other and has no consideration to highly divergent species. UniFrac takes into 
account the shared species between two groups, their abundance and their 
phylogenetic relationship. Applying qualitative and quantitative measures allude to 
different assumptions about the key factors that are driving microbial diversity 
(Lozupone et al., 2007). It is therefore important to use a variety of distance 
calculation methods to highlight patterns in the data. Both weighted and unweighted 
UniFrac measures have specific functions in microbial community analysis. 
Unweighted UniFrac, a qualitative measure of similarity, is best positioned in 
revealing communities that predominantly differ by what can sustain growth. 
Weighted UniFrac distance is a quantitative description of similarity, best suited in 
revealing community variations that are due to changes in relative abundance of 
species.  
In this study hypothesis tests on the unweighted UniFrac distances, grouping by 
genotype, was found to be highly significant using multiple methods of hypothesis 
testing (Table 5.6). Conversely, hypothesis testing on the weighted UniFrac distances 
did not show any significant trend, which backs up the lack of clustering in the 
weighted UniFrac PCoA plots (Figure 5.15). The clustering of samples by genotype 
by unweighted UniFrac suggests a strong relationship in terms of qualitative 
community membership. Therefore the incidence of particular OTUs is a higher 
factor separating the samples by genotype as opposed to the flourishment of shared 
species. Mechanistically this suggests the direct microbicidal activity of CAMP could 
be targeting certain genera more than others. 
The unweighted UniFrac pairwise distances show Camp-/- knockout animals are 
significantly more diverse than the wildtype controls (P<0.0001). The weighted and 
unweighted UniFrac UPMGA trees generally support the clustering seen in the 
PCoA plots (Figure 5.17). 
Supplier, housing laboratory, strain, diet, and gender can all affect diversity and be 




background animal strain can regulate many experimental phenotypes that also might 
play a role in mediating microbial communities (Turnbaugh et al., 2006, Hooper and 
Gordon, 2001). Indeed background strain even within animal facility can all have 
huge impact on microbial community structure (Friswell et al., 2010, Campbell et al., 
2012). Different suppliers of the same strain have also been shown to have different 
microbial complexity. For this reason, control animals in this study were sourced ‘in-
house’ from backcrossing Camp-/- to C57BL/6J animals. Although control 
C57BL/6J animals here were from backcrosses, they were not littermate controls. It 
is possible in the few generations the Camp-/- and C57BL/6J animals were bred in 
isolation there has been some amplification of divergent bacterium caused either by 
mutation or exposure. Looking at littermate controls is also an option in this study, 
but this too can be complicated by what mice are exposed to dependent upon their 
parents and grandparents, cage effects can also possibly hide the effects of the 
genotype. It would be of interest to determine the transmissibility of the microbiome 
by co-housing wildtype with Camp-/- mice and including a larger number of animals.  
A strength of this study design was that samples were collected from multiple cages, 
multiples sexes, and at multiple time-points. Regardless of sex and pregnancy status, 
the clustering of samples by genotype was robust at every time-point considered. 
Camp-/- and C57BL/6J mice demonstrated disparate gut microbiota. This microbial 
change, as the data in this chapter suggests, is driven by community-wide effects 
involving the loss and gain of multiple bacteria. I hypothesise that alteration in 
relative abundance of these bacterial populations maybe a result of the thinning of 
the protective mucin layer. Disruption of this mucin layer has been shown to enhance 
the ability of opportunistic pathogens to invade the mucosa. This could be the 
attributing factor to why Camp-/- mice are more susceptible to DSS colitis and 
infection with pathogenic organisms. Identifying the mechanisms behind this will be 






Pregnancy modulation of the microbiome 
There are great metabolic changes in pregnancy, especially in late gestation, which 
could have impact on microbial communities. Late gestation is associated with 
remodelling of adipose tissue deposits which aid growth of the placenta and fetus 
(Resi et al., 2012). There has been conflicting reports in humans whether pregnancy 
is associated with shifts in gut bacteria (Collado et al., 2008, Koren et al., 2012, 
DiGiulio et al., 2010). It has been reported that the bio-mass of the bacteria in the 
mother’s gut increases during gestation and this was associated with an increase in 
bacterial diversity (Koren et al., 2012). Koren et al., (2012) went on to suggest that 
the pregnancy related changes in the gut microbiome are akin to that seen in obesity.  
In this chapter, I investigate microbial shifts in murine pregnancy by longitudinally 
sampling mice throughout gestation and interrogating the microbiome by 16S rRNA 
gene sequencing. 
Akkermenisa and Bifidobacterium have been related to pregnancy in mice. Gohir et 
al., (2015) displayed that these genera were increased after conception. In this study I 
found no Akkermenisa or Bifidobacterium in wildtype female C57BL/6J animals. 
This could obviously be a reflection of the differences in bacteria burden between 
animal facilities. Gohir et al., (2015) uses the same animal sampled prior to 
pregnancy as the non-pregnant control group. Indeed in this study I also sample 
animals prior to conception to account for intra and inter-animal variation. Strength 
of my study design was that I also collected samples from non-pregnant littermate 
control mice in parallel, to account for environmental changes that might occur 
within the time period of the study. In addition, it is not known whether singly 
housing females for experiment would impact on the microbiome. The majority of 
the trends seen in pregnancy were also seen in non-pregnant littermate control 
samples collected at the same time-point, with the exception of Candidatus 
arthromitus which significantly increases with gestation compared to non-pregnancy 
(p =0.020). This is a clear indication that in murine pregnancy there are very little 




Candidatus arthromitus is an ideal candidate to be a true pregnancy associated 
bacteria. Candidatus arthromitus, also known as segmented filamentous bacteria 
(SFB), colonises both the gut of human and mice in an age dependent manor (Jiang 
et al., 2001, Yin et al., 2013). In humans, colonisation occurs within 2 years of age 
but then disappears by the age of 3 (Yin et al., 2013). In mice, pups are colonised 
from birth, where SFB peaks at around day 12 then dramatically drops post weaning 
to adult levels (Jiang et al., 2001). SFB is unique, whereby it is one of the only 
bacteria that can be in direct contact with intestinal epithelial cells. Its presence and 
abundance has been correlated with reduced colonisation of many different 
pathogenic bacteria (Gauguet et al., 2015, Heczko et al., 2000). Most interestingly it 
has been shown that SFB serves a protective role in shaping adult metabolism. Cox 
et al., (2014) showed that giving mice low dose antibiotic treatment at birth alters 
metabolic hormones, expression of immunity genes and adult fat mass. Importantly 
the authors showed that the mice treated at birth with antibiotics consistently 
displayed reduced levels of SFB but also Lactobacillus. Moreover, young mice 
populated with SFB developed less severe Staphylococcus aureus pneumonia 
(Gauguet et al., 2015). Co-housing SFB-negative and SFB-positive mice for two 
weeks transferred the SFB and also this protective phenotype. This SFB mediated 
resistance to infection was associated with a type 17 innate immune response (Ivanov 
et al., 2009). It is accepted that the maternal microbiota can be passed onto offspring 
by direct colonisation at or around the time of birth. Collectively it would therefore 
be beneficial for the nursing dam to maintain high levels of SFB in their gut for 
continuous seeding to pups in the critical first few weeks of life. To support this it 
would be important to establish whether the levels of SFB remain high in the 
mother’s gut postpartum well into the weening stage. The preliminary data I have 
from n=3 mice sampled at 1 day postpartum suggest the maternal increase seen 
during pregnancy might be indeed be maintained, but more time-points are needed to 
establish this.  
A slight caveat to this study design is the unequal proportion of non-pregnant (n=4) 
to pregnant animals (n=8); greater power could also be given to conclusions if the 




I have shown that SFB is increased in mid to late gestation, which is fitting that 
bacteria which occur early in life, and has beneficial activity would be increased in 
the maternal microbiome. Clearly further studies are required to examine both the 
causal mechanism for the increase in SFB, and the influence this has on the 
metabolic function of the offspring. Key candidates for causal mechanisms are sex 
hormones and preparations for the metabolic demands of lactation. In humans, 
during the first week of the postpartum period oestrogen levels fall dramatically. 
Alterations in this postpartum phase have been shown in the vaginal microbiome, 
where a high proportion of mothers displayed depleted Lactobacillus spp. 3 weeks 
after labour (MacIntyre et al., 2015).  
 
5.5 Summary 
In summary, in this chapter I have shown: 
- Camp-/- and wildtype mice demonstrated disparate gut microbiota as 
indicated by statistically significant taxonomic differences. This community-
wide effect involves the loss and gain of multiple bacteria. Most notably 
Camp-/- mice show an enrichment of S24-7 family of bacteria and a depletion 
of Prevotella. 
- Camp-/- mice have an altered microbiome and they are more diverse than 
wildtype controls.  
- In murine pregnancy, there are very little globally cumulative or progressive 
shifts in bacteria, with the exception of Candidatus arthromitus. 
- Candidatus arthromitus significantly increases with gestation compared to 









Chapter 6 Murine Vaginal Microbiome 
6.1 Introduction 
In contrast to humans it has been proposed only a small percentage of female mice 
harbour Lactobacillus species at the vaginal mucosa (McGrory and Garber, 1992). 
Bacterial species identified to reside in the murine reproductive tract have mostly 
been through culture-dependent techniques (Noguchi et al., 2003). Very little is 
known about the species level richness of bacteria that colonise the murine vaginal 
mucosa. MacManes (2011) conducted a study looking at two different strains of wild 
mice, and showed there was a greater degree of diversity in the vaginal bacteria of a 
promiscuous strain of mice. Only one study has used a bacterial next generation 
sequencing approach to detail this microbial environment (Barfod et al., 2013).  
This chapter investigates microbial change of vaginal bacteria in mice. The first main 
interest of this chapter was to discover what bacteria are present in the vaginal 
mucosa, how consistent the communities are and what level of sequencing depth is 
required to gain insight on microbial diversity. The next progression was to establish 
whether the vaginal microbiome of animals lacking cathelicidin is altered in 





6.2.1 Murine Non-pregnant Vaginal Microbiome  
Vaginal lavages were collected from eight wildtype C57BL/6J mice housed in two 
separate cages. Bacterial DNA was extracted with the PowerSoil® DNA Isolation 
Kit following the manufactures protocol. Sample processing, multiplexing and 
library preparation was conducted as described in section 4.8 using the Ion Torrent 
Protocol. Emulsion PCR was supported on the Ion OneTouch® using the 400 
Template Kit (v2) according to the manufacturer’s instructions. Sequencing and base 
calling was conducted on a 314 chip, supported on the Ion Torrent PGM. After base 
calling, the PGM software filters individual reads to discard sub-threshold and 
polyclonal sequences. The raw sequence count from this 314 PGM chip was 509,851 
reads. Sequences were then binned by sample using the sample-specific barcodes 
that were incorporated into the fusion primers. Quality filtering was done in Galaxy, 
using a workflow detailed in the appendix. In brief, reads were quality filtered on the 
following criteria; i) identical match to a barcode sequence, ii) maximum of 2 
mismatches in the complementary primer sequence, iii) average quality score of 
>=25 in a sliding window of 6bp, iv) read-length after trimming between 150–500bp. 
This quality filtering reduced the raw read count from 509,851 to 192,888 sequences, 
which was then used as the input for QIIME analysis. Before OTU picking, 
reference-based and de novo based chimera detection was carried out using 
USEARCH 6.1. This highlighted 2,632 reference based chimeric reads and 496 de 
novo chimeric reads, which were discarded. OTUs were clustered at 97% similarity 
using UCLUST, and candidate sequences for each OTU were aligned using 
PyNAST. The taxonomy was assigned using RDP Classifier with a confidence value 
threshold of 60%. To exclude potentially contaminating taxa while preserving actual 
OTUs in the community, singletons were removed (2.9% total reads and 40.3% of 




Four phyla; Firmicutes, Bacteroidetes, Proteobacteria, and Actinobacteria, 
dominated the microbiota in most samples (Figure 6.1). At the phylum level sample 
001, 002, 004, 006, and 007 were dominated by Firmicutes and 003, 005 and 008 
had a majority of Bacteroidetes. 
 
001 002 003 004 005 006 007 008 
 
Figure 6.1 Bar Chart of Relative Proportions of Bacteria in Vagina; 
Phylum Level 
Phyla level classification in the vaginal microbiota of non-pregnant C57BL/6J mice. 
Each bar represents an individual sample. 001-004 were housed in cage 1 and 005-
008 were housed in cage 2. Proportions are shown as a percentage of total reads 






At the genus level, four groups dominate the vaginal microbiome; Lactobacillus, 
Enterococcus, Planceccacace, and the S24-7 family of bacteria (Figure 6.2). The 
S24-7 family of bacteria is a distinct group of Bacteroidetes that has been recently 
identified as a new group that preside in the mouse gastrointestinal tract (Salzman et 
al., 2002b). It seems that many of the Bacteroidetes species in mice such as S24-7 do 
not fit into existing genera well. While samples 003, 005 and 008 have similar 
distribution of genera, there is much variability across the other samples. Sample 001 
is dominated by Lactobacillus while sample 002 is dominated by Enterococcus.  
 
001 002 003 004 005 006 007 008 
 
Figure 6.2 Bar Charts of Relative Proportions of Bacteria in Vagina; 
Genus Level 
Genus level classification in the vaginal microbiota of non-pregnant C57BL/6J mice. 
Each bar represents an individual sample. 001-004 were housed in cage 1 and 005-
008 were housed in cage 2. Proportions are shown as a percentage of total reads 
ranging from 17,392 – 25,555 per sample. For visual clarity, only the top 4 most 




Alpha rarefaction was performed using the number of observed species and Shannon 
diversity metrics in the QIIME package. The number of species identified across the 
eight samples is highly variable (Figure 6.3). At 20,000 sequences, sample 001 has 
well over 1000 OTU clusters, while sample 002 has just 200 OTUs. The plateau in 
the Shannon refraction plot suggests the sequencing depth is sufficient to capture a 




Figure 6.3 Rarefaction Curves; Observed OTUs in Murine Vagina 
Rarefaction curves created for observed species (OTUs) plotted against simulated 
sequencing effort; each line represents an individual sample. Total reads ranging 








Figure 6.4 Rarefaction Curves; Shannon Index in Murine Vagina 
Rarefaction curves created for Shannon Index plotted against simulated sequencing 
effort. Each line represents an individual sample. Total reads ranging from 17,392 – 







This first Ion Torrent run, sequencing wildtype non-pregnant vaginal communities, 
aimed to establish, i) what bacteria are present at the vaginal mucosa ii) what level of 
sequencing is required to gain insight on microbial diversity. 
There was a notable amount of variability in the genera seen across the 8 samples 
taken from vaginal lavages (Figure 6.2). At the phylum level, 5 of the animals were 
dominated by Firmicutes (001, 002, 004, 006, and 007), whereas 3 animals had a 
majority of Bacteroidetes (003, 005 and 008) (Figure 6.1). In women, the 
composition in the vagina is mostly dominated by Firmicutes, while some women 
have a dominance of Actinobacteria phyla; Bacteroidetes are rarely seen. In contrast 
to humans it has been proposed only a small percentage of female mice harbour 
Lactobacillus species at the vaginal mucosa (McGrory and Garber, 1992). In this 
study, only 6 of the 8 mice had OTUs classified as Lactobacillus, in 5 of these 6 mice 
Lactobacillus was a minor component. Enterococcus, Planceccacace, and the S24-7 
family were other highly abundant species.  
The plateau in the Shannon Index prior to 5,000 sequences (Figure 6.4) suggests the 
sequencing effort in this run has adequately sampled the population. The number of 
OTUs across the study-set is highly inflated over what I had expected. At the current 
level of sequencing, the human vaginal microbiome is establishing around 200 
bacterial assigned OTUs across study sets (Ravel et al., 2011, Drell et al., 2013, 
Martin et al., 2013). After chimera checking there were 2738 OTUs in this study, 
while some of these are true OTUs, many could be spurious clusters from PCR or 
experimental artefacts. Some of these are likely to be chimeric reads that have not 
been detected. In addition, the premature truncation of reads on the PGM platform 
and at quality filtering could be inflating unique clusters. The Ion Torrent chemistry 
offers the continuous sequencing of reads up to 400bp, which has the potential to 
span the full 16S rRNA V1-V2 target region. The V1-V2 region was only sequenced 
in this study in the forward direction. The standard Ion Torrent chemistry does not 
support paired end sequencing, however, the reverse direction can be sequenced as 




semiconductor sequencing; this can inflate OTUs as the partial sequence fragments 
may not contain enough taxonomic information for robust classification. In addition, 
as the base calling quality drops toward the end of the read, many sequences are 
additionally truncated in the Galaxy workflow (see appendix). 
It is well documented that the Ion Torrent platform exhibits a higher rate of 
sequencing errors than Illumina sequencing technologies. I chose to pursue the 
Illumina MiSeq platform for subsequent investigations of the vaginal microbiome 
due to the added benefit of paired end sequencing, in addition to this known 
advantage in base calling. Illumina sequencing chemistry can sequence 300bp 
paired-end reads, which covers the majority of the approximately 340-370bp V1-V2 
amplicon. The non-overlapping region is proximal on both sequencing reads; where 
quality is normally the highest. 
In addition to using the MiSeq Illumina platform, several other optimisation steps 
were attempted in aim of reducing the variability in the vaginal community. These 
optimisation steps included different sampling methods and extraction protocols. 
These are detailed in section 4.6 and 4.7, but to summarise, whole tissue compared to 
vaginal lavage provided more consistent bacterial yield. For this reason, post-mortem 
sampling of whole vaginal tissue for bacterial extraction was adopted. In addition, 
the FastDNA® SPIN Kit was chosen as it provided more consistency in bacterial 





6.2.2 Camp-/- Pregnant Vaginal Microbiome Study  
Virgin female and male mice of either C57BL/6J (n=10♀) or Camp-/-(n=8♀) were 
set-up in mating pairs and females were checked for a copulatory plug over 4 
consecutive days. On Day 4 female animals were removed from the mating and 
singly housed for the remainder of the experiment. Subsequently the majority of the 
female animals became pregnant; those that did not provided the non-pregnant 
control group. On Day 17 animals were culled and vaginal tissue collected. All 
vaginal tissue samples were stored at -20°C within 2-hours of collection, and 
extracted within 3 weeks. Sample extraction, multiplexing and library preparation 
was conducted as described in section 4.8 using the MiSeq protocols for nested PCR. 




Table 6.1 Murine Experimental Numbers - Camp-/- Vaginal Pregnancy 
Microbiome study 
This table details the number of samples that had a specific PCR band and the total 
number collected. 
 
Of the 22 vaginal tissue samples collected, only 14 had a specific band at PCR and 
passed quality control (Table 6.1). The final data set comprised of 4 Camp-/- samples 
and 10 samples from C57BL/6J mice. As there was only 1 pregnant Camp-/- sample 







Day 17 5 of 8 2 of 4 1 of 6 3 of 4 





Observed species (Sobs), Shannon Diversity, and Inverse Simpson Index were 
calculated for each sample on the rarefied but unfiltered OTU data (Figure 6.5). 
There was no significant difference between any of the diversity measures between 
wildtype C57BL/6J and Camp-/- animals. The Shannon Diversity and inverse 
Simpson Index are much lower than was seen in the fecal community (section 5.3.6); 
this is a result of the vaginal microbiome being dominated by just a few high 
abundant OTUs.  
 
 
Figure 6.5 Alpha Diversity of Camp-/- vs. Wildtype Vaginal Microbiome  
Boxplots representing median, IQR, whisker length represents 1.5x IQR of the (a) 
Observed species, (b) Shannon Diversity, (c) and Inverse Simpson Index measures 






Figure 6.6 shows relative abundance of the top 25 most abundant OTUs classified at 
the genus level. The highest abundant OTU in most samples was classified as 
Ralstonia spp. One Camp-/- sample had a dominance of Staphylococcus, and two 
C57BL/6J samples had high proportions of Streptococcus. 
 
Figure 6.6 Heat map of most Abundant OTUs showing their Genus 
Level Classification in Vaginal Samples from Camp-/- and C57BL/6J 
mice 





Ralstonia spp. are known contaminants in molecular grade water (Grahn et al., 2003, 
Barton et al., 2006, Laurence et al., 2014), and I have shown this species is a 
potential source of contamination by sequencing a mock community (detailed in 
section 4.18). For this reason, OTUs classified as Ralstonia were removed from the 
data-set prior to beta-diversity distance calculations. The pairwise UniFrac distances 
were visualised using Principle co-ordinate Analysis (PCoA) (Figure 6.7 and Figure 
6.8). In both the weighted and unweighted PCoA plots, there was no clear separation 






Figure 6.7 UniFrac Distance 2D PCoA plots of Vaginal Community – 
Colour by Genotype 
(a) Unweighted and (b) weighted UniFrac 2D PCoA plots illustrating the relationship 
between the bacterial diversity of vaginal samples from n=14 mice. Points are 
coloured by genotype and shape by gestation status. Each point represents an 






Figure 6.8 UniFrac Distance 2D PCoA plots of Vaginal Community – 
Colour by Pregnancy Status 
(a) Unweighted and (b) weighted UniFrac 2D PCoA plots illustrating the relationship 
between the bacterial diversity of vaginal samples from n=14 mice. Points are 
coloured by gestation status and shape by genotype. Each point represents an 





6.2.2.1 Conclusion  
The vaginal microbiome was problematic due to low bacterial yields. Of the 22 
samples collected, only 14 had a specific PCR band and could be carried forward for 
microbial sequencing. This left n=10 wildtype samples and n=4 Camp-/- samples, of 
which only 1 was from a pregnant animal. Microbial sequencing revealed Ralstonia 
species as the most highly abundant genera in the vaginal samples. Ralstonia is a 
known contaminate of molecular grade water and I have also demonstrated this 
species is a potential contaminate in the mock community. As both the extraction 
negative and PCR negative did not display any PCR product, it was surprising to see 
contaminates in the samples from the vagina. After removal of the contaminating 
sequences, there is no clear grouping with regard to the genotype of the mouse like 
there was in the fecal samples. There was also no clear clustering with regards to 
whether the samples were taken from pregnant or non-pregnant mice, or if they were 







Under normal conditions it is common for female animals caged together to 
synchronise estrus cycling. The eight non-pregnant mice from experiment detailed in 
section 6.2.1 were housed in two separate cages but there was no apparent similarity 
of vaginal community within cage. The estrus stage of the mice used in this 
experiment was not determined, so it cannot be confirmed that all mice in the same 
cage were synchronised. It has previously been shown that the total numbers of 
bacteria are statistically higher during estrus than diestrus or metestrus in the murine 
vagina (Noguchi et al., 2003). In addition, Noguchi et al., (2003) showed the number 
of aerobes was higher than the total number of anaerobes during estrus. 
Synchronising the mice stage of estrus would perhaps result in higher potential 
bacterial recovery and more uniformity across samples. Hormones could be used in 
non-pregnant mice to synchronise estrus in aim of reducing this variability. 
In section 6.2.2, I collected vaginal samples from animals at the same stage of 
pregnancy. In addition to gaining insight into the maternal vaginal community, 
sampling during pregnancy aimed to reduce the potential estrus cycling variability. 
The pregnant samples did not show any distinct clustering in the UniFrac PCoA plots 
(Figure 6.8), suggesting the vaginal microbiome while pregnant is also highly 
variable.  
After review of the literature, only one other study attempts to categorise the murine 
vaginal commensal microbiome using 16S rRNA gene sequencing (Barfod et al., 
2013). Similarly, Barfod et al., (2013) highlighted that the vaginal community of 
BALB/c mice was highly variable. Although the authors only had 8 samples they 
showed the vaginal community had two sub-clusters. One sub-cluster appeared to be 
closely related to the lung microbiota, whereas the other sub-cluster did not show 
similarity to either of the other two sample sites the authors investigated (lung and 
cecum). Barfod et al., (2013) attributed Streptococcus (Gram-positive) as the species 
driving the separation of the two clusters; the authors also listed Acinetobacter, 
Sphinogmonas, Enterococcus and Polaromonas as genera from the vaginal mucosa. 




Bacteroidaceae and Staphylococci as found in the non-pregnant vagina, however, 
these observations were not consistent and were highly variable (Noguchi et al., 
2003). 
Further work is needed to refine and understand the commensal vaginal bacteria in 
mice. Due to the differences in commensal bacteria between women and mice, it is 
imaginable that an approach inoculating germ-free mice could recreate the human 








Role of Host Defence Peptides 
in an Infection/Inflammation 





Chapter 7 Role of Host Defence Peptides in an Infection/ 
Inflammation Induced Mouse Model of Preterm Labour  
7.1 Introduction 
Local inflammation in the decidua and chorion is thought to be important in the 
initiation of preterm labour (Galinsky et al., 2013, Vrachnis et al., 2010). This 
inflammation is frequently caused by ascending opportunistic commensal bacteria 
from the vagina, through the cervix and into the fetal membranes (Allam et al., 2013, 
DiGiulio et al., 2010). In humans, amniotic fluid cultures from most women with 
preterm labour are negative for bacterial growth, although amniotic fluid 
inflammatory cytokines and LPS binding proteins have been shown to be increased 
(Gardella et al., 2001). This lack of bacterial detection could be due to the limitations 
of the culture-dependent techniques.  
As most women presenting with preterm labour do not have elevated white blood 
cells or symptoms of illness, exploring a localised model of inflammation at the 
maternal-fetal interface is used to mimic conditions present in PTL. 
Stimulation of the TLR-4 pathway with LPS has been a central method of invoking 
preterm labour in animal models. Delivery of LPS intrauterine, between two 
amniotic sacs, in pregnant mice has been reported to induce high rates of preterm 
labour, resulting in minimum maternal mortality and showing high reproducibility 
(Rinaldi et al., 2014, Rinaldi et al., 2015, Sykes et al., 2013). 
Cells in the female reproductive tract are a major source of multiple microbicides 
including the defensins and cathelicidin. LL-37 is found at high levels in fetal skin, 
vaginal epithelial cells, amniotic fluids, vaginal fluid and the vernix caseosa 
(reviewed in Yarbrough et al., (2015)). Steady state defensin expression is cell 
specific and compartmentalised in the female reproductive tract in pregnant and non-
pregnant women (King et al., 2003b, Fleming et al., 2003, Quayle et al., 1998). 
Further work on human extra-placental membranes in ex-vivo cultures has shown 




hBD3 and DEFB14 have potent anti-inflammatory effects on human and mouse 
primary monocyte derived macrophages (Semple et al., 2010). hBD3 and DEFB14 
effectively inhibit the LPS-activated TLR4-induced TNF and IL-6 response through 
both the MyD88 and TRIF pathways, shown both in-vitro and in-vivo (Semple et al., 
2010, Semple et al., 2011). Preliminary unpublished data from Fiona Semple in the 
Dorin lab indicates that in-vivo, Defb14-/- mice have an increased sensitivity to LPS 
when delivered intraperitoneally. Interestingly, hBD3 can act in synergy with LL-37 
reducing the LPS-induced secretion of cytokines in gingival cells (Bedran et al., 
2014). 
LL-37/hCAP18 has numerous immune modulatory properties that can contribute to 
infection and inflammatory phenotypes (discussed in section 1.2.2). Mice null for 
Camp, the murine orthologue of LL-37/hCAP18, have many inducible phenotypes; 
showing increased susceptibility to bacterial infections across many body sites, 
detailed in section 1.2.2.  
As hBD3 and LL-37 suppress the inflammatory response of cells to LPS through 
TLR-4, the hypothesis is that in-vivo they might offer protection from preterm birth 
caused by inflammation.  
In this chapter I use LPS, a cell wall component of gram negative bacteria, as the 
agent to induce inflammation and subsequent preterm labour in mice. Initially this 
agent was administered intrauterine (between two amniotic sacs) by aid of a 
laparotomy, but subsequently a more elegant approach of delivering the intrauterine 
injection guided by ultrasound sonography (USS) was utilised (described in Rinaldi 
et al.,(2015)). Animals lacking the host defence peptide genes Defb14 (Defb14-/-) or 
Camp (Camp-/-) were given LPS intrauterine during late gestation to determine 






7.2 Experimental Details 
7.2.1 Fertility in Host Defence Peptide Knockout Mice  
The fertility of Camp-/- (n=46) and Defb14-/- mice (n=18) was determined by 
looking at several pregnancy indices; plug rate, pregnancy rate and first litter size. 
The plug rate was determined as the fraction of female mice where a copulatory plug 
was found (within 4-days of being placed with a male), compared to the total number 
set-up. Subsequent pregnancy rate is the fraction of the plugged females who 
continued pregnancy to gestational day 17, compared to the total number plugged. 
First litter sizes are described here as the number of viable fetus found in-utero on 
day 17 of gestation. 
7.2.2 Timed Collection Experiment 
Detailed experimental method for timed collection experiment is given in section 
2.1.5. In brief, at day 17 of murine gestation, 1µg or 20µg of LPS was injected 
between two fetal-sacs as guided by ultrasound sonography. Animals were then 
culled 6-hours post treatment where tissue and blood serum were collected for 
molecular analysis. In parallel non-anaesthetic non-treatment day 17 pregnant 
females (NTxC) were also culled for control tissue and blood serum for comparison. 
The number of animals in each treatment group is detailed in Table 7.1.  
 
 C57BL/6J Camp-/- 
NTxC n = 3 n = 3 
LPS [1µg] n = 3 n = 3 
LPS [20µg] n = 6 n = 6 
Table 7.1 Timed Collection Experiment - Animal Numbers and 
Treatment  
Treatments and genotype of animals for timed collection experiment using USS 





7.2.3 Laparotomy Model of PTL Experiment 
Detailed experimental method for laparotomy model of PTL experiment is given in 
section 2.1.2. In brief, at day 17 of murine gestation a laparotomy was performed to 
expose the uterine horns, 20µg of LPS or sterile physiological saline was then 
injected between two fetal-sacs. Uterine horns are then returned to the abdominal 
cavity and the incision was sutured closed. Animals were left to recover and the 
interval to delivery was recorded in hours. The number of live born pups was also 
recorded at the first observation after the initiation of labour. Animals that have 
preterm labour delivered within 36 hours while those that go to term delivered 
between 36 and 96 hours post-injection. In parallel non-surgery non-treatment 
control day 17 pregnant females (NTxC) were also set-up to establish normal interval 
to delivery. The number of animals in each treatment group is detailed in Table 7.2. 
 
 C57BL/6N Defb14-/- 
NTxC n = 3 n = 6 
Saline n = 9 n = 6 
LPS [20µg] n = 8 n = 10 
Table 7.2 Laparotomy Model of PTL Experiment Numbers 





7.2.4 Ultrasound Sonography guided Model of PTL 
Detailed experimental method for USS guided model of PTL experiment is given in 
section 2.1.3. In brief, at day 17 of murine gestation, 1µg or 20µg of LPS or sterile 
physiological saline was injected between two fetal-sacs as guided by ultrasound 
sonography. Animals are left to recover and the interval to delivery is recorded in 
hours. The number of live born pups is also recorded at the first observation after the 
initiation of labour. Animals that have preterm labour will deliver within 36 hours 
while those that go to term will deliver between 36 and 96 hours post-injection. The 
number of animals in each treatment group is detailed in Table 7.3. 
 
 C57BL/6J Camp-/- 
Saline n = 6 n = 3 
LPS [1µg] n = 10 n = 6 
LPS [20µg] n = 6 n = 6 
Table 7.3 USS Model of PTL Experiment Numbers 
Treatments and genotype of animals for USS guided model of PTL experiment.  
 
7.2.5 Statistical Analysis 
Interval to Delivery  
All data is presented as mean ± SEM. Interval to delivery data was log transformed 
prior to statistical analysis. Two-way ANOVA was used to highlight LPS treatment 
and genotype effects, significant differences were identified by Dunnett’s multiple 





Number of Live Born Pups 
All data is presented as mean ± SEM. Live born pups fractions were ArcSin 
transformed prior to analysis. Two-way ANOVA was used to highlight LPS 
treatment and genotype effects, significant differences were identified by Dunnett’s 
multiple comparison test compared to the physiological saline injection group.  
RT-qPCR 
All data is presented as mean ± SEM normalised to β-Actin and relative to CAL. The 
calibrator used in this chapter was a cDNA pool from mouse placenta, uterus and 
fetal membrane from a single animal undergoing no treatment. Data was log 
transformed prior to analysis.  
Where comparing two groups, NTxC and LPS, an unpaired t-test was performed. 
Two-way ANOVA was used to highlight LPS treatment and genotype effects, 
significant differences in genotype were identified with Bonferroni’s post-test, and 
significant differences in LPS treatment identified with Tukey’s post-test.  
Camp mRNA gene expression significance was measured by one-way ANOVA with 
Tukey’s post-test in timed-collection experiment.  
Circulating Serum Cytokines 
All data is presented as mean ± SEM. Two-way ANOVA was used to highlight LPS 
treatment and genotype effects, significant differences in genotype were identified 
with Bonferroni’s post-test, and significant differences in LPS treatment identified 







7.3.1 Fertility of Camp-/- and Defb14-/- Animals 
Camp-/- mice showed a slight but significant decrease in the plug rate (Fisher’s exact 
test, P =0.04) compared to wildtype C57BL/6J mice (Figure 7.1.a). Both Defb14-/- 
and Camp-/- mice had comparable subsequent successful pregnancy and litter sizes 
to that of their wildtype controls (Figure 7.1.b and Figure 7.2). In addition, there is 
no evidence of spontaneous preterm labour in either Defb14-/- (Figure 7.8) or Camp-
/- (data not shown) animals; the gestational intervals are in line with that widely 
reported for this background strain. 
 
Figure 7.1 Fertility of Camp-/- and Defb14-/- mice 
(a) Plug rate, (b) Pregnancy ratio in Camp-/- and Defb14-/- mice compared to their 








Figure 7.2 Litter Size of Camp-/- and Defb14-/- mice 
Boxplots representing median, IQR with min, max whisker of first litter size in 
Camp-/- and Defb14-/- mice compared to their wildtype controls; C57BL/6J and 





7.3.2 HDPs and Inflammatory Gene Response to LPS-induced 
model of PTL in C57BL/6J mice - Timed Collection 
 
7.3.2.1 Defb14 mRNA Expression following PTL model 
In C57BL/6J animals, Defb14 mRNA expression 6-hours post intrauterine LPS 
[20µg] injection showed no significant increase in the placenta, fetal membrane or 
uterus as compared to non-treatment control animals by RT-qPCR (Figure 7.3). 
Defb14 mRNA levels in the fetal membrane were at the lower limits of detection, 
and some samples were undetected (Figure 7.3.c) 
 
 
Figure 7.3 Expression of Defb14 in LPS-induced PTL Model 
Relative mRNA expression of Defb14 in (a) Placenta (b) Uterus, and (c) Fetal 
Membrane tissues collected in C57BL/6J mice 6-hours post injection of 20µg LPS 
(n=6) or non-treatment controls (NTxC, n=3). Data presented is mean fold-increase 






7.3.2.2 Camp mRNA Expression following PTL model 
6-hours post intrauterine LPS [20µg] treatment Camp mRNA expression levels in 
wildtype C57BL/6J mice showed a significant increase in the placenta (P <0.05), 
fetal membrane (P <0.01), and uterus (P <0.01) compared to non-treatment control 




Figure 7.4 Expression of Camp in LPS-induced PTL Model 
Relative mRNA expression of Camp in (a) Placenta, (b) Uterus, and (c) Fetal 
Membrane tissues collected in C57BL/6J animals 6-hours post LPS [20µg] treatment 
(n=6) or non-treatment controls (NTxC, n=3). Data presented is mean fold-increase 







7.3.2.3 Inflammatory and Immune Cell Mediators in Placenta  
Intrauterine LPS [20µg] injection significantly increased the expression of all 
investigated inflammatory and immune cell mediators in placental tissues of 
C57BL/6J mice (Figure 7.5). 
The neutrophil chemokines, Cxcl1 and Cxcl2, in placental tissues showed significant 
increases after LPS [20µg] injection compared to non-treatment controls. Cxcl1 
mRNA expression displayed a mean 45.16 ± 7.06 fold-increase (P <0.001), 
compared to non-treatment animals. Cxcl2 mRNA expression increased on average 
83.02 ± 20.09 fold, compared to those animals not-treated (P <0.01). 
Similarly, the pro-inflammatory cytokines, Il-1β and Tnf, are also significantly 
increased in placental tissues following LPS [20µg] treatment; displaying a 14.43 ± 
3.15 mean fold-increase (P <0.01) and 6.5 ± 1.46 mean fold-increase (P <0.01) 
respectively. 
Placental mRNA expression of Ptgs2 (Cox-2) showed a 3.61 ± 0.94 fold-increase in 






Figure 7.5 Placental Inflammatory and Immune Cell Mediator Response 
to LPS-induced PTL Model 
Relative mRNA expression of (a) Cxcl1(b) Cxcl2 (c) Ptgs2 (d) Il-1β (e) Tnf in 
placenta tissues collected in C57BL/6J mice 6-hours post LPS [20µg] injection (n=6) 
or NTxC (n=3). Data presented as mean fold-increase and SEM, normalised to β-





7.3.2.4 Inflammatory and Immune Cell Mediators in Uterus 
Intrauterine LPS [20µg] injection also significantly increased the expression of 
several inflammatory and immune cell mediators in uterine tissues of C57BL/6J mice 
compared to those not treated (Figure 7.6). 
The neutrophil chemokines, Cxcl1 and Cxcl2, in uterine tissue showed significant 
increase after LPS [20µg] injection compared to non-treatment controls (P <0.0001 
and P <0.01 respectively). mRNA Cxcl1 expression displayed a mean 443.6 ± 52.89 
fold-increase compared to non-treatment animals. Cxcl2 mRNA expression increased 
on average 319.1 ± 84.93 fold compared to those animals not-treated  
Similarly, the pro-inflammatory cytokines, Il-1β and Tnf, are also increased in 
uterine tissues following LPS [20µg] treatment (P <0.001 and P <0.0001 
respectively). Il-β exhibited a mean fold increase of 49.35 ± 9.14, and on average Tnf 
increased 13.96 ± 1.425 fold compared to the mean of those animals not treated. 
Uterine mRNA expression of Ptgs2 (Cox-2) showed a significant (P <0.01) mean 






Figure 7.6 Uterine Inflammatory and Immune Cell Mediator Response to 
LPS-induced PTL Model 
Relative mRNA expression of (a) Cxcl1(b) Cxcl2 (c) Ptgs2 (d) Il-1β (e) Tnf in 
uterine tissues collected in C57BL/6J mice 6-hours post LPS [20µg] injection (n=6) 
or NTxC (n=3). Data is presented as mean fold-increase and SEM, normalised to β-







7.3.2.5 Inflammatory and Immune Cell Mediators in Fetal Membrane 
Intrauterine LPS [20µg] injection significantly increased the expression of neutrophil 
chemokines, Cxcl1 and Cxcl2, and Ptgs2 in fetal membrane tissues of C57BL/6J 
mice (Figure 7.7). mRNA Cxcl1 expression was significantly increased (P <0.05) in 
fetal membranes, showing a mean 11.32 ± 5.53 fold-increase in LPS treatment 
compared to non-treatment animals. Cxcl2 mRNA expression increased 3.22 ± 1.56 -
fold, compared to those animals not-treated (P <0.05). 
Fetal membrane mRNA expression of Ptgs2 (Cox-2) showed a small but significant 
(P <0.05) increase of 1.64 ± 0.57 in response to LPS [20µg] treatment as compared 
to non-treatment animals.  
The pro-inflammatory cytokines, Il-1β and Tnf, did not show a significant increase in 





Figure 7.7 Fetal Membrane Inflammatory and Immune Cell Mediator 
Response to LPS-induced PTL Model 
Relative mRNA expression of (a) Cxcl1(b) Cxcl2 (c) Ptgs2 (d) Il-1β (e) Tnf in fetal 
membrane tissues collected in C57BL/6J mice 6-hours post LPS [20µg] injection 
(n=6) or NTxC (n=3). Data presented is mean fold-increase and SEM, normalised to 






7.3.3 Defb14 in LPS Induced Preterm Labour; Laparotomy 
Model  
7.3.3.1 Interval to Delivery 
C57BL/6N and Defb14-/- mice received an intrauterine injection of LPS [20µg], 
physiological sterile saline or no-treatment on day 17 of gestation and the interval to 
delivery was recorded in hours (Figure 7.8). 
The normal gestational interval of C57BL/6N and Defb14-/- mice undergoing no-
treatment was comparable. C57BL/6N mice deliver on average 62.0 ± 1.5 (n=3) and 
Defb14-/- mice deliver 57.1 ± 3.3 (n=6) hours after being set-up on day 17 with no 
other intervention. This is equivalent to labour on day 19.5 of gestation, which is in 
line with what has widely been reported for this background strain. 
Intrauterine injection of LPS [20µg] on day 17 of gestation caused preterm labour 
(defined as delivery within 36 hours) in 17 out of the 18 total animals treated at this 
dose. LPS [20µg] injection significantly reduces the interval to delivery in 
C57BL/6N and Defb14-/- mice compared to saline injection controls (two-way 
ANOVA; Dunnett’s post-test; P<0.0001 at both genotypes). However, there was no 
significant difference in the interval to delivery between C57BL/6N and Defb14-/- 
mice (two-way ANOVA). C57BL/6N mice deliver on average 14.1 ± 2.0 (n=8) and 
Defb14-/- mice deliver 18.4 ± 6.4 (n=10) hours post LPS [20µg] injection. 
Injection of physiological sterile saline by laparotomy induced some variation in the 
interval to delivery, where 2 of the 10 C57BL/6N mice had preterm labour (defined 
as delivery within 36 hours). This did not reach statistical significance in C57BL/6N 
or Defb14-/- mice when compared to the respective animals not treated (two-way 





Figure 7.8 Interval to Delivery in Defb14-/- mice; LPS-induced PTL 
Model 
Time to delivery in C57BL/6N and Defb14-/- mice receiving intrauterine injection of 
LPS [20µg], physiological sterile saline or non-treatment controls (NTxC). Data 
presented as mean hours post-treatment on day 17 and SEM. (two-way ANOVA; 






7.3.3.2 Pup Survival 
Post-delivery the number of live born pups in a litter was recorded for C57BL/6N 
and Defb14-/- animals and presented as a ratio to the number of viable fetuses 
counted at the time of surgery on day 17 of gestation (Figure 7.9). As the number of 
viable fetuses in NTxC animals is not determined at the time of surgery, the fraction 
of live born pups presented is calculated against the total number of pups delivered. 
Injection of LPS [20µg] by laparotomy resulted in significant amounts of fetal death 
in both C57BL/6N and Defb14-/-mice; where no pups were found born live in this 
treatment group (Two-way ANOVA; Dunnett’s post-test; P<0.0001 at both 
genotypes). 
Injection of physiological sterile saline by laparotomy results in an increase in the 
amount of fetal death seen compared to those animals undergoing no-treatment. This 
reached significance in just the C57BL/6N animals (two-way ANOVA; Dunnett's 
post-test compared to saline group; P <0.01), where those receiving sterile saline 
(n=10) had on average 0.54 ± 0.13 live born pups compared to those undergoing no-






Figure 7.9 Live Born Pup Ratio in Defb14-/- mice; LPS-induced PTL 
Model 
Live born pups in C57BL/6N and Defb14-/- mice receiving intrauterine injection of 
LPS [20µg], physiological sterile saline or non-treatment controls (NTxC). Data 
presented as mean fraction of viable fetuses on day 17 and SEM. (two-way ANOVA; 




7.3.4 Camp in LPS Induced Preterm Labour; Ultrasound Model 
7.3.4.1 Interval to Delivery 
C57BL/6J and Camp-/- mice received either, an intrauterine injection of LPS [20µg], 
LPS [1µg] or physiological sterile saline guided by USS on day 17 of gestation. The 
interval to delivery was recorded in hours (Figure 7.10). The normal gestational 
interval of C57BL/6J and Camp-/- mice undergoing no-treatment is comparable and 
in line with that reported for this background strain (data not presented). 
Intrauterine injection of LPS [20µg] on day 17 of gestation by USS significantly 
induces preterm labour in C57BL/6J mice, where the average interval to delivery was 
26.8 ± 8.8 (n=6) hours post-LPS injection (two-way ANOVA; Dunnett’s post-test 
compared to saline group; P<0.001). Camp-/- mice treated in the same way also had 
significant amounts of preterm labour in response to LPS at 20µg (two-way 
ANOVA; Dunnett’s post-test compared to saline group; P<0.001). However, there is 
no significant difference in the interval to delivery between C57BL/6J and Camp-/- 
mice. 
Reducing the dose of LPS to 1µg also robustly induced preterm labour in both 
C57BL/6J and Camp-/- mice. Though like LPS at 20µg, there was no significant 
difference in the average interval to labour in Camp-/- mice (44.4 ± 12.6 hours) 
compared to C57BL/6J mice (26.1 ± 2.6 hours) at the 1µg dose. 
Injection of physiological sterile saline by USS only induced preterm labour in one 
animal. There is no significant difference in the interval to delivery in C57BL/6J and 
Camp-/- animals when treated with saline alone; C57BL/6J mice deliver on average 







Figure 7.10 Interval to Delivery in Camp-/- mice; LPS-induced PTL 
Model 
Time to delivery in C57BL/6J and Camp-/- mice receiving intrauterine injection of 
LPS [20µg], LPS [1µg] or physiological sterile saline. Data presented as mean hours 
post-treatment on day 17 and SEM. (two-way ANOVA; Dunnett's post-test 






7.3.4.2 Pup Survival 
Post-delivery the number of live born pups in a litter was recorded for C57BL/6J and 
Camp-/- animals and presented as a ratio to the number of viable fetuses counted at 
the time of surgery on day 17 (Figure 7.11).  
Injection of 20µg LPS resulted in large amounts of fetal death in both C57BL/6J and 
Camp-/- mice. Only one C57BL/6J animal had live pups after 20µg LPS treatment, 
this animal also delivered at term. LPS at 1µg also resulted in large amounts of fetal 
death in both genotypes. 
Injection of physiological sterile saline by USS results in some fetal death in both 
C57BL/6J and Camp-/- mice. On average C57BL/6J mice have 0.60 ± 0.20 (n=6) 
live born pups and Camp-/- mice have 0.38 ± 0.21 live born pups after saline 
injection (n=3).  
 
Figure 7.11 Live Born Pup Ratio in Camp-/- mice; LPS-induced PTL 
Model 
Live born pups in C57BL/6J and Camp-/- mice receiving intrauterine injection of 
LPS [20µg], LPS [1µg] or physiological sterile saline. Data presented as mean 
fraction of viable fetuses on day 17 and SEM. (two-way ANOVA; Dunnett's post-





7.3.4.3 Inflammatory and Immune Cell Mediators in Placenta, Uterus and 
Fetal Membrane in response to LPS induced PTL 
Placental, uterine and fetal membrane tissue were analysed for the mRNA gene 
expression of several key inflammatory and immune cell mediators in LPS-induced 
PTL in Camp-/- and wildtype animals. The genes investigated were the pro-
inflammatory cytokines, Tnf and Il-β, the strong neutrophil chemoattractants, Cxcl1 
and Cxcl2, Ptgs2, which is important in the degradation of prostaglandins, and the 
Host Defence Peptide, Camp. 
As expected, placental, uterus and fetal membrane tissue collected 6-hours post 
treatment in all Camp-/- mice showed no expression of the Camp gene, confirming 
these animals are null (Figure 7.13.b, Figure 7.15.b, and Figure 7.17.b) 
7.3.4.3.1 Placenta 
Chemoattractants 
There was a small but significant difference in the expression of the neutrophil 
chemoattractant Cxcl1 between C57BL/6J and Camp-/- mice following injection of 
LPS at 1µg (Two-way ANOVA with Bonferroni post-test; P =0.03) (Figure 7.12.a). 
In response to 1µg of LPS there was 13.6 ± 0.8 fold increase in expression of Cxcl1 
compared to NTxC in C57BL/6J mice. Whereas 1µg of LPS injected Camp-/- mice 
displayed a mean fold increase of 5.5 ± 3.0 in Cxcl1 compared to NTxC. Sample size 
in this group is n=3; this genotypic difference in Cxcl1 was not seen at a dose of 
20µg of LPS which has a larger samples size of n=5/6. 
In C57BL/6J and Camp-/- mice, LPS injection had a significant effect (two-way 
ANOVA; P <0.0001) on Cxcl1 expression levels measured by RT-qPCR in placental 
tissue compared to NTxC. LPS increased Cxcl1 expression in a dose-responsive 
manner in both C57BL/6J and Camp-/- mice. Cxcl1 expression level of 20µg LPS 
injected mice compared to 1µg LPS injection is statistically significant in C57BL/6J 
animals (two-way ANOVA, with Tukey’s post-test; P <0.05). In response to 1µg of 




C57BL/6J mice. Whereas 20µg of LPS injected in C57BL/6J mice displayed a 42.2 
± 4.8 fold increase in Cxcl1 compared to NTxC. This significant dose-response was 
also seen in the Camp-/- mice, which had a 5.5 ± 3.0 fold and 31.9 ± 7.4 fold 
increase in Cxcl1 gene expression in response to 1µg and 20µg of LPS respectively 
(two-way ANOVA, with Tukey’s post-test; (P <0.001)). 
Cxcl2 expression was significantly increased in response to all doses of LPS in both 
C57BL/6J and Camp-/- mice compared to NTxC (two-way ANOVA; P <0.0001 for 
both 1µg and 20µg) (Figure 7.12.b). The increase in Cxcl2 expression in 1µg 
compared to 20µg LPS dose was statistically significant in C57BL/6J (P <0.01) and 
Camp-/- (P <0.001) mouse placental tissue. 
Pro-inflammatory Cytokines 
There was no difference in the expression of the pro-inflammatory cytokines Tnf or 
Il-β between C57BL/6J and Camp-/- mice following injection of LPS either at 20µg 
or 1µg dose (two-way ANOVA) (Figure 7.12c, Figure 7.12.d). 
In C57BL/6J and Camp-/- mice, LPS injection had a significant effect (two-way 
ANOVA; P <0.0001) in Tnf expression levels measured by RT-qPCR in the placenta. 
Tnf expression in the placenta was significantly elevated in response to LPS in 
C57BL/6J mice (P <0.0001 at both doses). 20µg of LPS injection in C57BL/6J mice 
displayed an 84.0 ± 13.0 fold increase in Tnf levels compared to NTxC. This 
significant increase in Tnf gene expression was also seen in the Camp-/- mice, (P 
<0.0001 at both doses) where 20µg of LPS increase Tnf gene expression 60.1 ± 8.1 
fold compared to the NTxC group.  
Similarly in C57BL/6J and Camp-/- mice, LPS injection had a significant effect 
(two-way ANOVA; P <0.0001) in Il-1β expression levels measured by RT-qPCR in 
the placenta. Il-1β expression in the placenta was significantly elevated in response 
to LPS in C57BL/6J mice (P <0.05 at 1µg dose, P <0.0001 at 20µg). 20µg of LPS in 
C57BL/6J mice displayed a 15.4 ± 2.2 fold increase in Il-1β compared to NTxC. This 




<0.0001 at 1µg, P <0.001 at 20µg) where at 20µg there was a 20.4 ± 2.7 fold 
increase (Two-way ANOVA, with Tukey’s post-test). 
Ptgs2 (Cox-2) 
In C57BL/6J and Camp-/- mice, LPS injection had a significant effect (two-way 
ANOVA; P <0.0001) on Ptgs2 expression levels measured by RT-qPCR in placental 
tissue (Figure 7.13.a). There was a small but significant interaction between LPS and 
genotype (Two-way ANOVA; P = 0.02). Ptgs2 expression in the placenta was 
significantly elevated in response to LPS in C57BL/6J mice (P <0.01 at 1 µg, P 
<0.0001 at 20 µg). 20µg of LPS injected in C57BL/6J mice displayed a 4.6 ± 0.3 
fold increase in Ptgs2 compared to the NTxC group. A significant increase in Ptgs2 
gene expression was only seen in the Camp-/- mice treated with 20µg of LPS (P 
<0.001), where 20µg of LPS increases Ptgs2 gene expression 4.8 ± 0.7 fold 
compared to NTxC.  
Given the significant interaction effect of LPS and Genotype a two-way ANOVA 
with Tukey’s post-test indicated a significant dose-responsive LPS effect in only 
Camp-/- mice (two-way ANOVA, with Tukey’s post-test, P <0.001). Camp-/- mice 
had a 1.4 ± 0.5 fold and 4.8 ± 0.7 fold increase in Ptgs2 gene expression in response 






Figure 7.12 Placental Inflammatory and Immune Cell Mediator 
Response in Camp-/- LPS-induced PTL Model 
Relative mRNA expression of (a) Cxcl1 (b) Cxcl2 (c) Tnf (d) Il-1β in placenta tissues 
collected in C57BL/6J and Camp-/- mice 6-hours post injection of LPS [20µg], LPS 
[1µg] or no-treatment controls (NTxC). Data presented is mean fold-increase and 
SEM, normalised to β-Actin and relative to CAL. (Two-way ANOVA with Tukey’s 
post-test; *, P <0.05, **, P <0.01, ***, P<0.001, ****, P<0.0001 compared to NTxC, 
#, P <0.05, ###, P<0.001, ####, P<0.0001 1µg compared to 20µg. Two-way 






Figure 7.13 Placental Ptgs2 and Camp Response in Camp-/- LPS-
induced PTL Model 
Relative mRNA expression of (a) Ptgs2 and (b) Camp in placenta tissues collected in 
C57BL/6J and Camp-/- mice 6-hours post injection of LPS [20µg], LPS [1µg] or no-
treatment controls (NTxC). Data presented is mean fold-increase and SEM, 
normalised to β-Actin and relative to CAL. (Two-way ANOVA with Tukey’s post-
test; ***, P<0.001, ****, P<0.0001 compared to NTxC, ###, P<0.001 1µg compared 
to 20µg. Two-way ANOVA with Bonferroni post-test; &, P<0.05 C57BL/6J 
compared to Camp-/- mice. For figure (b) Camp expression one-way ANOVA with 









There was no difference in the expression of the neutrophil chemoattractants Cxcl1 
or Cxcl2 between C57BL/6J and Camp-/- mice following injection of LPS at either 
20µg or 1µg dose (two-way ANOVA) (Figure 7.14.a, Figure 7.14,b).  
In C57BL/6J and Camp-/- mice, LPS injection had a significant effect (two-way 
ANOVA; P <0.0001) on Cxcl1 expression levels measured by RT-qPCR in uterine 
tissue compared to NTxC. LPS increased Cxcl1 expression in a dose-responsive 
manner in both C57BL/6J and Camp-/- mice. Cxcl1 expression level of 20µg LPS 
injected mice compared to 1µg LPS injection is statistically significant in C57BL/6J 
animals (two-way ANOVA, with Tukey’s post-test; P <0.05). In response to 1µg of 
LPS there was 57.5 ± 22 fold increase in expression of Cxcl1 compared to NTxC in 
C57BL/6J mice. Whereas 20µg of LPS injected in C57BL/6J mice displayed a 444.6 
± 36.1 fold increase in Cxcl1 compared to NTxC. This significant dose-response was 
also seen in the Camp-/- mice, which had a 91.9 ± 47.9 fold and 420.2 ± 121.6 fold 
increase in Cxcl1 gene expression in response to 1µg and 20µg of LPS respectively 
(two-way ANOVA, with Tukey’s post-test; P <0.05). 
Cxcl2 expression was significantly increased in response to all doses of LPS in both 
C57BL/6J and Camp-/- mice compared to NTxC (two-way ANOVA; P <0.0001 for 
both 1µg and 20µg). The dose-responsive manner of LPS in Cxcl2 response did not 
reach statistical significance in either, C57BL/6J or Camp-/- mice.  
Pro-inflammatory cytokines 
There was no difference in the expression of the pro-inflammatory cytokines Tnf or 
Il-β between C57BL/6J and Camp-/- mice following injection of LPS at either 20µg 
or 1µg dose (two-way ANOVA) (Figure 7.14.c, Figure 7.14.d). 
In C57BL/6J and Camp-/- mice, LPS injection had a significant effect (two-way 
ANOVA; P <0.0001) in Tnf expression levels measured by RT-qPCR in the uterus. 




C57BL/6J mice (P <0.001 at 1µg and P <0.0001 at 20µg). 20µg of LPS in C57BL/6J 
mice displayed a 15.0 ± 1.0 fold increase in Tnf compared to NTxC. This significant 
increase in Tnf gene expression was also seen in the Camp-/- mice, (P <0.0001 at 
both doses) where 20µg LPS injection increase Tnf gene expression 15.0 ± 2.6 fold 
compared to NTxC. Similarly in C57BL/6J and Camp-/- mice, LPS injection had a 
significant effect (two-way ANOVA; P <0.0001) in Il-1β expression levels measured 
by RT-qPCR in the uterus. 
Il-1β expression in the uterus was significantly elevated in response to LPS in 
C57BL/6J mice (P <0.001 both doses). 20µg of LPS injection in C57BL/6J mice 
displayed a 50.3 ± 6.2 fold increase in Il-1β compared to NTxC. This significant 
increase in Il-1β gene expression was also seen in the Camp-/- mice, (P <0.0001) 
given 20µg of LPS (Two-way ANOVA, with Tukey’s post-test). 
Ptgs2 (Cox-2) 
In C57BL/6J and Camp-/- mice, LPS injection had a significant effect (two-way 
ANOVA; P <0.01) on Ptgs2 expression levels measured by RT-qPCR in uterine 
tissue. A significant increase in Ptgs2 was only seen at the 20µg LPS dose in 
C57BL/6J and Camp-/- mice (P <0.05 for both genotypes) compared to NTxC (two-
way ANOVA, with Tukey’s post-test; P <0.05). In response to 20µg of LPS in 
C57BL/6J and Camp-/- mice there was a 7.2 ± 1.2 fold increase and 9.6 ± 3.1 fold 
increase in Ptgs2 respectively compared to NTxC. Two-way ANOVA with Tukey’s 
post-test indicated a small (P = 0.41) but significant difference in Ptgs2 expression 








Figure 7.14 Uterine Inflammatory and Immune Cell Mediator Response 
in Camp-/- LPS-induced PTL Model 
Relative mRNA expression of (a) Cxcl1 (b) Cxcl2 (c) Tnf and (d) Il-1β in uterus 
tissues collected in C57BL/6J and Camp-/- mice 6-hours post injection of LPS 
[20µg], LPS [1µg] or no-treatment controls (NTxC). Data presented is mean fold-
increase and SEM, normalised to β-Actin and relative to CAL. (two-way ANOVA 
with Tukey’s post-test; *, P <0.05, **, P <0.01, ***, P<0.001, ****, P<0.0001 







Figure 7.15 Uterine Ptgs2 and Camp Response in Camp-/- LPS-induced 
PTL Model 
Relative mRNA expression of (a) Ptgs2 (b) Camp in uterus tissues collected in 
C57BL/6J and Camp-/- mice 6-hours post injection of LPS [20µg], LPS [1µg] or no-
treatment controls (NTxC). Data presented is mean fold-increase and SEM, 
normalised to β-Actin and relative to CAL. (two-way ANOVA with Tukey’s post-
test; *, P <0.05, **, P <0.01, ***, P<0.001, ****, P<0.0001 compared to NTxC, #, P 
<0.05 1µg compared to 20µg. For figure (b) Camp expression one-way ANOVA 






7.3.4.3.3 Fetal Membrane 
Chemoattractants 
There was no difference in the expression of the neutrophil chemoattractants Cxcl1 
or Cxxl2 between C57BL/6J and Camp-/- mice following injection of LPS at either 
20µg or 1µg dose (two-way ANOVA) in fetal membrane tissue (Figure 7.16.a, 
Figure 7.16.b). 
In C57BL/6J and Camp-/- mice, LPS injection had a significant effect (two-way 
ANOVA; P <0.0001) on Cxcl1 expression levels measured by RT-qPCR in fetal 
membrane tissue compared to NTxC. Cxcl1 expression was only significantly 
increased in the 20µg treated animals (P <0.05 in C57BL/6J, P <0.001 in Camp-/-) 
In response to 20µg of LPS there was a 12.3 ± 3.8 fold increase in expression of 
Cxcl1 compared to NTxC in C57BL/6J mice. 20µg of LPS injected Camp-/- mice 
displayed a mean fold increase of 65.9 ± 26.6 in Cxcl1 compared to NTxC. 
LPS injection had a significant effect (two-way ANOVA; P <0.001) on Cxcl2 
expression levels measured by RT-qPCR in fetal membrane tissue compared to 
NTxC. Cxcl2 expression was only significantly increased in response to 20 µg LPS 
in Camp-/- mice compared to NTxC (P <0.01).  
Pro-inflammatory Cytokines 
LPS injection had no significant effect (two-way ANOVA) in Tnf expression levels 
measured by RT-qPCR in the fetal membrane (Figure 7.16.c). 
Il-1β expression levels measured by RT-qPCR in the fetal membrane only showed a 
modest response to LPS (two-way ANOVA; P <0.05) (Figure 7.16.d). Il-1β 
expression in the fetal membrane was only significantly elevated in response to 20 






LPS injection had a significant effect (two-way ANOVA; P <0.0001) on Ptgs2 
expression levels measured by RT-qPCR in fetal membrane tissue (Figure 7.17.a). Il-
1β expression in the fetal membrane was only significantly elevated in response to 20 
µg of LPS in C57BL/6J (P <0.05) and Camp-/- mice (P <0.01). 20µg of LPS in 
C57BL/6J mice displayed a 2.6 ± 0.4 fold increase in Ptgs2 compared to NTxC. 
Camp-/- mice treated with 20 µg LPS increase Ptgs2 gene expression 5.6 ± 1.5 fold 






Figure 7.16 Fetal Membrane Inflammatory and Immune Cell Mediator 
Response in Camp-/- LPS-induced PTL Model 
Relative mRNA expression of (a) Cxcl1 (b) Cxcl2 (c) Tnf and (d) Il-1β in fetal 
membrane tissues collected in C57BL/6J and Camp-/- mice 6-hours post injection of 
LPS [20µg], LPS [1µg] or no-treatment controls (NTxC). Data presented is mean 
fold-increase and SEM, normalised to β-Actin and relative to CAL. (two-way 
ANOVA with Tukey’s post-test; *, P <0.05, **, P <0.01, ***, P<0.001, ****, 





Figure 7.17 Fetal Membrane Ptgs2 and Camp Response in Camp-/- LPS-
induced PTL Model 
Relative mRNA expression of (a) Ptgs2 and (b) Camp in fetal membrane tissues 
collected in C57BL/6J and Camp-/- mice 6-hours post injection of LPS [20µg], LPS 
[1µg] or no-treatment controls (NTxC). Data presented is mean fold-increase and 
SEM, normalised to β-Actin and relative to CAL. (two-way ANOVA with Tukey’s 
post-test; *, P <0.05, **, P <0.01 compared to NTxC, #, P <0.05 1µg compared to 
20µg. For figure (b) Camp expression one-way ANOVA with Tukey’s post-test; **, 





7.3.4.4 Circulating Serum IL-6 and TNF levels in response to LPS induced 
PTL 
6-hours post-injection of LPS or saline, TNF and IL-6 were measured in maternal 
circulating serum in LPS-induced PTL by ELISA (Figure 7.18).  
Both circulating TNF and Il-6 protein levels were increased in response to LPS 
(Figure 7.18). However, there was no difference in the level of these cytokines 
between C57BL/6J and Camp-/- mice following injection of LPS at either 20µg or 
1µg dose (two-way ANOVA). 
In C57BL/6J and Camp-/- mice, LPS injection had a significant effect (two-way 
ANOVA; P <0.0001) in circulating TNF levels. TNF was significantly elevated in 
response to LPS in C57BL/6J mice (P <0.05 at 1µg and P <0.0001 at 20µg). This 
significant increase in TNF level was only seen in the Camp-/- mice when given 
20µg of LPS (P <0.001). 
Similarly LPS injection had a significant effect (two-way ANOVA; P <0.0001) in 
circulating IL-6 levels measured by ELISA in the serum. IL-6 was significantly 
elevated in response to LPS in C57BL/6J mice (P <0.01 at 1µg and P <0.001 at 
20µg). This significant increase in IL-6 level was only seen in the Camp-/- mice 







Figure 7.18 IL-6 and TNF in Circulating Serum in Camp-/- LPS-induced 
PTL Model 
(a) IL-6 and (b) TNF protein levels in circulating serum collected in C57BL/6J and 
Camp-/- mice 6-hours post injection of LPS [20µg], LPS [1µg] or non-treatment 
controls (NTxC) and measured by ELISA. Data presented is mean pg/ml and SEM 
(two-way ANOVA with Tukey’s post-test; *, P <0.05, **, P <0.01, ***, P<0.001, 







Interval to Delivery and Pup Survival  
In this chapter, I have addressed the murine expression of the HDPs, Defb14 and 
Camp, in the reproductive tract and whether they have a role modulating the 
inflammation that maybe the inducing factor of preterm labour. Defb14-/- and Camp-
/- mice have no marked reduction in fertility neither do they display any evidence of 
spontaneous PTL. I found that a dose of 20µg LPS injected intrauterine on day 17 of 
gestation by laparotomy significantly and robustly induces preterm labour in 
C57BL/6N mice. The Defb14-/- mice that were treated the same way showed no 
significant difference from the C57BL/6N mice in the interval to delivery (Figure 
7.8), or in the number of live born pups (Figure 7.9). Thus at this concentration of 
LPS delivered by the laparotomy technique there was no evidence for an influence of 
Defb14 on preterm labour in mice. 
Injection of 20µg and 1µg of LPS intrauterine on day 17 of gestation by USS 
significantly induces preterm labour in C57BL/6J animals. Camp-/- mice receiving 
the same treatment displayed no significant difference in the interval to delivery or 
the number of live born pups to that of C57BL/6J mice (Figure 7.10; Figure 7.11). At 
20µg and 1µg LPS dose, delivered by the ultrasound technique, there was no 
evidence for an influence of Camp on preterm labour in mice. Some of the Camp-/- 
animals given 1µg of LPS went on to deliver at term and had associated increase in 
pup survival. However there was no significant difference in pup survival in Camp-/- 
animals between the Saline and LPS treatment group; more animal numbers are 
needed here to fully exclude effect. 
Pup Survival and Model Refinement 
Some of the physiological saline injection control mice delivered preterm and 
showed a large number of fetal deaths when treatment was given by laparotomy. 
This model of preterm labour was refined for subsequent experiments where 
injection of treatments was adapted to be guided by ultrasound sonography. This 




neutrophil influx to the uterus (Rinaldi et al., 2015, Rinaldi et al., 2014). This model 
displayed a small improvement in the number of live-born pups in the saline 
injection group of Camp-/- and C57BL/6J control mice. Due to the slight difference 
in background strain of the Defb14-/- and Camp-/- animals (C57BL/6N and 
C57BL/6J respectively), direct comparisons between modes of treatment delivery 
would not be valid here (see Rinaldi et al., (2015) for a direct and robust 
comparison). Moreover, the laparotomy and USS model experiments in this chapter 
had been conducted in different SPF animal facilities. The effect of differential 
bacterial burden between animal facilities on steady state immune profiles remains to 
be established. 
hBD3 and Defb14 
hBD3 expression is known to be upregulated in many cell types when treated with 
bacterial stimuli. Oral squamous cells (Shuyi et al., 2011), gingival epithelial cells 
and dendritic cells (Yin et al., 2010) all show a marked increase in hBD3 in response 
to LPS treatment in-vitro. Garcia-Lopez et al., (2010) displayed that hBD3 secretion 
was increased in fetal membranes in a tissue-specific manner; application of E.coli to 
the choriodecidua increased both gene and protein expression. Mouse bone marrow 
dendritic cells (BMDCs) treated with LPS in-vitro increase the expression of Defb14 
gene and protein (Semple et al., 2010). Mouse lung epithelial cells also increase 
Defb14 expression in response to TLR stimuli (Rohrl et al., 2008). It is therefore 
unexpected that in this chapter LPS treatment intrauterine did not result in increased 
endogenous gene expression of Defb14 in response to PTL.  
Gene level mRNA for Defb14 can also be stimulated by the pro-inflammatory 
cytokines TNF and INF-γ (Rohrl et al., 2008). In this chapter, mice treated with LPS 
had increases in circulating TNF protein level and local Tnf mRNA expression in 
utero-placenta tissues, nonetheless this had no effect on Defb14 gene expression in 
tissues collected 6-hours post injection. It is possible that increase in transcription of 
Defb14 comes into effect later than the 6-hours investigated here. Yin et al., (2010) 




epithelial cells at 24-hours post treatment in-vitro, but showed an increase at 48-
hours at the protein level. 
Defb14 in mouse pregnancy has not been well studied. Hickey et al., (2013) found 
that in non-pregnant animals Defb14 had specific estrus cycle mRNA expression 
profiles and the level in the vagina was much higher than that in the uterus. Indeed, 
in Chapter 2, I show mRNA level of Defb14 to be 1368 fold higher in the vagina 
than in the uterus. It is therefore possible that Defb14 has a greater importance in the 
lower reproductive tract, which has constant exposure to bacteria.  
Dose of LPS in PTL 
The hypothesis of this chapter was that mice null for Defb14 or Camp would have 
increased rates of preterm labour and the interval to delivery would be shorter than 
wildtype animals. However, it is possible that 20µg of LPS is excessive in this 
system and any effects of the host defence peptides might be masked by this bolus of 
endotoxin. Rinaldi et al., (2014) had previously shown that reducing the LPS 
concentration below 15µg delivered by laparotomy caused no-significant increase in 
the rate of animals delivering preterm. In the less invasive USS mode of LPS 
delivery the lower dose threshold for causing preterm labour has yet to be 
established. 
Given the published dose response data from the laparotomy model the experiments 
conducted in this chapter, using a lower dose of 1µg of LPS induced preterm labour 
rates higher than expected in the C57BL/6J animals. Eight out of 10 C57BL/6J 
animals delivered preterm, and three out of five of the Camp-/- animals had PTL in 
response to 1µg of LPS (Figure 7.10). 
To further refine this model it would have been ideal to use LPS at a dose sufficient 
to only induce preterm labour in 50% of the wildtype animals, thus highlighting 
whether the rates of preterm labour in the HDP knockout mice are higher. I sought to 
achieve this by lowering the dose to 1µg of LPS but in this system eight out of 10 
wildtype animals delivered preterm (80%), thus conducting a dose response lower 




Inflammatory and Immune Cell Mediators in Camp-/- PTL  
Given the anti-inflammatory effects of human LL-37 on placental explants I have 
shown in Chapter 2, and the known ability of CAMP to bind to LPS, I investigated 
differences in immune response of Camp-/- mice compared to wildtype in LPS-
induced PTL model. Placental, uterine and fetal membrane tissue were analysed for 
the mRNA gene expression of several key inflammatory and immune cell mediators; 
Tnf, Il-β, Cxcl1, Cxcl2 and Ptgs2. Broadly most of these mediators showed no 
difference in expression between Camp-/- and wildtype animals at either the 1µg or 
20µg dose in utero-placental tissue. Cxcl1 and Ptgs2 expression in the placenta at 
1µg LPS injection showed a small but significant (P<0.05) difference in the mRNA 
expression level between Camp-/- and wildtype animals, although the sample sizes 
here are small (n=3 per group).  
A 6-hour post-injection time-point was chosen for tissue and blood serum collection 
to highlight effects of LPS on inflammatory and immune cell mediators in pregnancy 
tissues and circulating serum. This was an intermediate stage between treatment and 
the initiation of labour, which would be variable between mice. As many cytokines 
and immune cell mediators have unique temporal and presumably spatial patterning 
in response to endotoxin, a single time-point is a limiting factor in this study. 
Rinaldi et al., (unpublished) had previously shown that saline injection by USS in 
C57BL/6J mice did not result in any significant increase in key immune markers 
when compared to non-treated animals of the same gestation. Therefore, in this 
chapter, the immune marker levels of LPS [20µg/1µg] treatment was compared to 
non-treatment animals. 
In humans, labour at term and preterm has been associated with pro-inflammatory 
mediators in amniotic fluid and at the local maternal fetal interface (Gardella et al., 
2001, Galinsky et al., 2013, Vrachnis et al., 2010). These inflammatory cytokines can 
stimulate prostaglandin production and propagate neutrophil chemotaxis, infiltration, 
and activation, resulting in metalloproteases (MMPs) synthesis and release. 
Prostaglandins can directly stimulate myometrial contractions, in addition to indirect 




Crankshaw and Dyal, 1994). COX-2 is an inducible labour associated gene, which is 
expressed at term in the human myometrium; while MMPs can aid tissue 
remodelling in the cervix and fetal membrane (Heng et al., 2012) 
Chemokines in term labour in both humans (Hamilton et al., 2013) and mice 
(Shynlova et al., 2013a) have shown increased production. To investigate the role of 
these immune mediators in the mouse model of preterm labour I looked at Cxcl1 and 
Cxcl2 the strong neutrophil chemoattractants in response to different doses of LPS. 
These chemokines increased in utero-placental tissue in a mostly dose-responsive 
manner, the consequences of this are likely to include neutrophil influx. Leucocytes 
are a large source of pro-inflammatory cytokines and prostaglandins thus are capable 
of initiating or strengthening an inflammatory cascade and triggering labour by 
activating the fetal membrane tissues and uterine epithelia. However, Rinaldi et al 
(2014) showed that neutrophil influx to the decidua is not necessary for initiation of 
preterm labour in an animal model of PTL. 
Many chemokines are reported to be increased in normal mouse labour (Shynlova et 
al., 2013a), but how the levels in response to LPS-induced PTL compares to 
spontaneous term-labour was not studied in this chapter. 
Prostaglandins are important inflammatory mediators involved in parturition. PTGS2 
(COX-2) is expressed at term in the human myometrium and also in animal cervical 
fibroblasts (Sato et al., 2001); there is also some evidence that low expression may 
be protective against preterm labour (Hirsch et al., 2006). To investigate the role of 
Ptgs2 in the mouse model of preterm labour I looked at Ptgs2 gene expression in 
utero-placental tissues; this mediator increased in a mostly dose-responsive manner 
to LPS.  
Cytokines in Blood Serum  
6-hours post-injection of LPS or saline, TNF and IL-6 were measured in maternal 
circulating serum in LPS-induced PTL by ELISA. Elevated serum cytokines have 
been associated with PTL, although most women with utero-placental infection do 




rapid induction of pro-inflammatory cytokines after intraperitoneal injection in non-
pregnant mice. In one study, IL-6 and TNF in the serum increased sharply, peaking 
at 2-hours and returned to baseline levels by 6-hours post injection (Copeland et al., 
2005). In this chapter, I found that the increase of TNF and IL-6 in maternal serum 
was still detectable 6-hours post LPS-treatment. The timing of peak response and 
duration before returning to baseline of these cytokines in LPS-induced PTL remains 
to be established. 
Mice as a model for PTL 
There is known variability in the maternal and fetal inflammatory response to 
different serotypes of LPS used to induce preterm labour (Migale et al., 2015). In this 
study the serotype of LPS (O111:B4) was kept constant, nonetheless cross-study 
comparisons will be problematic. There are limitations of using mouse as a model for 
preterm labour, due to the physiological differences to human pregnancy. One main 
difference between humans and mice is progesterone production. Humans first 
maintain pregnancy by the production of progesterone in the corpus lutum; this is 
then superseded by placental progesterone production. In humans, labour is not 
associated with a systemic withdrawal of progesterone (Elovitz and Mrinalini, 2004), 
however emerging evidence suggests there may be local functional progesterone 
withdrawal prior to the onset of labour (Mesiano et al., 2002, Pieber et al., 2001). In 
mice however, the contribution of placental progesterone is not thought to supersede 
that of the corpus lutum, and removing the ovaries during pregnancy induces labour 
(Condon et al., 2004). It has been proposed that Surfactant Protein A (SP-A) released 
from the pup lung initiates labour in mice as it causes activation and migration of 
amniotic fluid macrophages into the serum, leading to activation of pro-inflammatory 
factors such as NF-𝜅B and IL-1β (Condon et al., 2004, Mendelson and Condon, 
2005). However, the causative factor that initiates the inflammatory cascade in 





In this chapter, I have shown that: 
- Intrauterine injection of LPS induces preterm labour in wildtype C57BL/6J 
and C57BL/6N mice.  
- Defb14-/- and Camp-/- mice do not have an increased rate of preterm labour in 
a LPS induced inflammatory model.  
- Camp but not Defb14 is upregulated in utero-placental tissues in response to 
intrauterine LPS injection. 
- The inflammatory mediators; Cxcl1, Cxcl2, Tnf, and Il-1β are increased in 
response to LPS-induced PTL, some in a dose-responsive manner. 
- Camp-/- animals have a similar inflammatory response as wildtypes 
C57BL/6J mice when given LPS at 20µg or 1µg during pregnancy. 
 
In this model of preterm labour, it is not clear whether the HDPs, Defb14 and Camp 
are fundamental to immune defence of the reproductive tract in pregnancy, 













Chapter 8 Discussion 
Summary of Findings 
In a pregnant state, the hypothesis of this thesis is that HDPs have a dual role in 
preventing ascending infection, but also preventing an exacerbated inflammatory 
response that can cause preterm birth by initiation of the labour cascade. 
To explore this I determine whether bacterial stimuli can regulate HDPs expression 
in pregnancy tissues. I also explore what interactions HDPs have on the 
production/induction of important cytokines, which are vital to the inflammatory 
response. As hBD3 and LL-37 suppress the inflammatory response of cells to LPS 
through TLR-4, the hypothesis is that in-vivo they might offer protection from 
preterm birth caused by inflammation. With the aid of HDP knockout mice, the role 
of these peptides in infection/inflammation and continuation of pregnancy is 
investigated in a mouse-model of induced preterm-labour. Infection-induced preterm 
labour in women is associated with vaginal disruption of commensal bacteria as well 
as invading pathogens. To understand how ascending infection might be controlled 
by HDPs in pregnancy, I explore how HDPs regulate commensal bacteria. This is 
achieved by interrogating the maternal microbiome at mucosal sites in HDP 
knockout mice, utilising the bacterial 16S rRNA gene and next generation 
sequencing. 
In summary, in this thesis I have shown: 
- DEFB103 and CAMP are expressed in myometrium, placenta and amnion/chorion 
tissues in term human pregnancy. 
- Human placental explants respond to LPS challenge by increasing the production 
of pro-inflammatory cytokines. 
- LL-37 but not hBD3 peptide was able to modulate LPS induced inflammatory 





- Beta-defensins; Defb1, Defb4, Defb6, Defb14, and the cathelicidin, Camp, show 
spatial expression patterns along the female reproductive tract in mice. 
- Camp-/- and wildtype mice demonstrated disparate gut microbiota as indicated by 
statistically significant taxonomic differences. This community-wide effect involves 
the loss and gain of multiple bacteria.  
- Camp-/- mice have a more diverse gut microbiome than wildtype controls.  
- In murine pregnancy, there are very little global cumulative or progressive shifts 
in bacteria, with the exception of Candidatus arthromitus. 
- Candidatus arthromitus significantly increases with gestation compared to non-
pregnancy and is maintained at high levels 1 day postpartum. 
- Defb14-/- and Camp-/- mice do not have an increased rate of preterm labour in a 
LPS induced inflammatory model.  
- Camp-/- animals have a similar inflammatory response as wildtype mice when 







Preterm birth (<37 weeks gestation) is the main cause of morbidity and mortality in 
newborn infants, resulting in a multitude of developmental, neurological and 
cognitive problems (Galinsky et al., 2013). Although research into preterm labour 
has vastly increased in the last decade, this has not translated into a reduction in the 
incidence of preterm labour and improved neonatal outcomes. Preterm labour is 
complex and has multifactorial aetiologies; while some preterm labours are 
idiopathic, others can be brought on by rupture of the fetal membranes, cervical 
insufficiency, infection or medically indicated delivery (iatrogenic).  
The upper genital tract was generally considered sterile prior to the onset of labour 
(Jones et al., 2009). However, studies investigating bacterial DNA in placenta and 
fetal membranes discovered that women who present with preterm labour had a 
greater diversity of bacteria in these tissues (Prince et al., 2016, Aagaard et al., 
2014). Indeed, nearly 40% of preterm deliveries are associated with intrauterine 
infection and/or clinical inflammation (Romero et al., 2006). The proposed 
mechanisms by which infectious agents can transfer to the fetus is either by systemic 
maternal-fetal transfer, or more likely initiated by ascending opportunistic 
commensal or pathogenic bacteria from the vagina, through the cervix and into the 
fetal membrane (Allam et al., 2013, DiGiulio et al., 2010). Cells in the female 
reproductive tract, including vaginal epithelial cells, cervical glands, and neutrophils, 
are a major source of multiple microbicides including HDPs. Evidence of their 
importance has come from many animal and in-vitro studies. For example, mice null 
for Camp, the murine orthologue of LL-37/hCAP18 have increased susceptibility to 
bacterial urinary tract infections (Chromek et al., 2006). Defb1 homozygous 
knockout mice also have increased susceptibility to urinary tract infections whereby 
they were shown to retain Staphylococcus spp. in the bladder longer than wildtype 
mice (Morrison et al., 2002). In Chapter 3, I show DEFB103, which encodes hBD3, 
and CAMP, which encodes LL-37, are expressed in human term myometrium, 
placenta and amnion/chorion and there are tissue-specific increases during normal 
term labour without signs of infection. This suggests these HDPs could be having a 





providing additional microbicidal protection at this vulnerable phase of pregnancy or 
in the case of the myometrium; HDPs could be involved in tissue remodelling and 
repair. 
Steady state HDP expression is cell specific and compartmentalised in the female 
reproductive tract in pregnant and non-pregnant women. hBD1-4 and human alpha 
defensin 5 (HD5) have all been reported to be expressed with distinctive temporal 
profiles in the endometrial epithelium, vagina and cervix (King et al., 2003a, 
Fleming et al., 2003, Quayle et al., 1998). Similarly, in Chapter 3 I have shown that 
many mouse HDPs, specifically, Defb1, Defb4, Defb6, Defb14 and Camp are not 
uniformly expressed in the reproductive tract and show spatial patterns. The kinetics 
of this differential expression most likely reflects the differing immunological 
requirements along the length of the female reproductive tract. This confirms what 
Hickey et al., (2013) found in defensin mRNA expression profiles in the vagina and 
uterus of lab mice. 
In a steady state, I have shown Defb14 is highly expressed in the vagina, which 
suggests that this peptide is having a continuous role here, possibly in the 
maintenance of commensal microbiota and pathogen clearance. Indeed, lower levels 
of the human orthologue, hBD3 have been shown in women with vaginal microbiota 
dysbiosis (bacterial vaginosis) and colonisation with BV associated bacteria 
(Mitchell et al., 2013). At other mucosal sites, lower hBD3 levels have also been 
associated with infection, for example in periodontitis patients. hBD3 levels in 
gingival fluid in periodontitis patients were found to be lower than the levels in 
normal control individuals (Brancatisano et al., 2011). Interestingly, periodontitis is a 
risk factor for preterm birth and having a low birthweight baby. The causality of this 
is still unclear but systemic and fetomaternal increases in pro-inflammatory 
cytokines, which are deleterious to the fetus, are thought to be involved (Walia and 
Saini, 2015). It is not known what causes the reduction in hBD3 levels seen in 
mucosal dysbiosis; this could be due to host genetic variation or possible bacterial 
inhibition or degradation. Klebsiella pneumoniae is known to inhibit the production 
of hBD3 and cysteine proteases can directly degrade hBD3 peptide (Cogen et al., 





linked to the inflammatory disease psoriasis (Hollox et al., 2008). An interesting 
study looking at the beta-defensin copy number and the nasopharynx microbiota 
from otitis media prone children showed that copy number was associated with the 
composition of specific pathogens in these children (Jones et al., 2014). Collectively, 
it would therefore be valid to investigate beta-defensin copy number in association 
with the vaginal microbiome in women. It is possible that pregnancy modifies the 
interaction between bacteria and the host mucosa. Therefore correlating the CNV of 
the beta-defensin loci and vagina microbiome in pregnancy would provide insight 
into maternal microbiome modulation. The commensal vaginal microbiome of 
Defb14 null mice was not studied in this thesis; this could well be an avenue for 
investigation. Due to concerns with low bacterial yield and variability, an equally 
valid approach would be looking at in-vivo vaginal pathogen clearance and in-vitro 
bacterial killing from vaginal lavages. Given the impact on outcomes of pregnancy 
caused by vaginal bacteria, it is fundamentally essential that we continue to research 
vaginal microbiome modulation and dysbiosis to improve female reproductive 
health.  
Although in Chapter 7 I show Defb14-/- mice do not have an increased rate of PTL 
using an LPS-induced model, it would be interesting to investigate the role of Defb14 
in the lower reproductive tract in response to pathogens during pregnancy by using a 
model of ascending infection. In-vivo inoculation of pathogenic organisms into the 
vagina of Defb14 null mice while pregnant would be a valid investigation. It has 
been demonstrated that during murine pregnancy the cervical plug prevents from 
ascending infection of E.coli (Racicot et al., 2013). It is highly plausible that Defb14 
null animals would have defective bacterial killing that could allow bacteria to 
colonise in the vagina, transverse the cervix, influencing the continuation of 
pregnancy. This would allow for a better understanding in the role Defb14/hBD3 
plays in protecting the genital tract during pregnancy. Defensins are however a 
multigene family and they may well have redundant compensatory roles in the 
vagina mucosa. Indeed, in Chapter 3 I found Defb4, mouse orthologue of hBD2, was 
also highly expressed in the vagina in a steady state. To determine the collective role 
of these peptides it would be appropriate to knockout multiple highly expressed 





deletion of the beta-defensin region on chromosome 8 that would be suited for such 
an investigation. The female mice are sub-fertile but further investigation has not 
been carried out. 
Some HDPs are inducible upon stimulation with pathogenic agents, which is when 
they are most likely to be expressed. It was surprising that Defb14, the murine 
orthologue of DEFB103, was not increased in the placenta and uterus 6 hours after 
LPS exposure in wildtype pregnant mice. In humans, hBD3 is known to be inducible 
upon stimulation. In gingival fibroblasts, hBD3 expression increases in response to 
bacterial infection with Candida albicans (Gursoy and Kononen, 2012). Oral 
squamous cells (Shuyi et al., 2011), gingival epithelial cells and dendritic cells (Yin 
et al., 2010) all show a marked increase in hBD3 in response to LPS treatment in-
vitro. The lack of Defb14 increase in response to LPS in this thesis could be a factor 
of the time-point that the tissues were collected in the experiment. A 6-hour post-
injection time-point was chosen for tissue and blood serum collection. This was an 
intermediate stage between treatment and the initiation of labour, which would be 
variable between mice. As many cytokines and immune cell mediators have unique 
temporal and presumably spatial patterning in response to endotoxin, a single time-
point is a limiting factor in this study. 
Although inflammation is a crucial mechanism in response to injury and pathogen 
clearance, inappropriate or excessive induction of the inflammatory response in 
pregnancy can cause initiation of the labour cascade and subsequent preterm 
delivery. There is therefore a great need to understand the pathophysiology of 
infection/inflammation in the context of preterm labour concerning both host-genetic 
and environmental risk factors. The immunomodulatory effect of HDPs in 
reproductive tissues in response to infection/inflammation has not been well studied. 
In a pregnant state, the hypothesis of this thesis is that HDPs prevent an exacerbated 
inflammatory response that can cause preterm birth by initiation of the labour 
cascade. To explore this I determine whether bacterial stimuli can regulate HDPs 
expression in pregnancy tissues. I also explore what interactions HDPs have on the 
production/induction of important cytokines, which are vital to the inflammatory 





pro-inflammatory cytokines. LL-37 but not hBD3 peptide was able to modulate this 
inflammation by inhibiting the release of these pro-inflammatory cytokines. It is of 
importance to understand how the inflammatory process leads to preterm labour with 
the end goal of delaying or preventing this process in women. Further study could 
lead to the development of new antimicrobial therapies for infection and threatened 
preterm birth.  
Mouse Model of PTL 
Ethically and practically the number of samples that can be obtained from women 
during pregnancy is limited. In addition, there are multiple compounding factors 
concerning ethnicity, BMI, smoking status and the multifactorial aetiologies of 
preterm labour. Many different animals have been used to understand the 
mechanisms of labour and to search for therapeutics that might have benefit to both 
the mother and neonate. Each animal has associated limitations and benefits as a 
model for parturition, concerning the correlation to human reproductive biology 
(reviewed in Elovitz and Mrinalini, (2004) and Bezold et al., (2013)). Mice have 
extensively been used in labour studies as they have the advantage that tissue can be 
collected at multiple time-points, in addition to the advantage of their short 
gestational period. The immune profile of mice is reasonably well annotated and the 
relative ease of genetic modification makes it possible to elude causative effects. 
There are some notable differences in mouse physiology that are limitations in using 
mouse as a model for parturition; one main feature being the production of 
progesterone. Humans first maintain pregnancy by the production of progesterone in 
the corpus lutum; this is then superseded by placental progesterone production 
(Elovitz and Mrinalini, 2004). In contrast, in mice, placental progesterone is not 
thought to supersede that of the corpus lutum and so removal of the ovaries during 
pregnancy induces labour (Condon et al., 2004). That said, there is emerging 
evidence in humans that suggests there may be local functional progesterone 
withdrawal prior to the onset of labour (Pieber et al., 2001, Mesiano et al., 2002). 
Mice also have multiple pregnancies and deliver fetus still in their gestational sac, 
which is not always ruptured at labour. Contrastingly, in women, the fetal 





labour models have focused on stimulation with agents to create an infection and/or 
inflammatory state. Stimulation of the TLR4 pathways with LPS has been the central 
method of invoking preterm labour in animal models. To establish whether HDPs are 
critical in the continuation of pregnancy I used a LPS induced mouse–model of 
preterm labour. The initial model of PTL adopted in this thesis was highly invasive 
in nature; involving a laparotomy to expose the uterine horns for intrauterine 
injection. This was a limitation of this model as some mice receiving only saline 
control went on to have preterm labour. An approach established by Sara Rinaldi and 
Sarah Stock at the University of Edinburgh, used ultrasound sonography to guide 
intrauterine injection. This refined model was adopted in the later experiments in this 
thesis, reducing the need for invasive surgery. This is in keeping with the “3Rs” 
which is a framework aiming to ‘refine, reduce and replace’ animals used in 
research.  
Intrauterine injection of LPS induced preterm labour in wildtype mice but the 
Defb14-/- and Camp-/- mice did not have an increased rate of preterm labour. Key 
inflammatory mediators are increased in response to LPS-induced PTL, some in a 
dose-responsive manner, but knockout animals have a similar inflammatory response 
as wildtype mice when given LPS during pregnancy. At this dose of LPS in this 
model of preterm labour, is not clear whether the HDPs, Defb14 and Camp are 
fundamental to immune defence of the reproductive tract in pregnancy, preventing 
excessive inflammation that can cause preterm labour. As previously discussed, 
additional studies with lower doses of LPS are needed to fully establish the role of 
HDP in LPS-induced PTL.  
Microbiome 
Being able to survey all the microbes in a community is important especially for 
applications looking at low abundant species, slow-growing bacteria or bacteria that 
cannot easily be cultured. The use of 16S rRNA gene sequencing is becoming a more 
popular method for species identification in research, but also in clinical settings for 
the discovery of novel bacteria in culture-negative infections (reviewed in Woo et al., 





microbiome under controlled conditions. Understanding host-microbiome interaction 
is vital when looking at disease causality. The advantage of the mouse is that we can 
manipulate host genetics to elude gene function. In addition, animals allow for select 
colonisation and perturbations such as antibiotics and dietary changes. As the 
number and diversity of species we can identify is expanding, there needs to be a 
parallel advancement of annotation of bacterial genome databases. The microbiome 
field has yet to establish a gold standard for looking at microbial communities. This 
thesis has put into place a number of techniques and experimental protocols for 16S 
rRNA gene sequencing on next-generation sequencing platforms. Using this 
approach I was able to show the mucosal microbiome of Camp-/- animals were 
significantly different to that of wildtype controls, showing increased diversity in the 
microbes present. While this thesis has displayed a relatively comprehensive 
understanding of the major players present in the microbiome in Camp-/- mice, it has 
not addressed what these genotype related bacteria are doing. Metagenomics will 
help to understand the interactions between the gene of the bacteria and the 
microbiota. It would be of interest to study the metabolome in combination with 
transcriptomics to gain insight into how these differences in bacterial populations 
maybe interacting with the host. Determining the transmissibility of the microbiome 
is also a key avenue for investigation. This can be achieved by co-housing wildtype 
with Camp-/- mice and interrogating the microbiome. As Camp-/- animals are known 
to have increased susceptibility to DSS colitis (Tai et al., 2013, Koon et al., 2011) it 
is possible that this could be a result of having an altered microbiome as has been 
demonstrated in Chapter 5. Testing the susceptibility to DSS of animals that have 
been co-housed would highlight whether this susceptibility phenotype can be 
transferred by the transfer of microbes. 
There has been much interest on the maternal microbiome during pregnancy and in 
the preconception period, but little is known about the postpartum microbiome and 
the effects of diet during the lactation stage. As baby’s first colonisation and re-
seeding in the first few weeks of life comes from the mother, promoting postpartum 
microbial health could improve the metabolic functions in offspring later in life. In 
murine pregnancy, there were very little global cumulative or progressive shifts in 





with gestation compared to non-pregnancy. Candidatus arthromitus, also known as 
segmented filamentous bacteria has been shown to serve a protective role in shaping 
adult metabolism (Jiang et al., 2001). I have shown that SFB is increased in mid to 
late gestation, which is fitting that bacteria which occur early in life and has 
beneficial activity would be increased in the maternal microbiome. Clearly further 
studies are required to examine both the causal mechanism for the increase in SFB, 
and the influence this has on the metabolic function of the offspring. 
Apart from primates, which are expensive to work with, there are very few animal 
models to test the effects of exogenous perturbation on commensal vaginal 
communities. Mice could provide a useful tool to develop and test concepts although 
there are clear differences in physiology that make this challenging. In contrast to 
humans it has been proposed only a small percentage of female mice harbour 
Lactobacillus species at the vaginal mucosa (McGrory and Garber, 1992). In Chapter 
6, I have shown that the commensal vaginal microbiome in mice is highly variable. 
After review of the literature, this is only the second study to look at laboratory 
murine vaginal microbiome by high throughput sequencing (Barfod et al., 2013). 
Concordantly Barfod et al., (2013) also concluded there was high variability in 
vaginal communities. Collectively this suggests that the murine vagina is perhaps not 
an ideal fit for looking at commensal bacterial disturbances in small sample sizes.  
Treatments for Infection Associated PTL 
In the context of infection, delaying myometrial contractions by the use of anti- 
inflammatory agents to target inflammatory signalling pathways might actually be 
doing more harm. Initiation of the labour cascade could be a conserved mechanism 
to deliver the fetus out of the inflamed in-utero environment. That said, anti-
inflammatory agents could also resolve the intrauterine inflammation that threatens a 
preterm delivery. There is therefore a delicate balance in the treatment of PTL, 
between dampening the inflammatory environment enough that any negative effects 
of retaining pregnancy improve neonatal outcome. Preventing infection in the first 
instance is going to be a vital mode for improving neonatal outcome. As it are 





microbial health even prior to conception will be paramount. The combination of 
antimicrobial and anti-inflammatory properties of HDPs make these peptides 
attractive as a treatment. The biphasic pro- and anti-inflammatory properties of 
HDPs are a benefit, but could also be a concern for therapeutic use. Further studies 
are needed to investigate HDP and pro-inflammatory processes such as chemotaxis 
in pregnancy.  
Conclusion 
The development of preventative therapies for preterm labour requires a mechanistic 
understanding of how the pro-inflammatory profile is induced. HDPs have been 
shown to have multiple roles in this pro-inflammatory process. This thesis has 
demonstrated that Host Defence Peptides are expressed in pregnancy tissues and 
have anti-inflammatory properties in response to bacterial stimuli. It is not clear 
whether the HDP, hBD3 and LL-37 are fundamental to the immune defence in 
pregnancy by preventing excessive inflammation. I have shown LL-37 may have a 
role in modulation of the maternal microbiota. Given the deleterious impact on 
outcomes of pregnancy caused by the vaginal bacteria, it is fundamentally essential 
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Materials and Methods 
In-vivo Mouse Experiments Source 
Hamilton 33-gauge needle Sigma Aldrich, Poole, Dorset, UK 
Hamilton syringe Sigma Aldrich, Poole, Dorset, UK 
Sodium Chloride 0.9% (physiological 
saline)  
Sigma Aldrich, Poole, Dorset, UK 
LPS Ultrapure (E. coli 0111:B4) Sigma Aldrich, Poole, Dorset, UK 
Vetergesic Alstoe Ltd, York, UK 
Isoflurane Merial Animal Health Ltd, Harlow, 
Essex, UK 
RNAlater® Sigma Aldrich, Poole, Dorset, UK 
Paraformaldehyde Sigma Aldrich, Poole, Dorset, UK 
Povidone Iodine (10% w/v) Sigma Aldrich, Poole, Dorset, UK 
Coated Vicryl (W9443) Violet 4/0 16mm 
3/8 circle conventional cutting needle 
MidMeds Ltd, Waltham Abbey, UK 
Mersilk (W580) Black 5/0 12mm 3/8 
circle reverse cutting needle  
MidMeds Ltd, Waltham Abbey, UK 
BD Microtainer® Blood Collection 
Tubes Clot Activator/ SST Gel 
Becton, Dickinson and Company, New 
Jersey, USA 
Ultrasound; Visualsonics high resolution 
Vevo 770 ultrasound scanner 
FUJIFILM VisualSonics, Inc, Ontario, 
Canada 
Ultrasound; Vevo 770 Imaging Station 
(Integrated Rail System) 
FUJIFILM VisualSonics, Inc, Ontario, 
Canada 
D1 Digital Video Recorder  Swann, UK 
 
Estrus Cycling and Staging Source 
PMSG Sigma Aldrich, Poole, Dorset, UK 
hCG Sigma Aldrich, Poole, Dorset, UK 





Ex-vivo Experiments Source 
hBD3 (chemically synthesized and 
folded) 
Peptide Institute (#4382‐s) 
LPS Ultrapure (E. coli 0111:B4) Sigma Aldrich, Poole, Dorset, UK 
Scrambled LL-37 Almac, Gladsmuir, UK 
Recombinant LL-37 Almac, Gladsmuir, UK 
RPMI 1640 medium Sigma Aldrich, Poole, Dorset, UK 
Fetal Calf Serum Mycoplex, Teddington, UK 
Penicillin Sigma Aldrich, Poole, Dorset, UK 
Streptomycin Sigma Aldrich, Poole, Dorset, UK 





MaxiSorp®, Nunc, Flat-bottomed 96-
well plates 
Affymetrix, California, USA 
3,3′,5,5′-Tetramethylbenzidine (TMB) 
Liquid Substrate 
Sigma Aldrich, Poole, Dorset, UK 
Tween 20 Sigma Aldrich, Poole, Dorset, UK 
Reagent Diluent Concentrate 2 (10x) R&D Systems, Abingdon, UK 
Dulbeccos Phosphate buffered saline 1x 
(PBS)  
Gibco, Life Technologies Ltd, Paisley, 
UK 





RNA Exaction Source 
TRI reagent® Sigma Aldrich, Poole, Dorset, UK 
Phase Lock Gel Heavy 2 ml tubes 5 PRIME, Inc, Gaithersburg, USA 
1-Bromo‐3‐chloropropane Sigma Aldrich, Poole, Dorset, UK 
RNeasy Mini Kit Qiagen, Crawley, West Sussex, UK 
Nanodrop ND‐1000 Thermo Fisher Scientific, Waltham, USA 
TissueLyser I Qiagen, Crawley, West Sussex, UK 
Precellys®24  Bertin Corp, Rockville, USA 
Chloroform Sigma Aldrich, Poole, Dorset, UK 
Isopropanol Sigma Aldrich, Poole, Dorset, UK 
RNA Bee - RNA Isolation Reagent AMS Biotechnology Ltd, Abingdon, UK 
Lysing Matrix D, 2 mL MP Biomedicals, California, USA 








High-Capacity cDNA Reverse 
Transcription Kit 
Applied Biosystems, Life Technologies 
Ltd, Paisley, UK 
DNase 1 Qiagen, Crawley, West Sussex, UK 
TaqMan® Gene Expression Master Mix 
(x2) 
Applied Biosystems, Life Technologies 
Ltd, Paisley, UK 
TaqMan® Assays Probes Applied Biosystems, Life Technologies 
Ltd, Paisley, UK 
Human ACTB (Beta Actin) Endogenous 
Control (FAM™/MGB probe) 
Applied Biosystems, Life Technologies 
Ltd, Paisley, UK 
Eukaryotic 18S rRNA Endogenous 
Control (FAM™/MGB probe)  
Applied Biosystems, Life Technologies 
Ltd, Paisley, UK 
Mouse ACTB (Actin, Beta) Endogenous 
Control (FAM™ Dye/MGB probe) 
Applied Biosystems, Life Technologies 
Ltd, Paisley, UK 
ABI PRISM® 7000 Sequence Detection 
System 
Applied Biosystems, Life Technologies 
Ltd, Paisley, UK 
The LightCycler® 480 Real-Time PCR 
System 
Roche Diagnostics Limited, Life 




16S rRNA qPCR Source 
LightCycler® 480 SYBR Green II 
Master’ 






PowerSoil® DNA Isolation Kit MO BIO, Carlsbad, USA 
FastDNA® SPIN Kit MP Biomedicals, Santa Ana, USA 
FastPrep® Instrument MP Biomedicals, Santa Ana, USA 
Q5® High-Fidelity DNA Polymerase kit New England Biolabs, Massachusetts, 
USA 
Agilent 2100 Bioanalyzer Agilent Technologies, California, USA 
Bioanalyzer Chips DNA 1000 Agilent Technologies, California, USA 
Bioanalyzer Chips DNA High Sensitivity Agilent Technologies, California, USA 
Qubit™ 2 Fluorometer Thermo Fisher Scientific, Waltham, USA 
Qubit dsDNA HS Assay Kit Thermo Fisher Scientific, Waltham, USA 
Qubit dsDNA BS Assay Kit Thermo Fisher Scientific, Waltham, USA 
100bp ladder New England Biolabs, Massachusetts, 
USA 
Loading Dye New England Biolabs, Massachusetts, 
USA 
Agarose Sigma Aldrich, Poole, Dorset, UK 
Ethidium Bromide Sigma Aldrich, Poole, Dorset, UK 
ExoSAP-IT®  Affymetrix, California, USA 
dNTPs Life Technologies Ltd, Paisley, UK 
Ion Torrent PGM  Life Technologies Ltd, Paisley, UK 
KAPA Library Quantification kit KAPA Biosystems 
Ion OneTouchTM 400 Template Kit v2  Life Technologies Ltd, Paisley, UK 







Step 1: Input dataset 
Input Dataset 
select at runtime 
Input FASTQ File 
Step 2: FastQC:Read QC 
Short read data from your current history 
Output dataset 'output' from step 1 
Title for the output file - to remind you what the job was for 
FastQC 
Contaminant list 
select at runtime 
 
Step 3: Cutadapt 
Fastq file to trim 
Output dataset 'output' from step 1 
3' Adapters 
3' Adapters 1 
Source 
Enter custom sequence 
Enter custom 3' adapter sequence 
AAAAAAA 
3' Adapters 2 
Source 
Enter custom sequence 
Enter custom 3' adapter sequence 
TTTTTTT 
3' Adapters 3 
Source 
Enter custom sequence 
Enter custom 3' adapter sequence 
GGGGGGG 
3' Adapters 4 
Source 
Enter custom sequence 
Enter custom 3' adapter sequence 
CCCCCCC 
5' or 3' (Anywhere) Adapters 




Minimum overlap length 
1 








Additional output options 
Default 
Discard Reads With 
Homopolymers >7bp 
Step 4: Cutadapt 
Fastq file to trim 
Output dataset 'output' from step 3 
3' Adapters 
5' or 3' (Anywhere) Adapters 





5' or 3' (Anywhere) Adapters 1 
Source 
Enter custom sequence 
Enter custom 5' or 3' adapter sequence 
AGTTTGATYMTGGCTCAG 




Minimum overlap length 
3 








Additional output options 
Additional output files 
Rest of Read 
False 




Step 5: Cutadapt 
Fastq file to trim 
Output dataset 'output' from step 4 
3' Adapters 
3' Adapters 1 
Source 
Enter custom sequence 
Enter custom 3' adapter sequence 
ACTCCTACGGRAGGCAGCA 
5' or 3' (Anywhere) Adapters 




Minimum overlap length 
3 








Additional output options 
Additional output files 
Rest of Read 
True 




Trim The 3'' Primer 
Off Reads 





Output dataset 'output' from step 5 








Maximum number of bases to exclude from the window during aggregation 
0 
Aggregate action for window 
mean of scores 




3' primer was 
trimmed) sent for 
Quality Filtering 
Step 7: FASTQ Quality Trimmer 
FASTQ File 
Output dataset 'untrimmed_output' from step 5 








Maximum number of bases to exclude from the window during aggregation 
0 
Aggregate action for window 
mean of scores 




Not Full Length Reads 
(i.e 3' primer was Not 
trimmed) sent for 
Quality Filtering 
Step 8: Filter FASTQ 
FASTQ File 









Maximum number of bases allowed outside of quality range 
0 
This is paired end data 
False 
Quality Filter on a Range of Bases 
Filter Trimmed Reads 
by Size 
Step 9: Filter FASTQ 
FASTQ File 





Filter Not Trimmed 








Maximum number of bases allowed outside of quality range 
0 
This is paired end data 
False 
Quality Filter on a Range of Bases 
Step 10: FastQC:Read QC 
Short read data from your current history 
Output dataset 'output_file' from step 8 
Title for the output file - to remind you what the job was for 
FastQC 
Contaminant list 
select at runtime 
FastQC output 
Step 11: Concatenate datasets 
Concatenate Dataset 




Output dataset 'output_file' from step 9 
Combine Datasets 
Step 12: FastQC:Read QC 
Short read data from your current history 
Output dataset 'output_file' from step 9 
Title for the output file - to remind you what the job was for 
FastQC 
Contaminant list 
select at runtime 
FastQC output 
Step 13: FastQC:Read QC 
Short read data from your current history 
Output dataset 'out_file1' from step 11 
Title for the output file - to remind you what the job was for 
FastQC 
Contaminant list 
select at runtime 
FastQC output 
Step 14: FASTQ to FASTA 
FASTQ file to convert 
Output dataset 'out_file1' from step 11 
Convert FASTQ to 
FASTA. Output Enter 
QIIME Workflow. 














Full Taxonomic Classifications (LEfSe) 
Full Taxonomic Classification Annotated Classification 
Bacteria.Bacteroidetes.Bacteroidia.Bacteroidales.Prevotellaceae p.Bacteroidetes.f.Prevotellaceae 
Bacteria.Bacteroidetes.Bacteroidia.Bacteroidales.Prevotellaceae.Prevotella p.Bacteroidetes.g.Prevotella 
Bacteria.Bacteroidetes.Bacteroidia.Bacteroidales.Prevotellaceae.Prevotella.Otu00045 p.Bacteroidetes.g.Prevotella.Otu00045 
Bacteria.Bacteroidetes.Bacteroidia.Bacteroidales.Prevotellaceae.Prevotella.Otu00089 p.Bacteroidetes.g.Prevotella.Otu00089 
Bacteria.Firmicutes.Clostridia.Clostridiales.Lachnospiraceae.Blautia.Otu00017 p.Firmicutes.g.Blautia.Otu00017 
Bacteria.Firmicutes.Clostridia.Clostridiales.Lachnospiraceae.Blautia.Otu00037 p.Firmicutes.g.Blautia.Otu00037 
Bacteria.Firmicutes.Clostridia.Clostridiales.Lachnospiraceae.Blautia.Otu00042 p.Firmicutes.g.Blautia.Otu00042 
Bacteria.Firmicutes.Clostridia.Clostridiales.Lachnospiraceae.Blautia.Otu00060 p.Firmicutes.g.Blautia.Otu00060 
Bacteria.Firmicutes.Clostridia.Clostridiales.Lachnospiraceae.Blautia.Otu00105 p.Firmicutes.g.Blautia.Otu00105 
Bacteria.Firmicutes.Erysipelotrichia p.Firmicutes.c.Erysipelotrichia 
Bacteria.Firmicutes.Erysipelotrichia.Erysipelotrichales p.Firmicutes.o.Erysipelotrichales 
Bacteria.Firmicutes.Erysipelotrichia.Erysipelotrichales.Erysipelotrichaceae p.Firmicutes.f.Erysipelotrichaceae 
Bacteria.Firmicutes.Erysipelotrichia.Erysipelotrichales.Erysipelotrichaceae.Allobaculum p.Firmicutes.g.Allobaculum 
Bacteria.Firmicutes.Erysipelotrichia.Erysipelotrichales.Erysipelotrichaceae.Allobaculum.Otu00019 p.Firmicutes.g.Allobaculum.Otu00019 
Bacteria.Bacteroidetes.Bacteroidia.Bacteroidales.S24_7.unclassified.Otu00003 p.Bacteroidetes.f.S24_7.Otu00003 
Bacteria.Bacteroidetes.Bacteroidia.Bacteroidales.S24_7.unclassified.Otu00022 p.Bacteroidetes.f.S24_7.Otu00022 
Bacteria.Bacteroidetes.Bacteroidia.Bacteroidales.unclassified.unclassified.Otu00039 p.Bacteroidetes.g.unclassified.Otu00039 
Bacteria.Firmicutes.Clostridia.Clostridiales.Lachnospiraceae.Blautia.Otu00069 p.Firmicutes.g.Blautia.Otu00069 
Bacteria.Firmicutes.Clostridia.Clostridiales.Lachnospiraceae.unclassified.Otu00043 p.Firmicutes.f.Lachnospiraceae.unclassified.Otu00043 
Bacteria.Firmicutes.Clostridia.Clostridiales.Lachnospiraceae.unclassified.Otu00047 p.Firmicutes.f.Lachnospiraceae.unclassified.Otu00047 
Bacteria.Firmicutes.Clostridia.Clostridiales.Lachnospiraceae.unclassified.Otu00170 p.Firmicutes.f.Lachnospiraceae.unclassified.Otu00170 
Bacteria.Firmicutes.unclassified.unclassified.unclassified.unclassified p.Firmicutes.g.unclassified 
Bacteria.Tenericutes.Mollicutes.Anaeroplasmatales p.Tenericutes.o.Anaeroplasmatales 
Bacteria.Tenericutes.Mollicutes.Anaeroplasmatales.Anaeroplasmataceae p.Tenericutes.f.Anaeroplasmataceae 
Bacteria.Tenericutes.Mollicutes.Anaeroplasmatales.Anaeroplasmataceae.Anaeroplasma p.Tenericutes.g.Anaeroplasma 
Bacteria.Tenericutes.Mollicutes.Anaeroplasmatales.Anaeroplasmataceae.Anaeroplasma.Otu00072 p.Tenericutes.g.Anaeroplasma.Otu00072 
Bacteria.Bacteroidetes.Bacteroidia.Bacteroidales.Prevotellaceae p.Bacteroidetes.f.Prevotellaceae 
Bacteria.Bacteroidetes.Bacteroidia.Bacteroidales.Prevotellaceae.Prevotella p.Bacteroidetes.g.Prevotella 
Bacteria.Bacteroidetes.Bacteroidia.Bacteroidales.Prevotellaceae.Prevotella.Otu00045 p.Bacteroidetes.g.Prevotella.Otu00045 
Bacteria.Bacteroidetes.Bacteroidia.Bacteroidales.Prevotellaceae.Prevotella.Otu00089 p.Bacteroidetes.g.Prevotella.Otu00089 
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